How Medicare Part D, Medicaid, Electronic Prescribing, and ICD-10 Could Improve Public Health (But Only If CMS Lets Them) by Herbst, Jennifer L.
Health Matrix: The Journal of Law-
Medicine
Volume 24 | Issue 1
2015
How Medicare Part D, Medicaid, Electronic
Prescribing, and ICD-10 Could Improve Public
Health (But Only If CMS Lets Them)
Jennifer L. Herbst
Follow this and additional works at: https://scholarlycommons.law.case.edu/healthmatrix
Part of the Health Law and Policy Commons
This Note is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It
has been accepted for inclusion in Health Matrix: The Journal of Law-Medicine by an authorized administrator of Case Western Reserve University
School of Law Scholarly Commons.
Recommended Citation
Jennifer L. Herbst, How Medicare Part D, Medicaid, Electronic Prescribing, and ICD-10 Could Improve Public Health (But Only If CMS
Lets Them), 24 Health Matrix 209 (2014)
Available at: https://scholarlycommons.law.case.edu/healthmatrix/vol24/iss1/9
HEALTH MATRIX· VOLUME 24 · 2014 
Antitrnst and the Future of Nursing 
The Board's opinion is not and cannot be altered by representa-
tions that a particular CRNA [Certified Registered Nurse 
Anesthetist] has received postdoctoral training in such areas or 
has performed such activities in this or another state. A non-
physician may have education, training, and, indeed, expertise 
in such an area but expertise cannot, in and of itself, supply au-
thority under law to practice medicine. 286 
As a legal matter, the analysis may be trivially correct: education, 
training, experience, and expertise do not, in themselves, bestow legal 
authority or lift statutory prohibitions .. As a policy matter, however, 
we might wonder about the bases on which we both assign and limit 
the authority to meet demand - unmet needs - for health care. 
However we allocate research resources, tolerate uncertainty, and 
calibrate substantiation standards, we might say this much when 
substantiation appears to approach zero: based on competition 
principles at least, nothing ought to beget nothing, except, perhaps, 
scrutiny. 
286. Safriet, supra note 97, at 454. 
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How MEDICARE p ART D, MEDICAID, 
ELECTRONIC PRESCRIBING, AND ICD-
10 COULD IMPROVE PUBLIC HEALTH 
(BUT ONLY IF CMS LETS THEM) 
Jennifer L. Herbstt 
ABSTRACT 
A simple change to the Medicare and Medicaid outpatient prescrip-
tion drug billing systems could improve patient safety and the systems' 
long-term fiscal stability. Including diagnosis codes on prescription drug 
claims (codes already in use for other billing purposes) would transform 
the Medicare Part D and Medicaid prescription drug claims databases 
into powerful public health research tools - ones that could provide 
much-needed (and, to date, elusive) information on how prescription 
drugs work in vulnerable patient populations underrepresented in clinical 
research. 
Achieving the full potential of this proposal, though, depends upon 
the federal agency responsible for Medicare and Medicaid, the Centers 
for Medicare and Medicaid Services (CMS), maintaining its current 
reimbursement policy, which is perhaps best characterized as one of 
benign neglect of the statutory standard for coverage. If, instead of 
continuing coverage for the vast majority of prescription drugs, CMS 
decided to deny payment for the millions of prescriptions falling short of 
the statutory standard (and thus avoid spending billions of federal 
health care dollars), prescribers would find themselves in an ethical 
dilemma between truth-telling and effectively treating their patients. 
Due to the systemic incentives for prescribers and pharmacists to 
miscode diagnoses in order to get CMS to pay for the prescription drugs 
needed by patients, the decision to treat patients effectively in the short-
term under a strict coverage enforcement policy would undermine the 
potential to more effectively treat vulnerable patients, reduce prescrip-
tion errors, and properly allocate federal health care dollars in the 
future. Even in the midst of a financial crisis, or perhaps especially 
because of our current financial crisis, we cannot afford to sacrifice 
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improved patient safety and better informed long-term management of 
federal health care dollars for a short-term reduction in federal spending 
on prescription drugs. 
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INTRODUCTION 
The United States' health care system is broken. An estimated 1.5 
million people are sickened or killed every year due to preventable 
prescription drug errors. 1 As much as half of the $65.8 billion (and 
growing) spent annually by the Medicare program on outpatient pre-
scription drugs is being misspent.2 Most prescription drugs have not been 
1. 
2. 
PHILIP ASPDEN ET AL., INST. OF MED., PREVENTING MEDICINE ERRORS: 
QUALITY CHASM SERIES 5 (2007). 
OFFICE OF INSPECTOR GEN., U.S. DEP'T OF HEALTH & HUMAN SERVS., 
ENSURING THAT MEDICARE PART D REIMBURSEMENT IS LIMITED TO DRUGS 
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tested for safety and efficacy in our most vulnerable populations 
children, pregnant women, the chronically disabled, and elderly - and 
yet they are the most likely to need and receive prescription drugs 
covered by government insurance programs. 3 Between the expansion of 
Medicaid coverage under the Patient Protection and Affordable Care 
Act (the primary insurance coverage for over 32 million American 
children)4 and the 65-plus-year-old Medicare-eligible population growing 
from 40 million people to 72 million people in the next twenty years,5 the 
federal health care systems' payment of prescription drugs for our most 
vulnerable populations will only continue to increase.6 The Food and 
Drug Administration (FDA)'s prescription drug review and approval 
process is unable to detect effectively many risks of prescription drugs 
until after they have been approved and used by thousands or millions of 
patients.7 It is not much of a stretch to suggest that our Medicare and 
Medicaid programs are paying for an uncontrolled trial of prescription 
drugs in vulnerable populations without much prospect for collecting 
meaningful data to inform future treatment decisions in these popula-
tions. 
A single, simple step (to the billing system, of all things) could start 
to remedy these ills: Make patient diagnosis codes a necessary condition 
for payment of outpatient prescription drugs by Medicare Part D and 
Medicaid. With the increasing adoption of electronic medical records and 






PROVIDED FOR MEDICALLY ACCEPTED INDICATIONS 6 (2011) [hereinafter 
OIG p ART D REIMBURSEMENT REPORT], available at 
https://oig.hhs.gov/oei/reports/oei-07-08-00152.pdf; CONG. BUDGET 
OFFICE, MARCH 2012 MEDICARE BASELINE 1 (2012), available at 
http://cbo.gov/sites/default/files/cbofiles/attachments/43060_Medicare.p 
df. 
More specifically, the clinical studies used for FDA approval are not 
designed to test safety (instead they are focused primarily on efficacy) and 
tend to exclude the frail elderly, young children, pregnant women, and 
patients with comorbidities that could interact with the drugs. Aaron S. 
Kesselheim, Off-Label Drug Use and Promotion: Balancing Public Health 
Goals and Commercial Speech, 37 AM. J.L. & MED. 225, 233-38 (2011). 
Distribution of Medicaid Enrollees by Enrollment Group, FY2010, KAISER 
FAM. FOUND., http://kff.org/medicaid/state-indicator/distribution-by-
enrollment-group/ (last visited Apr. 18, 2014). 
WAN HE ET AL., U.S. CENSUS BUREAU, CURRENT POPULATION REPORTS, 
65+ IN THE UNITED STATES: 2005, at 12 (2005), available at 
http://www.census.gov/prod/2006pubs/p23-209.pdf. 
CONG. BUDGET OFFICE, supra note 2. 
Kesselheim, supra note 3, at 233 ("New drugs commonly are tested at most 
on a few thousand patients, so even the more common side effects may 
occur only in a handful of cases, and rare but deadly side effects may not 
emerge at all."). 
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INTRODUCTION 
The United States' health care system is broken. An estimated 1.5 
million people are sickened or killed every year due to preventable 
prescription drug errors.1 As much as half of the $65.8 billion (and 
growing) spent annually by the Medicare program on outpatient pre-
scription drugs is being misspent.2 Most prescription drugs have not been 
1. PHILIP ASPDEN ET AL., INST. OF MED., PREVENTING MEDICINE ERRORS: 
QUALITY CHASM SERIES 5 (2007). 
2. OFFICE OF INSPECTOR GEN., U.S. DEP'T OF HEALTH & HUMAN SERVS., 
ENSURING THAT MEDICARE PART D RETh1BURSEMENT IS LIMITED TO DRUGS 
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tested for safety and efficacy in our most vulnerable populations 
children, pregnant women, the chronically disabled, and elderly - and 
yet they are the most likely to need and receive prescription drugs 
covered by government insurance programs.3 Between the expansion of 
Medicaid coverage under the Patient Protection and Affordable Care 
Act (the primary insurance coverage for over 32 million American 
children)4 and the 65-plus-year-old Medicare-eligible population growing 
from 40 million people to 72 million people in the next twenty years, 5 the 
federal health care systems' payment of prescription drugs for our most 
vulnerable populations will only continue to increase.6 The Food and 
Drug Administration (FDA)'s prescription drug review and approval 
process is unable to detect effectively many risks of prescription drugs 
until after they have been approved and used by thousands or millions of 
patients.7 It is not much of a stretch to suggest that our Medicare and 
Medicaid programs are paying for an uncontrolled trial of prescription 
drugs in vulnerable populations without much prospect for collecting 
meaningful data to inform future treatment decisions in these popula-
tions. 
A single, simple step (to the billing system, of all things) could start 
to remedy these ills: Make patient diagnosis codes a necessary condition 
for payment of outpatient prescription drugs by Medicare Part D and 
Medicaid. With the increasing adoption of electronic medical records and 
electronic prescribing (aided in large part by federal incentive pro-
3. 
PROVIDED FOR MEDICALLY ACCEPTED INDICATIONS 6 (2011) [hereinafter 
OIG p ART D REIMBURSEMENT REPORT]' available at 
https://oig.hhs.gov/oei/reports/oei-07-08-00152.pdf; CONG. BUDGET 
OFFICE, MARCH 2012 MEDICARE BASELINE 1 (2012), available at 
http://cbo.gov/sites/default/files/cbofiles/attachments/43060_Medicare.p 
df. 
More specifically, the clinical studies used for FDA approval are not 
designed to test safety (instead they are focused primarily on efficacy) and 
tend to exclude the frail elderly, young children, pregnant women, and 
patients with comorbidities that could interact with the drugs. Aaron S. 
Kesselheim, Off-Label D1"Ug Use and Promotion: Balancing Public Health 
Goals and Commercial Speech, 37 AM. J.L. & MED. 225, 233-38 (2011). 
4. Distribution of Medicaid Enrollees by Enrollment Group, FY2010, KAISER 
FAM. FOUND., http:/ /kff.org/ medicaid/ state-indicator/ distribution-by-
enrollment-group / (last visited Apr. 18, 2014). 
5. WAN HE ET AL., U.S. CENSUS BUREAU, CURRENT POPULATION REPORTS, 
65+ IN THE UNITED STATES: 2005, at 12 (2005), available at 
http://www.census.gov/prod/2006pubs/p23-209.pdf. 
6. CONG. BUDGET OFFICE, supra note 2. 
7. Kesselheim, s'upra note 3, at 233 ("New drugs commonly are tested at most 
on a few thousand patients, so even the more common side effects may 
occur only in a handful of cases, and rare but deadly side effects may not 
emerge at all."). 
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grams), 8 the automatic inclusion of diagnostic coding generated for the 
health care provider's patient files (and already necessary for provider 
billing purposes) on outpatient prescriptions would be relatively easy to 
build into the record and prescribing systems. This article strives to 
explain how the addition of diagnosis codes to outpatient prescriptions 
for Medicare Part D and Medicaid beneficiaries could significantly 
improve pharmacists' review of prescriptions for errors, the drug safety 
surveillance efforts of the FDA, and the appropriate allocation of 
Medicare and Medicaid resources by CMS, but only if CMS is willing to 
continue its current policy of paying for all outpatient prescriptions not 
subject to prior authorization (contrary to the letter of the Medicare 
Part D and Medicaid statutes).9 
In Part I, I explain the role of diagnostic information in the current 
legal framework for Medicare and Medicaid reimbursement of outpatient 
prescription drugs as well as the federal government's current billing and 
enforcement policy in spite of the legal framework. Part II then looks at 
the potential disadvantages of strict enforcement of the Medicare Part D 
and Medicaid coverage laws (at least in the short term) due to (A) the 
disconnect between "medically accepted indications" (the statutory 
standard for coverage by the Medicare Part D and Medicaid programs) 
and the actual practice of medicine, (B) the informational uncertainty 
accompanying the pending transition from the current diagnostic coding 
system, ICD-9-CM, to its successor, ICD-10-CM, and (C) the systemic 
incentives for miscoding created by coverage denials based upon the 
diagnostic information. 
As seen in Part III, the significant public health interests potentially 
served by adding diagnostic codes to outpatient prescriptions - better 
informed pharmacist review of prescriptions for medication errors, 
8. The American Recovery and Reinvestment Act of 2009 provided financial 
incentives for health care providers to adopt electronic health records. See 
CTRS. FOR MEDICARE & MEDICAID SERVS., CMS PROPOSES DEFINITION OF 
MEANINGFUL USE OF CERTIFIED ELECTRONIC HEALTH RECORDS (EHR) 
TECHNOLOGY (2009), available at 
http://www.cms.hhs.gov/ apps/media/fact_sheets.asp. 
9. While Medicare Part D sponsors (the contractors charged with 
administering the Medicare prescription drug benefit on behalf of CMS) are 
technically supposed to ensure that the drugs paid for by the Medicare 
Part D program are used exclusively for "medically-accepted indications," 
sponsors are not expected to recoup any incorrect payments from 
pharmacists or patients unless the drug was subject to a sponsor's prior 
authorization. As a result, sponsors pay most prescriptions dispensed for 
Medicare Part D beneficiaries, regardless of use, with little to no risk to the 
sponsor, pharmacist, or patient. See generally CTRS. FOR MEDICARE AND 
MEDICAID SERVS., MEDICARE PRESCRIPTION DRUG BENEFIT MANUAL §§ 
10.6, 10.6.1 (2010), available at 
http://www.cms.gov/Medicare/Prescription-Drug-
Coverage /PrescriptionDrugCovContra/Downloads/ Chapter6. pdf; OIG 
PART D REIMBURSEMENT REPORT, supra note 2. 
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improved drug safety surveillance and comparative effectiveness research 
based on actual prescribing practices and patient adherence data - will 
only be realized if the information in the outpatient prescription drug 
claims database is an accurate reflection of actual medical practice and 
pharmacy. This information has been historically elusive for health care 
practitioners, researchers, and policymakers alike and an outpatient 
prescription drug claims database with diagnostic information would be 
a tremendously valuable public health research tool. In order to increase 
the likelihood that the diagnostic information submitted for payment is 
accurate, prescribers and pharmacists will need to understand diagnostic 
coding as a part of effective, coordinated patient care as opposed to a 
mere administrative requirement for payment. 
I conclude by suggesting an incremental implementation process in 
order for CMS and FDA (and, by proxy, patients, health care providers, 
and taxpayers) to benefit from the outpatient prescription drug use data 
generated by the federal health care system. 
I. THE ROLE OF DIAGNOSTIC INFORMATION IN THE CURRENT 
LEGAL FRAMEWORK FOR REIMBURSEMENT OF OUTPATIENT 
PRESCRIPTION DRUGS UNDER MEDICARE AND MEDICAID 
Federal statutes make Medicare Part D and Medicaid outpatient 
prescription drug coverage contingent on whether a patient's diagnosis is 
one of the indications for which the FDA has approved the drug or 
otherwise supported by peer-reviewed scientific evidence summarized in 
recognized drug compendia. Congress chose to call this universe of drug 
uses "medically accepted indications. "10 In order to determine the 
eligibility of a particular prescription for Medicare or Medicaid coverage, 
the claims administrator needs to know the drug name, dosage, quantity, 
and patient diagnosis. 11 At present, outpatient prescriptions lack patient 
10. 42 U.S.C. § 1396a(a)(54) (2012) (indicating that if a state decides to 
extend Medicaid coverage to outpatient prescription drugs, coverage must 
comply with the federal requirements for payment for covered outpatient 
drugs under 42 U.S.C. § 1396r-8; § 1396r-8(k)(6) (defining "medically 
accepted indication" for Medicaid statute in terms of FDA-approved 
indications and compendia identified in § 1396r-8(g)(l)(B)(i)); § 1396r-
8(d)(4)(C) (indicating that a drug may be excluded from a state's 
Medicaid formulary if the use is not a medically accepted indication). See 
also§ 1396r-8(k)(2) (defining "covered outpatient drug" for Medicaid);§ 
1395w-102(e) (defining "covered Part D drug" and "medically accepted 
indication"); 42 C.F.R. § 423.100 (2012) (defining Medicare "Part D drug" 
by referring to Medicaid statute definition of "medically accepted 
indication" at 42 U.S.C. § 1396r-8(k)(6)). 
11. E.g., Prescription Drug Claim Form-Medicare Part D, BLUECROSS 
BLUESIDELD OF LA., 
https://www.bcbsla.com/Docs/RxBL UE_Prescription_ Claim_Form. pdf 
(last visited Apr. 18, 2014) (requiring information on drug name, dosage, 
and quantity for Medicare Part D reimbursement). See supra note 10; 
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grams), 8 the automatic inclusion of diagnostic coding generated for the 
health care provider's patient files (and already necessary for provider 
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build into the record and prescribing systems. This article strives to 
explain how the addition of diagnosis codes to outpatient prescriptions 
for Medicare Part D and Medicaid beneficiaries could significantly 
improve pharmacists' review of prescriptions for errors, the drug safety 
surveillance efforts of the FDA, and the appropriate allocation of 
Medicare and Medicaid resources by CMS, but only if CMS is willing to 
continue its current policy of paying for all outpatient prescriptions not 
subject to prior authorization (contrary to the letter of the Medicare 
Part D and Medicaid statutes). 9 
In Part I, I explain the role of diagnostic information in the current 
legal framework for Medicare and Medicaid reimbursement of outpatient 
prescription drugs as well as the federal government's current billing and 
enforcement policy in spite of the legal framework. Part II then looks at 
the potential disadvantages of strict enforcement of the Medicare Part D 
and Medicaid coverage laws (at least in the short term) due to (A) the 
disconnect between "medically accepted indications" (the statutory 
standard for coverage by the Medicare Part D and Medicaid programs) 
and the actual practice of medicine, (B) the informational uncertainty 
accompanying the pending transition from the current diagnostic coding 
system, ICD-9-CM, to its successor, ICD-10-CM, and (C) the systemic 
incentives for miscoding created by coverage denials based upon the 
diagnostic information. 
As seen in Part III, the significant public health interests potentially 
served by adding diagnostic codes to outpatient prescriptions - better 
informed pharmacist review of prescriptions for medication errors, 
8. The American Recovery and Reinvestment Act of 2009 provided financial 
incentives for health care providers to adopt electronic health records. See 
CTRS. FOR MEDICARE & MEDICAID SERVS., CMS PROPOSES DEFINITION OF 
MEANINGFUL USE OF CERTIFIED ELECTRONIC HEALTH RECORDS (EHR) 
TECHNOLOGY (2009), available at 
http://www.cms.hhs.gov/ apps/media/fact_sheets.asp. 
9. While Medicare Part D sponsors (the contractors charged with 
administering the Medicare prescription drug benefit on behalf of CMS) are 
technically supposed to ensure that the drugs paid for by the Medicare 
Part D program are used exclusively for "medically-accepted indications," 
sponsors are not expected to recoup any incorrect payments from 
pharmacists or patients unless the drug was subject to a sponsor's prior 
authorization. As a result, sponsors pay most prescriptions dispensed for 
Medicare Part D beneficiaries, regardless of use, with little to no risk to the 
sponsor, pharmacist, or patient. See generally CTRS. FOR MEDICARE AND 
MEDICAID SERVS., MEDICARE PRESCRIPTION DRUG BENEFIT MANUAL §§ 
10.6, 10.6.1 (2010), available at 
http://www.ems.gov/Medicare /Prescription-Drug-
Coverage /PrescriptionDrugCovContra/Downloads/ Chapter6. pdf; OIG 
PART D REIMBURSEMENT REPORT, supra note 2. 
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improved drug safety surveillance and comparative effectiveness research 
based on actual prescribing practices and patient adherence data - will 
only be realized if the information in the outpatient prescription drug 
claims database is an accurate reflection of actual medical practice and 
pharmacy. This information has been historically elusive for health care 
practitioners, researchers, and policymakers alike and an outpatient 
prescription drug claims database with diagnostic information would be 
a tremendously valuable public health research tool. In order to increase 
the likelihood that the diagnostic information submitted for payment is 
accurate, prescribers and pharmacists will need to understand diagnostic 
coding as a part of effective, coordinated patient care as opposed to a 
mere administrative requirement for payment. 
I conclude by suggesting an incremental implementation process in 
order for CMS and FDA (and, by proxy, patients, health care providers, 
and taxpayers) to benefit from the outpatient prescription drug use data 
generated by the federal health care system. 
I. THE ROLE OF DIAGNOSTIC INFORMATION IN THE CURRENT 
LEGAL FRAMEWORK FOR REIMBURSEMENT OF OUTPATIENT 
PRESCRIPTION DRUGS UNDER MEDICARE AND MEDICAID 
Federal statutes make Medicare Part D and Medicaid outpatient 
prescription drug coverage contingent on whether a patient's diagnosis is 
one of the indications for which the FDA has approved the drug or 
otherwise supported by peer-reviewed scientific evidence summarized in 
recognized drug compendia. Congress chose to call this universe of drug 
uses "medically accepted indications. "10 In order to determine the 
eligibility of a particular prescription for Medicare or Medicaid coverage, 
the claims administrator needs to know the drug name, dosage, quantity, 
and patient diagnosis. 11 At present, outpatient prescriptions lack patient 
10. 42 U.S.C. § 1396a(a)(54) (2012) (indicating that if a state decides to 
extend Medicaid coverage to outpatient prescription drugs, coverage must 
comply with the federal requirements for payment for covered outpatient 
drugs under 42 U.S.C. § 1396r-8; § 1396r-8(k)(6) (defining "medically 
accepted indication" for Medicaid statute in terms of FDA-approved 
indications and compendia identified in § 1396r-8(g)(l)(B)(i)); § 1396r-
8(d)(4)(0) (indicating that a drug may be excluded from a state's 
Medicaid formulary if the use is not a medically accepted indication). See 
also§ 1396r-8(k)(2) (defining "covered outpatient drug" for Medicaid); § 
1395w-102(e) (defining "covered Part D drug" and "medically accepted 
indication"); 42 C.F.R. § 423.100 (2012) (defining Medicare "Part D drug" 
by referring to Medicaid statute definition of "medically accepted 
indication" at 42 U.S.C. § 1396r-8(k)(6)). 
11. E.g., Prescr'iption Drug Claim Form-Medicare Part D, BLUECROSS 
BLUESHIELD OF LA., 
https://www.bcbsla.com/Docs/RxBLUE_Prescription_Claim_Form.pdf 
(last visited Apr. 18, 2014) (requiring information on drug name, dosage, 
and quantity for Medicare Part D reimbursement). See supra note 10; 
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diagnostic information (the "information gap" identified in a prior 
article), 12 making real-time review for coverage eligibility impossible. In 
order to close this information gap, CMS could require patient diagnosis 
information, in the form of an International Classification of Diseases 
(ICD) code, for reimbursement of outpatient prescription drugs under 
Medicare and Medicaid. 
My proposal for CMS to require diagnostic information, in the form 
of _an ICD code, for reimbursement of outpatient prescription drug 
claims merely suggests an extension of the existing billing policy for the 
small group of outpatient drugs currently covered by Medicare Part B. 
Generally, Medicare Pa.rt B covers "reasonable and necessary" outpa-
tient medical services and items for the "diagnosis or treatment of illness 
or injury or to improve the functioning of a malformed body member. "13 
Medicare Part B does not cover most outpatient prescription drugs - it 
has historically only covered drugs, which are administered by doctors 
during office or hospital visits. 14 This relatively limited Part B coverage 
has been extended, though, to include a handful of other specific classes 
of prescription drugs and biologics that may be purchased at retail 
pharmacies, including blood clotting factors for hemophilia patients,15 
immunosuppressive therapy after organ transplantation, 16 erythropoietin 
for dialysis patients,17 and anti-nausea drugs for those undergoing 
anticancer chemotherapy. 18 In each of these statutorily defined excep-
tions to the general Part B rule covering only drugs that "are not 
usually self-administered by the patient," Congress limited coverage to 
CTRS. FOR MEDICARE AND MEDICAID SERVS., supra note 9, at § 10.6 
(providing authority on need for diagnostic information). 
12. Jennifer L. Herbst, The Short-Sighted Value of Inefficiency: Why We 
Should Mind the Gap in the Reimbursement of Outpatient Prescription 
Drugs, 2 CASE W. RES. J.L. TECH. & INTERNET 1 (2011). 
13. 42 U.S.C. § 1395y(a)(l)(A) (2012). 
14. U.S. Gov'T ACCOUNTING OFFICE, MEDICARE: PRESCRIPTION DRUG ISSUES 3 
(1987) ("Outpatient prescription drugs are generally not covered by 
Medicare Part B, with the exception of drugs that require injection by a 
physician or nurse."). 42 U.S.C § 1395k(a)(2)(B) (2012) (providing 
Medicare Part B coverage for "medical and other health services" rendered 
in an outpatient setting); § 1395x(s)(2) (A) (defining the term "medical and 
other health services" to include, in relevant part, "services and supplies 
(including drugs and biologicals which are not usually self-administered by 
the patient) furnished as an incident to a physician's professional service of 
kinds which are commonly furnished in physicians' offices and ~re 
commonly either rendered without charge or included in the physicians' 
bills .... " (emphasis added)). 
15. § 1395k(a)(2)(I). 
16. § 1395k(a)(2)(J). 
17. § 1395k(a)(2)(0). 
18. § 1395k(a)(2)(Q). 
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use for specific patient diagnoses (i.e., hemophilia, organ failure, kidney 
disease, cancer). CMS, in tum, has required diagnosis codes on all claims 
for reimbursement of prescription drugs under Part B, whether furnished 
by a physician or self-administered by a patient. 19 
The vast majority of outpatient prescription drugs taken by Medi-
care beneficiaries went uncovered by the program20 until the Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 added 
a prescription drug benefit to the Medicare program - Medicare Part 
D.21 Pa.rt D was considered at the time to be "the most significant 
change to the Medicare program since its inception in 1965. "22 Unlike the 
broad "reasonable and necessary" standard for Medicare Part B reim-
bursement, the legal framework for Medicare Part D limits federal 
reimbursement of outpatient prescription drugs to "medically accepted 
indication[s]," as defined by the Medicaid statute, allowing, but not 
19. See CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE CLAIMS 
PROCESSING MANUAL § 70 (2003), available at 
http://www.cms.gov/Regulations-and-
Guidance/Guidance/Manuals/Internet-Only-Manuals-IOMs-
Items/CMS018912.html (explaining an exception to the general Part B 
coverage rule that self-administered drugs, including self-administered oral 
versions of covered injectable cancer drugs, furnished to outpatients for 
therapeutic purposes are not covered by Medicare unless those drugs must 
be put directly into an item of durable medical equipment or a prosthetic 
device); Id. at § 80.1.3 ("A cancer diagnosis code must be reported when 
billing for [oral cancer drugs using] these HCPCS [Healthcare Common 
Procedure Coding System] codes. If there is no cancer diagnosis the claim 
is denied."); CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE BENEFIT 
POLICY MANUAL§ 50.4.1 (2009) [hereinafter MEDICARE BENEFIT POLICY 
MANUAL], available at 
http://www.cms.hhs.gov/Manuals/downloads/bpl02c15.pdf ("Use of the 
drug or biological must be safe and effective and otherwise reasonable and 
necessary ... Drugs or biologicals approved for marketing by the [FDA] 
are considered safe and effective for purposes of this requirement when 
used for indications specified on the labeling."). 
20. Some Medicare patients are able to get additional insurance through 
Medicaid, in which case Medicaid could cover the outpatient prescription 
drugs not paid for by Medicare. These patients are known as "dual eligible 
beneficiaries." MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE 
CONG.: NEW APPROACHES IN MEDICARE 71-72 (2004), available at 
http://www.medpac.gov/publications/congressional_reports/June04_ch3.p 
df. 
21. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 
Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2071-72 (2003). OIG PART D 
REIMBURSEMENT REPORT, supra note 2, at 2 ("Since January 1, 2006, most 
outpatient prescription drugs for Medicare beneficiaries and dually eligible 
beneficiaries ... have been covered by the Medicare Part D program."). 
22. Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194, 
4197 (Jan. 28, 2005) (codified at scattered parts of 42 C.F.R.). 
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diagnostic information (the "information gap" identified in a prior 
article), 12 making real-time review for coverage eligibility impossible. In 
order to close this information gap, CMS could require patient diagnosis 
information, in the form of an International Classification of Diseases 
(ICD) code, for reimbursement of outpatient prescription drugs under 
Medicare and Medicaid. 
My proposal for CMS to require diagnostic information, in the form 
of an ICD code, for reimbursement of outpatient prescription drug 
claims merely suggests an extension of the existing billing policy for the 
small group of outpatient drugs currently covered by Medicare Part B. 
Generally, Medicare Part B covers "reasonable and necessary" outpa-
tient medical services and items for the "diagnosis or treatment of illness 
or injury or to improve the functioning of a malformed body member. "13 
Medicare Part B does not cover most outpatient prescription drugs - it 
has historically only covered drugs, which are administered by doctors 
during office or hospital visits. 14 This relatively limited Part B coverage 
has been extended, though, to include a handful of other specific classes 
of prescription drugs and biologics that may be purchased at retail 
pharmacies, including blood clotting factors for hemophilia patients, 15 
immunosuppressive therapy after organ transplantation, 16 erythropoietin 
for dialysis patients,17 and anti-nausea drugs for those undergoing 
anticancer chemotherapy. 18 In each of these statutorily defined excep-
tions to the general Part B rule covering only drugs that "are not 
usually self-administered by the patient," Congress limited coverage to 
CTRS. FOR MEDICARE AND MEDICAID SERVS., supra note 9, at § 10.6 
(providing authority on need for diagnostic information). 
12. Jennifer L. Herbst, The Short-Sighted Value of Inefficiency: Why We 
Should Mind the Gap in the Reimbursement of Outpatient Prescription 
Drugs, 2 CASE w. R.Es. J.L. TECH. & INTERNET 1 (2011). 
13. 42 U.S.C. § 1395y(a)(l)(A) (2012). 
14. U.S. Gov'T ACCOUNTING OFFICE, MEDICARE: PRESCRIPTION DRUG ISSUES 3 
(1987) ("Outpatient prescription drugs are generally not covered by 
Medicare Part B, with the exception of drugs that require injection by a 
physician or nurse."). 42 U.S.C § 1395k(a)(2)(B) (2012) (providing 
Medicare Part B coverage for "medical and other health services" rendered 
in an outpatient setting);§ 1395x(s)(2)(A) (defining the term "medical and 
other health services" to include, in relevant part, "services and supplies 
(including drugs and biologicals which are not usually self-administered by 
the patient) furnished as an incident to a physician's professional service of 
kinds which are commonly furnished in physicians' offices and ~re 
commonly either rendered without charge or included in the physicians' 
bills . . . . " (emphasis added)). 
15. § 1395k(a)(2)(I). 
16. § 1395k(a)(2)(J). 
17. § 1395k(a)(2)(0). 
18. § 1395k(a)(2)(Q). 
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use for specific patient diagnoses (i.e., hemophilia, organ failure, kidney 
disease, cancer). CMS, in turn, has required diagnosis codes on all claims 
for reimbursement of prescription drugs under Part B, whether furnished 
by a physician or self-administered by a patient.19 
The vast majority of outpatient prescription drugs taken by Medi-
care beneficiaries went uncovered by the program20 until the Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 added 
a prescription drug benefit to the Medicare program - Medicare Part 
D.21 Part D was considered at the time to be "the most significant 
change to the Medicare program since its inception in 1965."22 Unlike the 
broad "reasonable and necessary" standard for Medicare Part B reim-
bursement, the legal framework for Medicare Part D limits federal 
reimbursement of outpatient prescription drugs to "medically accepted 
indication[s]," as defined by the Medicaid statute, allowing, but not 
19. See CTRS. FOR MEDICARE & MEDICAID 8ERVS., MEDICARE CLAIMS 
PROCESSING MANUAL § 70 (2003), available at 
http://www.cms.gov/Regulations-and-
Guidance/Guidance/Manuals/Internet-Only-Manuals-IOMs-
Items/CMS018912.html (explaining an exception to the general Part B 
coverage rule that self-administered drugs, including self-administered oral 
versions of covered injectable cancer drugs, furnished to outpatients for 
therapeutic purposes are not covered by Medicare unless those drugs must 
be put directly into an item of durable medical equipment or a prosthetic 
device); Id. at § 80.1.3 ("A cancer diagnosis code must be reported when 
billing for [oral cancer drugs using] these HCPCS [Healthcare Common 
Procedure Coding System] codes. If there is no cancer diagnosis the claim 
is denied."); CTHS. FOR MEDICARE & MEDICAID SERVS., MEDICARE BENEFIT 
POLICY MANUAL§ 50.4.1 (2009) [hereinafter MEDICARE BENEFIT POLICY 
MANUAL], available at 
http://www.cms.hhs.gov/Manuals/downloads/bpl02cl5.pdf ("Use of the 
drug or biological must be safe and effective and otherwise reasonable and 
necessary ... Drugs or biologicals approved for marketing by the [FDA] 
are considered safe and effective for purposes of this requirement when 
used for indications specified on the labeling."). 
20. Some Medicare patients are able to get additional insurance through 
Medicaid, in which case Medicaid could cover the outpatient prescription 
drugs not paid for by Medicare. These patients are known as "dual eligible 
beneficiaries." MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE 
CONG.: NEW APPROACHES IN MEDICARE 71-72 (2004), available at 
http://www.medpac.gov/publications/congressional_reports/June04_ch3.p 
df. 
21. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 
Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2071-72 (2003). OIG PART D 
REIMBURSEMENT REPOHT, supra note 2, at 2 ("Since January 1, 2006, most 
outpatient prescription drugs for Medicare beneficiaries and dually eligible 
beneficiaries ... have been covered by the Medicare Part D program."). 
22. Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194, 
4197 (Jan. 28, 2005) (codified at scattered parts of 42 C.F .R.). 
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requiring, states to limit their coverage of outpatient prescription drugs 
to "medically accepted indication[s]."23 
"Medically accepted indications" include any specific indication 
listed on the drug's labeling as approved by the FDA (also known as an 
"on-label" use) or any use supported by one or more citations found in 
recognized drug compendia, including the American Hospital Formulary 
Service Drug Information (AHFS-DI), the United States Pharmacopeia-
Drug Information (USP-DI), and the DrugDEX Information System.24 In 
addition to the on-label and compendia-listed indications, Medicaid also 
allows reimbursement for any use that is supported by peer-reviewed 
medical literature,25 but medical literature alone is not enough to provide 
Part D coverage26 unless the drug is "used in an anticancer chemothera-
peutic regimen" .27 The uses supported by compendia citations or peer-
23. See 42 U.S.C. § 1396d(a)(12) (2012) (defining the Medicaid program's 
"medical assistance" coverage to include payment for "prescribed drugs"); 
§ 1396r-8(k)(2)(A)(i) (defining the Medicaid program's "covered outpatient 
drugs" to include all prescription drugs approved by the FDA); § 1396r-
8(d)(l)(B)(i) (allowing states to limit coverage of outpatient drugs to 
"medically accepted indications"); § 1396r-8(k)(6) (defining "medically 
accepted indication" for Medicaid program). See also § 1395w-102(e); 42 
C.F.R. § 423.100 (defining Medicare "Part D drug" by referring to 
Medicaid statute definition of "medically accepted indication" at 42 U.S.C. 
§ 1396r-8(k)(6) (2012)). At least one federal court has decided that the 
regulation limiting Part D coverage to "medically accepted indications" is 
not consistent with Congressional intent. Layzer v. Leavitt, 770 F. Supp. 
2d 579, 586 (S.D.N.Y. 2011). But see Kilmer v. Leavitt, 609 F. Supp. 2d 
750, 753 (S.D. Ohio 2009) ("This Court is constrained by the plain 
language of the [Part D] statutory scheme to conclude that the medically 
accepted indication clause must be read as a limitation."); Nievod v. 
Sebellius, 2013 WL 503089, at *9 (N.D. Cal. 2013) (concluding "it is clear 
from the plain terms of the statute that a covered Part D drug is one that 
comports with the medically accepted indication requirement"); Rickhoff v. 
U.S. Sec'y ex rel. Dep't of Health & Human Servs., 2012 WL 6177411, at 
*4 (D. Ariz. 2012) ("Fentanyl in lozenge form is not a 'medically accepted 
indication' for non-cancer patients and thus is not a covered Part D 
drug."). 
24. 42 U.S.C. § 1396r-8(g)(l)(B)(i) (2012). In 2008, CMS approved two 
compendia in addition to those specifically referenced in the statute: the 
National Comprehensive Cancer Network Drugs & Biologics Compendium 
and Clinical Pharmacology. Ross MCKINNEY ET AL., AGENCY FOR 
HEALTHCARE RESEARCH AND QUALITY, WHITE PAPER: POTENTIAL 
CONFLICT OF INTEREST IN THE PRODUCTION OF DRUG COMPENDIA 5 (2009), 
available at 
http://www.cms.gov/Medicare / Coverage/DeterminationProcess /downloads 
/id64TA.pdf. 
25. § 1396r-8(g)(l)(B)(ii). 
26. Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194, 
4228-29 (Jan. 28, 2005) (codified at scattered parts of 42 C.F.R.). 
27. Compare 42 U.S.C. § 1395w-102 (e)(4)(A)(i) (defining drugs used for 
oncology purposes in terms of § 1395x(t)(2)(B), which includes uses 
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reviewed medical literature include both on-label uses as well as uses 
that are not included on the FDA-approved labeling for a drug ("off-
label" uses) .28 
Despite the statutory language limiting Medicare Part D and Medi-
caid payment for drugs to "medically accepted indications," there is no 
single database within the federal health care system in which a patient's 
outpatient prescription drug use can be cross-referenced with his medical 
diagnoses. 29 The claims administrators for Medicare Part D, known as 
Part D Plan (PDP) sponsors, "do not routinely collect diagnosis infor-
mation because CMS does not require diagnoses as a data element for 
Part D claims. PDP sponsors do not collect related diagnoses for Part D 
claims from pharmacies because it is not standard practice for prescrib-
ers to provide the diagnoses. "30 As a result, there is no real time, 
resource-efficient means of determining whether an outpatient prescrip-
tion is appropriately reimbursed under Medicare Part D or Medicaid. 
As a result, current CMS policy is not to enforce the coverage stat-
utes at the time of payment (either the patient's payment for the 
prescription or the government's payment of the dispensing pharmacist) 
or to recoup mispaid funds from pharmacists or patients.31 Instead, the 
government has generally been paying for outpatient prescriptions, 
regardless of diagnosis, then trying to recoup inappropriate payments for 
outpatient prescriptions for uses other than those considered "medically 
appropriate indications," through False Claims Act suits brought against 
pharmaceutical companies by the U.S. Department of Justice and state 
attorneys general.32 If either the multi-million and -billion dollar settle-
supported by "clinical evidence in peer reviewed medical literature"), with 
§ 1396r-8(k)(6) (noting the standard for all uses unrelated to cancer, which 
does not include uses supported by "clinical evidence in peer reviewed 
medical literature"). 
28. § 1395x(t)(2)(B). See also OIG PART D REIMBURSEMENT REPORT, supra 
note 2, at 3 ("Only one compendium needs to support an off-label use for 
that use to meet the medically accepted indications requirement for 
Medicare Part D reimbursement."). 
29. Reconciling the pharmacy-generated outpatient prescription drug claim 
databases with the physician-generated office visit claim databases is 
currently time- and cost-prohibitive on a large scale. See OIG PART D 
REIMBURSEMENT REPORT, supra note 2. 
30. Id. at 5. 
31. CTRS. FOR MEDICARE & MEDICAID SERVS., supra note 9, at§ 10.6.l ("When 
it was not reasonable to expect a Part D sponsor to require prior 
authorization to ensure a drug is being used for an accepted medical 
indication, CMS would not expect the sponsor to recover payments made to 
pharmacies or attempt to obtain reimbursement from enrollees." (emphasis 
added)). 
32. In a prior article, I argued that the enforcement of the federal coverage law 
should be shifted away from the Department of Justice and state attorneys 
general to a real-time review of prescriptions at the time of payment by the 
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requiring, states to limit their coverage of outpatient prescription drugs 
to "medically accepted indication[s]."23 
"Medically accepted indications" include any specific indication 
listed on the drug's labeling as approved by the FDA (also known as an 
"on-label" use) or any use supported by one or more citations found in 
recognized drug compendia, including the American Hospital Formulary 
Service Drug Information (AHFS-DI), the United States Pharmacopeia-
Drug Information (USP-DI), and the DrugDEX Information System.24 In 
addition to the on-label and compendia-listed indications, Medicaid also 
allows reimbursement for any use that is supported by peer-reviewed 
medical literature,25 but medical literature alone is not enough to provide 
Part D coverage26 unless the drug is "used in an anticancer chemothera-
peutic regimen". 27 The uses supported by compendia citations or peer-
23. See 42 U.S.C. § 1396d(a)(12) (2012) (defining the Medicaid program's 
"medical assistance" coverage to include payment for "prescribed drugs"); 
§ 1396r-8(k)(2)(A)(i) (defining the Medicaid program's "covered outpatient 
drugs" to include all prescription drugs approved by the FDA); § 1396r-
8(d)(l)(B)(i) (allowing states to limit coverage of outpatient drugs to 
"medically accepted indications"); § 1396r-8(k)(6) (defining "medically 
accepted indication" for Medicaid program). See also§ 1395w-102(e); 42 
C.F.R. § 423.100 (defining Medicare "Part D drug" by referring to 
Medicaid statute definition of "medically accepted indication" at 42 U.S.C. 
§ 1396r-8(k)(6) (2012)). At least one federal court has decided that the 
regulation limiting Part D coverage to "medically accepted indications" is 
not consistent with Congressional intent. Layzer v. Leavitt, 770 F. Supp. 
2d 579, 586 (S.D.N.Y. 2011). But see Kilmer v. Leavitt, 609 F. Supp. 2d 
750, 753 (S.D. Ohio 2009) ("This Court is constrained by the plain 
language of the [Part DJ statutory scheme to conclude that the medically 
accepted indication clause must be read as a limitation."); Nievod v. 
Sebellius, 2013 WL 503089, at *9 (N.D. Cal. 2013) (concluding "it is clear 
from the plain terms of the statute that a covered Part D drug is one that 
comports with the medically accepted indication requirement"); Rickhoff v. 
U.S. Sec'y ex rel. Dep't of Health & Human Servs., 2012 WL 6177411, at 
*4 (D. Ariz. 2012) ("Fentanyl in lozenge form is not a 'medically accepted 
indication' for non-cancer patients and thus is not a covered Part D 
drug."). 
24. 42 U.S.C. § 1396r-8(g)(l)(B)(i) (2012). In 2008, CMS approved two 
compendia in addition to those specifically referenced in the statute: the 
National Comprehensive Cancer Network Drugs & Biologics Compendium 
and Clinical Pharmacology. Ross MCKINNEY ET AL., AGENCY FOR 
HEALTHCARE RESEARCH AND QUALITY, WHITE PAPER: POTENTIAL 
CONFLICT OF INTEREST IN THE PRODUCTION OF DRUG COMPENDIA 5 (2009), 
available at 
http://www.cms.gov/Medicare / Coverage/DeterminationProcess /downloads 
/id64TA.pdf. 
25. § 1396r-8(g)(l)(B)(ii). 
26. Medicare Program; Medicare Prescription Drug Benefit, 70 Fed. Reg. 4194, 
4228-29 (Jan. 28, 2005) (codified at scattered parts of 42 C.F.R.). 
27. Compare 42 U.S.C. § 1395w-102 (e)(4)(A)(i) (defining drugs used for 
oncology purposes in terms of § 1395x(t)(2)(B), which includes uses 
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reviewed medical literature include both on-label uses as well as uses 
that are not included on the FDA-approved labeling for a drug ("off-
label" uses) .28 
Despite the statutory language limiting Medicare Part D and Medi-
caid payment for drugs to "medically accepted indications," there is no 
single database within the federal health care system in which a patient's 
outpatient prescription drug use can be cross-referenced with his medical 
diagnoses.29 The claims administrators for Medicare Part D, known as 
Part D Plan (PDP) sponsors, "do not routinely collect diagnosis infor-
mation because CMS does not require diagnoses as a data element for 
Part D claims. PDP sponsors do not collect related diagnoses for Part D 
claims from pharmacies because it is not standard practice for prescrib-
ers to provide the diagnoses. "30 As a result, there is no real time, 
resource-efficient means of determining whether an outpatient prescrip-
tion is appropriately reimbursed under Medicare Part D or Medicaid. 
As a result, current CMS policy is not to enforce the coverage stat-
utes at the time of payment (either the patient's payment for the 
prescription or the government's payment of the dispensing pharmacist) 
or to recoup mispaid funds from pharmacists or patients.31 Instead, the 
government has generally been paying for outpatient prescriptions, 
regardless of diagnosis, then trying to recoup inappropriate payments for 
outpatient prescriptions for uses other than those considered "medically 
appropriate indications," through False Claims Act suits brought against 
pharmaceutical companies by the U.S. Department of Justice and state 
attorneys general.32 If either the multi-million and -billion dollar settle-
supported by "clinical evidence in peer reviewed medical literature"), with 
§ 1396r-8(k)(6) (noting the standard for all uses unrelated to cancer, which 
does not include uses supported by "clinical evidence in peer reviewed 
medical literature"). 
28. § 1395x(t)(2)(B). See also OIG PART D REIMBURSEMENT REPORT, supra 
note 2, at 3 ("Only one compendium needs to support an off-label use for 
that use to meet the medically accepted indications requirement for 
Medicare Part D reimbursement."). 
29. Reconciling the pharmacy-generated outpatient prescription drug claim 
databases with the physician-generated office visit claim databases is 
currently time- and cost-prohibitive on a large scale. See OIG PART D 
REIMBURSEMENT REPORT, supra note 2. 
30. Id. at 5. 
31. CTRS. FOR MEDICARE & MEDICAID SERVS., supra note 9, at§ 10.6.l ("When 
it was not reasonable to expect a Part D sponsor to require prior 
authorization to ensure a drug is being used for an accepted medical 
indication, CMS would not expect the sponsor to recover payments made to 
pharmacies or attempt to obtain reimbursement from enrollees." (emphasis 
added)). 
32. In a prior article, I argued that the enforcement of the federal coverage law 
should be shifted away from the Department of Justice and state attorneys 
general to a real-time review of prescriptions at the time of payment by the 
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ment agreements with pharmaceutical companies33 or the recent memo-
randum from the Deputy Inspector General for the U.S. Department of 
Health and Human Services finding "50 percent of Medicare Part D 
claims of Medicare Part D claims for atypical antipsychotic drugs 
received by elderly nursing home residents from January 1 through June 
30, 2007 were erroneous because the claimed drugs were not provided for 
medically accepted indications"34 are any indication of the scope of the 
overpayment by the federal government for outpatient prescriptions, the 
practical result of this policy is a significant misspending of billions of 
taxpayer dollars within the federal health care system. 
II. How STRICT ENFORCEMENT OF THE COVERAGE LAW 
WOULD UNDERMINE LONG-TERM PATIENT SAFETY BY lNCEN-
TIVIZING MISCODING FOR SHORT-TERM PATIENT BENEFIT 
While the recent multi-million and -billion dollar False Claims Act 
settlements with pharmaceutical companies and the audit findings of 
erroneously paid Part D claims mentioned above may suggest a signifi-
cant misallocation of federal health care dollars, they also point to a real 
likelihood that strict enforcement of the coverage laws at the time of 
payment would result in widespread coverage denials, perhaps on the 
scale of millions of prescriptions. Given the socioeconomic situation of 
the majority of Medicare and Medicaid beneficiaries, coverage denials 
effectively prevent patient access to the prescribed drugs despite the fact 
that the health care providers who write the prescriptions have deemed 
them to be the best treatment for their patients. When confronted with 
administrative technicalities perceived as arbitrary or harmful to their 
patients, prescribers and pharmacists may decide to tailor their diagnos-
tic coding practices for payment (and thus, effective treatment) purposes 
rather than reflecting their patients' actual diagnoses. This section looks 
at the potential disadvantages of strict enforcement of the Medicare and 
Medicaid coverage laws due to (A) the disconnect between the statutory 
definition of "medically appropriate indications" and actual medical 
practice; (B) the further uncertainty accompanying the transition from 
one diagnostic coding system to another scheduled for October 1, 2015; 
Centers for Medicare and Medicaid Services (CMS) for efficiency purposes. 
Herbst, supra note 12, at 40. 
33. See, e.g., Press Release, U.S. Dep't of Justice, Office of Public Affairs, 
GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud 
Allegations and Failure to Report Safety Data (July 2, 2012), available at 
http://www.justice.gov/ opa/pr /2012/ July /12-civ-842.html (explaining that 
GlaxoSmithKline agreed to pay $2 billion to resolve its civil liabilities with 
the federal government under the False Claims Act, as well as the states). 
34. OIG PART D REIMBURSEMENT REPORT, supra note 2. 
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and ( C) the incentives for miscoding created by coverage denials based 
upon the diagnostic information. 
A. Limitations of Labels and Compendia: An Inherent Disconnect 
between Medicine and Science 
Medicine is a professional practice focused on diagnosing and treat-
ing individual patients' diseases or injuries. The traditional goals of 
medicine include physicians' obligations to 1) prevent and diagnose 
disease or injury; 2) cure or treat the disease/injury; 3) reduce suffering 
or, if that is not possible, help patients cope with a disease or injury; 4) 
educate patients about disease/injury and prognosis; 5) help patients die 
in peace and with dignity; 6) reassure the "worried well" who do not 
have a disease/injury.35 
Just as the practice of law requires advising an actual client, the 
practice of medicine requires an actual patient. Patients are as similar to 
one another, and as different from one another, as clients are. Medical 
advice, like legal advice, is individualized.36 Science, by comparison, is 
focused "on understanding nature and the universe through human 
observation, using theories that the human mind can reason from those 
observations, and reaching conclusions that can be tested through 
further observations of the universe. "37 Science is interested in creating 
generalizable knowledge and theories of how nature and the universe 
work.38 It need not, and indeed cannot, limit itself to individual, anecdo-
tal information. And there lies the rub - while science is a critically-
important tool for informing treatment decisions, it cannot account for 
all of the individual differences that medicine must consider. Yet the 
term "medically accepted indications" is defined in terms of scientific 
35. Dan Larriviere et al., Responding to Requests from Adult Patients for 
Neuroenhancements: Guidance of the Ethics, Law, and Humanities 
Committee, 73 NEUROLOGY 1406, 1407 (2009) (citing Howard Brody & 
Franklin G. Miller, The Internal Morality of Medicine: Explication and 
Application to Managed Care, 23 J. MED. & PHIL. 384, 386-87 (1998) 
(emphasis added)). 
36. Danielle Ofri, How Creative Is Your Doctor?, N.Y. TIMES (Mar. 14, 2013), 
http://well.blogs.nytimes.com/2013/03/14/how-creative-is-your-doctor 
("Patients and diseases do not come as prepackaged widgets. A slavish 
approach to standardized treatments without any creativity can do more 
harm than good."). 
37. ROBIN FELDMAN, THE ROLE OF SCIENCE IN LAW 115-16 (2009) (emphasis 
added). 
38. MEDICARE COVERAGE ADVISORY COMM., PROCESS FOR EVALUATION OF 
EFFECTIVENESS & COMM. OPERATIONS 3 (2006), available at 
http://www.ems.gov/Regulations-and-
Guidance/ Guidance/F ACA/ downloads/recommendations.pdf ("The 
committee's definition of adequate [scientific] evidence includes both the 
validity of the evidence and its general applicability to the population of 
interest, i.e. generalizability." (emphasis added)). 
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ment agreements with pharmaceutical companies33 or the recent memo-
randum from the Deputy Inspector General for the U.S. Department of 
Health and Human Services finding "50 percent of Medicare Part D 
claims of Medicare Part D claims for atypical antipsychotic drugs 
received by elderly nursing home residents from January 1 through June 
30, 2007 were erroneous because the claimed drugs were not provided for 
medically accepted indications"34 are any indication of the scope of the 
overpayment by the federal government for outpatient prescriptions, the 
practical result of this policy is a significant misspending of billions of 
taxpayer dollars within the federal health care system. 
II. How STRICT ENFORCEMENT OF THE COVERAGE LAW 
WOULD UNDERMINE LONG-TERM PATIENT SAFETY BY lNCEN-
TIVIZING MISCODING FOR SHORT-TERM PATIENT BENEFIT 
While the recent multi-million and -billion dollar False Claims Act 
settlements with pharmaceutical companies and the audit findings of 
erroneously paid Part D claims mentioned above may suggest a signifi-
cant misallocation of federal health care dollars, they also point to a real 
likelihood that strict enforcement of the coverage laws at the time of 
payment would result in widespread coverage denials, perhaps on the 
scale of millions of prescriptions. Given the socioeconomic situation of 
the majority of Medicare and Medicaid beneficiaries, coverage denials 
effectively prevent patient access to the prescribed drugs despite the fact 
that the health care providers who write the prescriptions have deemed 
them to be the best treatment for their patients. When confronted with 
administrative technicalities perceived as arbitrary or harmful to their 
patients, prescribers and pharmacists may decide to tailor their diagnos-
tic coding practices for payment (and thus, effective treatment) purposes 
rather than reflecting their patients' actual diagnoses. This section looks 
at the potential disadvantages of strict enforcement of the Medicare and 
Medicaid coverage laws due to (A) the disconnect between the statutory 
definition of "medically appropriate indications" and actual medical 
practice; (B) the further uncertainty accompanying the transition from 
one diagnostic coding system to another scheduled for October 1 2015· 
' ' 
Centers for Medicare and Medicaid Services (CMS) for efficiency purposes. 
Herbst, supra note 12, at 40. 
33. See, e.g., Press Release, U.S. Dep't of Justice, Office of Public Affairs, 
GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud 
Allegations and Failure to Report Safety Data (July 2, 2012), available at 
http://www.justice.gov/opa/pr/2012/July/12-civ-842.html (explaining that 
GlaxoSmithKline agreed to pay $2 billion to resolve its civil liabilities with 
the federal government under the False Claims Act, as well as the states). 
34. OIG PART D REIMBURSEMENT REPORT, supra note 2. 
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and (C) the incentives for miscoding created by coverage denials based 
upon the diagnostic information. 
A. Limitations of Labels and Compendia: An Inherent Disconnect 
between Medicine and Science 
Medicine is a professional practice focused on diagnosing and treat-
ing individual patients' diseases or injuries. The traditional goals of 
medicine include physicians' obligations to 1) prevent and diagnose 
disease or injury; 2) cure or treat the disease/injury; 3) reduce suffering 
or, if that is not possible, help patients cope with a disease or injury; 4) 
educate patients about disease/injury and prognosis; 5) help patients die 
in peace and with dignity; 6) reassure the "worried well" who do not 
have a disease/injury.35 
Just as the practice of law requires advising an actual client, the 
practice of medicine requires an actual patient. Patients are as similar to 
one another, and as different from one another, as clients are. Medical 
advice, like legal advice, is individualized. 36 Science, by comparison, is 
focused "on understanding nature and the universe through human 
observation, using theories that the human mind can reason from those 
observations, and reaching conclusions that can be tested through 
further observations of the universe. "37 Science is interested in creating 
generalizable knowledge and theories of how nature and the universe 
work.38 It need not, and indeed cannot, limit itself to individual, anecdo-
tal information. And there lies the rub - while science is a critically-
important tool for informing treatment decisions, it cannot account for 
all of the individual differences that medicine must consider. Yet the 
term "medically accepted indications" is defined in terms of scientific 
35. Dan Larriviere et al., Responding to Requests from Adult Patients for 
N euroenhancements: Guidance of the Ethics, Law, and Humanities 
Committee, 73 NEUROLOGY 1406, 1407 (2009) (citing Howard Brody & 
Franklin G. Miller, The Internal Morality of Medicine: Explication and 
Application to Managed Care, 23 J. MED. & PHIL. 384, 386-87 (1998) 
(emphasis added)). 
36. Danielle Ofri, How Creative Is Your Doctor?, N.Y. TIMES (Mar. 14, 2013), 
http://well.blogs.nytimes.com/2013/03/14/how-creative-is-your-doctor 
("Patients and diseases do not come as prepackaged widgets. A slavish 
approach to standardized treatments without any creativity can do more 
harm than good."). 
37. ROBIN FELDMAN, THE ROLE OF SCIENCE IN LAW 115-16 (2009) (emphasis 
added). 
38. MEDICARE COVERAGE ADVISORY COMM., PROCESS FOR EVALUATION OF 
EFFECTIVENESS & COMM. OPERATIONS 3 (2006), available at 
http://www.cms.gov/Regulations-and-
Guidance/ Guidance/F ACA/ downloads/recommendations.pdf ("The 
committee's definition of adequate [scientific] evidence includes both the 
validity of the evidence and its general applicability to the population of 
interest, i.e. generalizability." (emphasis added)). 
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evidence - specifically the clinical trials underpinning the FDA approval 
process for prescription drugs and compendia listings. 
FDA-approved "on-label" indications are reflective of the patient 
populations and endpoints studied in clinical trials funded and designed 
by manufacturers with the FDA's review and approval.39 The compendia 
are "listing[s] of drugs ... which summarizeD evidence on the effective-
ness of each drug ... and provide0 information regarding clinical 
indications and proper dosing. "40 The compendia are not overseen or 
published by any governmental body but instead by various institutions 
and traditional reference book publishing houses,41 in different formats, 
and updated at different intervals.42 
The "evidence" summarized in the compendia need not (and, in 
many cases, does not) reflect the current or best clinical trials.43 Further, 
the generalizable knowledge summarized in the compendia is not 
available simply because of its persuasive value as scientific evidence. 
Rather, the evidence is limited to research deemed worth a manufactur-
er's (or perhaps the government's) significant financial investment in the 
research, and the resulting data is persuasive enough to pass muster with 
the multiple entities involved in compendia development.44 While the 
compendia may be the best compilations of empirical information 
currently available for purposes of making decisions about appropriate 
drug use, they are neither representative of how doctors, physician 
assistants, and nurse practitioners prescribe nor how patients respond 
outside of a controlled research setting. 45 In adopting the compendia as 
39. See generally U.S. Gov'T ACCOUNTABILITY OFFICE, NEW DRUG 
DEVELOPMENT: SCIENCE, BUSINESS, REGULATORY, AND INTELLECTUAL 
PROPERTY ISSUES CITED AS HAMPERING DRUG DEVELOPMENT EFFORTS 
(2006). 
40. MCKINNEY ET AL., supra note 24, at 3. 
41. Medicare Program; Medicare Prescription Drug Benefit, 7 4 Fed. Reg. 
61,738, 61,901-02 (Nov. 25, 2009) (codified as amended at scattered parts 
of 42 C.F.R.). 
42. OIG PART D REIMBURSEMENT REPORT, supra note 2, at 3. 
43. "It found that the compendia often did not cite the most current or best 
performed clinical trials as part of their evidence base. There were large 
variations in whether, and how quickly, off-label indications were added to 
the compendia included in the study." MCKINNEY ET AL., supra note 24, at 
4. 
44. "By definition, drug compendia include information that has major 
financial implications for drug manufacturers. Listing of a product in an 
approved compendium confers a financial advantage to industry." Id. at 6. 
"Multiple parties are affected by decisions made during the development of 
drug compendia. These parties include the public, health care providers, 
pharmaceutical companies, private insurers, com:pe11dia staff, editorial 
boards of compendia, and compendia publishers." Id. at 6-7. 
45. See Leslie L. Roos et al., Strengths and Weaknesses of Health Insurance 
Data Systems for Assessing Outcomes, in 1 INST. OF MED., MODERN 
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the standard for "medically accepted indications," Congress conflated 
science with medicine. In doing so, it disconnected outpatient prescrip-
tion drug coverage from actual medical practice and individual patients 
(who, as discussed in more detail below in Part III, may or may not be 
represented in the clinical studies informing the FDA and compendia).46 
As Robin Feldman observed, "Science begins with observations and 
theories that are rationally acceptable and well supported, which is 
something far less than certain and infallible. Ignoring these qualifica-
tions, law tries to translate science into social and legal conclusions 
without understanding the perils of that translation. "47 In the context of 
Medicare Part D and Medicaid outpatient prescription drug coverage, 
one such peril of that translation is a disconnection between medical 
practice and the so-called "medically accepted indications." This discon-
nection, in turn, provides prescribers and pharmacists reason to question 
the legitimacy of coverage denials based solely upon lack of FDA or 
compendia recognition.48 
B. Transition from ICD-9-CM to ICD-10-CM: Diagnostic Coding in a 
State of Flux 
In addition to the systemic disconnect between medical practice and 
"medically accepted indications," U.S. health care providers are in the 
midst of a transition from one diagnostic coding system to another. 
Pursuant to the Health Insurance Portability and Accountability Act of 
1996 (HIPAA)'s provisions on "Administrative Simplification," the U.S. 
health care system requires providers to use the diagnostic coding system 
of International Classification of Diseases (ICD), Clinical Modification 
(currently the ICD-9-CM, but the ICD-10-CM will go into effect on 
October 1, 2015) when submitting electronic claims for diseases, injuries, 
impairments, other health-related problems, their manifestations, and 
METHODS OF CLINICAL INVESTIGATION 47, 50-51 (Annetine C. Gelijns ed., 
1990), available at http://www.nap.edu/openbook.php?record_id=1550. 
46. See, e.g., Layzer v. Leavitt, 770 F. Supp. 2d 579, 582 (S.D.N.Y. 2011) 
(finding "the medical necessity of Cetrntide to treat [Mrs. Layzer's] ovarian 
cancer ... has been firmly established ... No other drug on the Plan's 
formulary is as effective as Cetrotide for treating [her]," but the lack of the 
compendia listing barred Medicare Part D coverage of Cetrotide for her 
cancer); Nievod v. Sebellius, 2013 WL 503089, at *4 (N.D. Cal. 2013) 
("[T]he [administrative law judge] concluded that Plaintiff 'has such a rare 
disease that it may not appear in the approved references and drug 
compendia."' (citation omitted)). 
47. FELDMAN, supra note 37, at 140 (citing SHEILA JASANOFF, SCIENCE AT THE 
BAR: LAW, SCIENCE & TECHNOLOGYIN AMERICA xiii-xiv (1995)). 
48. Here, the concept of "legitimacy" is understood to be "the belief that 
authorities, institutions, and social arrangements are appropriate, proper, 
and just." Tom R. Tyler, Psychological Perspectives on Legitimacy and 
Legitimation, 57 ANN. REV. PSYCHOL. 375, 376 (2006). 
221 
HEALTH MATRIX· VOLUME 24 · 2014 
Medicare Part D, Medicaid, E-Prescribing1 ICD-101 & Public Health 
evidence - specifically the clinical trials underpinning the FDA approval 
process for prescription drugs and compendia listings. 
FDA-approved "on-label" indications are reflective of the patient 
populations and endpoints studied in clinical trials funded and designed 
by manufacturers with the FDA's review and approval. 39 The compendia 
are "listing[s] of drugs ... which summarizeD evidence on the effective-
ness of each drug ... and provide0 information regarding clinical 
indications and proper dosing. "40 The compendia are not overseen or 
published by any governmental body but instead by various institutions 
and traditional reference book publishing houses,41 in different formats, 
and updated at different intervals.42 
The "evidence" summarized in the compendia need not (and, in 
many cases, does not) reflect the current or best clinical trials.43 Further, 
the generalizable knowledge summarized in the compendia is not 
available simply because of its persuasive value as scientific evidence. 
Rather, the evidence is limited to research deemed worth a manufactur-
er's (or perhaps the government's) significant financial investment in the 
research, and the resulting data is persuasive enough to pass muster with 
the multiple entities involved in compendia development.44 While the 
compendia may be the best compilations of empirical information 
currently available for purposes of making decisions about appropriate 
drug use, they are neither representative of how doctors, physician 
assistants, and nurse practitioners prescribe nor how patients respond 
outside of a controlled research setting.45 In adopting the compendia as 
39. See generally U.S. Gov'T ACCOUNTABILITY OFFICE, NEW DRUG 
DEVELOPMENT: SCIENCE, BUSINESS, REGULATORY, AND INTELLECTUAL 
PROPERTY ISSUES CITED AS HAMPERING DRUG DEVELOPMENT EFFORTS 
(2006). 
40. McKINNEY ET AL., supra note 24, at 3. 
41. Medicare Program; Medicare Prescription Drug Benefit, 74 Fed. Reg. 
61, 738, 61,901-02 (Nov. 25, 2009) (codified as amended at scattered parts 
of 42 C.F.R.). 
42. OIG PART D REIMBURSEMENT REPORT, supra note 2, at 3. 
43. "It found that the compendia often did not cite the most current or best 
performed clinical trials as part of their evidence base. There were large 
variations in whether, and how quickly, off-label indications were added to 
the compendia included in the study." MCKINNEY ET AL., supra note 24, at 
4. 
44. "By definition, drug compendia include information that has major 
financial implications for drug manufacturers. Listing of a product in an 
approved compendium confers a financial advantage to industry." Id. at 6. 
"Multiple parties are affected by decisions made during the development of 
drug compendia. These parties include the public, health care providers, 
pharmaceutical companies, private insurers, compe11dia staff, editorial 
boards of compendia, and compendia publishers." Id. at 6-7. 
45. See Leslie L. Roos et al., Strengths and Weaknesses of Health Insurance 
Data Systems for Assessing Outcomes, in 1 INST. OF MED., MODERN 
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the standard for "medically accepted indications," Congress conflated 
science with medicine. In doing so, it disconnected outpatient prescrip-
tion drug coverage from actual medical practice and individual patients 
(who, as discussed in more detail below in Part III, may or may not be 
represented in the clinical studies informing the FDA and compendia).46 
As Robin Feldman observed, "Science begins with observations and 
theories that are rationally acceptable and well supported, which is 
something far less than certain and infallible. Ignoring these qualifica-
tions, law tries to translate science into social and legal conclusions 
without understanding the perils of that translation. "47 In the context of 
Medicare Part D and Medicaid outpatient prescription drug coverage, 
one such peril of that translation is a disconnection between medical 
practice and the so-called "medically accepted indications." This discon-
nection, in turn, provides prescribers and pharmacists reason to question 
the legitimacy of coverage denials based solely upon lack of FDA or 
compendia recognition.48 
B. Transition from ICD-9-CM to ICD-10-CM: Diagnostic Coding in a 
State of Flux 
In addition to the systemic disconnect between medical practice and 
"medically accepted indications," U.S. health care providers are in the 
midst of a transition from one diagnostic coding system to another. 
Pursuant to the Health Insurance Portability and Accountability Act of 
1996 (HIPAA)'s provisions on "Administrative Simplification," the U.S. 
health care system requires providers to use the diagnostic coding system 
of International Classification of Diseases (ICD), Clinical Modification 
(currently the ICD-9-CM, but the ICD-10-CM will go into effect on 
October 1, 2015) when submitting electronic claims for diseases, injuries, 
impairments, other health-related problems, their manifestations, and 
METHODS OF CLINICAL INVESTIGATION 47, 50-51 (Annetine C. Gelijns ed., 
1990), available at http://www.nap.edu/openbook.php?record_id=1550. 
46. See, e.g., Layzer v. Leavitt, 770 F. Supp. 2d 579, 582 (S.D.N.Y. 2011) 
(finding "the medical necessity of Cetrotide to treat [Mrs. Layzer's] ovarian 
cancer ... has been firmly established ... No other drug on the Plan's 
formulary is as effective as Cetrotide for treating [her]," but the lack of the 
compendia listing barred Medicare Part D coverage of Cetrotide for her 
cancer); Nievod v. Sebellius, 2013 WL 503089, at *4 (N.D. Cal. 2013) 
("[T]he [administrative law judge] concluded that Plaintiff 'has such a rare 
disease that it may not appear in the approved references and drug 
compendia."' (citation omitted)). 
47. FELDMAN, supra note 37, at 140 (citing SHEILA JASANOFF, SCIENCE AT THE 
BAR: LAW, SCIENCE & TECHNOLOGYJN AMERICA xiii-xiv (1995)). 
48. Here, the concept of "legitimacy" is understood to be "the belief that 
authorities, institutions, and social arrangements are appropriate, proper, 
and just." Tom R. Tyler, Psychological Perspectives on Legitimacy and 
Legitimation, 57 ANN. REV. PSYCHOL. 375, 376 (2006). 
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causes of injury, disease, impairment, or other health-related problems.49 
The ICD was initially developed by the World Health Organization 
(WHO) as a means to classify causes of death.50 Relying heavily on the 
WHO's work, the U.S. Centers for Disease Control and Prevention 
(CDC) National Center for Health Statistics developed a clinical modifi-
cation of the classification to include morbidity (or non-fatal disease) 
purposes, the ICD-9-CM (soon to be the ICD-10-CM).51 
The ICD-10-CM is made up of approximately 70,000 diagnosis codes 
comprised of three to seven alphanumeric characters, a significant 
expansion in detail and precision from the approximately 14,500 diagno-
sis codes comprising the ICD-9-CM.52 This expansion was meant to 
address the ICD-9-CM's inability to accommodate new codes for diagno-
ses and procedures that have been added to the health care repertoire 
since its inception in 1979.53 The ICD-10-CM provides more information 
49. Protecting Access to Medicare Act of 2014, Pub. L. No. 113-93, § 212, 128 
Stat. 1040, 1047 (2014); 45 C.F.R. § 162.1002 (2012); Health Insurance 
Reform: Standards for Electronic Transactions, 65 Fed. Reg. 50,312, 50,324 
(Aug. 17, 2000) (codified as amended at 42 C.F.R. 160, 162); 
Administrative Simplification: Adoption of a Standard for a Unique Health 
Plan Identifier; Addition to the National Provider Identifier Requirements; 
and a Change to the Compliance Date for the International Classification 
of Diseases, 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data 
Code Sets, 77 Fed. Reg. 54,664 (Sept. 5, 2012). Drugs, by contrast, are 
coded pursuant to "the National Drug Codes maintained and distributed 
by the U.S. Department of Health and Human Services, in collaboration 
with drug manufacturers." Health Insurance Reform: Standards for 
Electronic Transactions, 65 Fed. Reg. 50,313, 50,324-25 (Aug. 17, 2000) 
(codified at 45 C.F.R. §§ 160, 162). 
50. "The 11th revision of the classification has already started and will 
continue until 2015." International Classification of Diseases, WORLD 
HEALTH 0RG, http://www.who.int/classifications/icd/en/ (last visited Apr. 
18, 2014). 
51. See Classifications of Diseases1 Functioning, and Disability, CTR. FOR 
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/nchs/icd.htm (last 
updated June 19, 2013). 
52. CTRS. FOR DISEASE CONTROL AND PREVENTION, DIAGNOSIS CODE SET 
GENERAL EQUIVALENCE MAPPINGS: ICD-10-CM TO ICD-9-CM AND ICD-9-
CM TO ICD-10-CM (2013), available at 
ftp://ftp.cdc.gov/pub /Health_Statistics /N CHS /Publications /ICD lOCM/2 
013 / (select guest as username, download zip file). 
53. HIP AA Administrative Simplification: Modifications to Medical Data Code 
Set Standards to Adopt ICD-10-CM and ICD-10-PCS, 74 Fed. Reg. 3328, 
3330 (Jan. 16, 2009) (to be codified at 45 C.F.R § 162). See also Anna 
Wilde Mathews, Walked into a Lamppost? Hurt While Crocheting? Help Is 
on the Way: New Medical-Billing System Provides Precision; Nine Codes 
for Macaw Mishaps, WALL ST. J. (Sept. 13, 2011), 
http://online.wsj.com/article/SB1000142405311190410340457656074274602 
1106.html ("To~ay, hospitals and doctors use a system of about 18,000 
codes to descnbe medical services in bills they send to insurers. 
Apparently, that doesn't allow for quite enough nuance. A new federally 
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and detail within the codes than ICD-9-CM, including "more detail on 
socioeconomics, ambulatory care conditions, problems related to lifestyle, 
and the results of screening tests. "54 
Even though diagnostic information is necessary for enforcement of 
the Medicare Part D and Medicaid coverage laws, the ICD-10-CM 
coding system may not be sufficient for all coverage determinations. 
While many of the codes signify a single diagnosis, some codes (known 
as "combination codes") in both the ICD-9-CM and ICD-10-CM contain 
more than one diagnosis. 55 Few, if any, prescription drugs are indicated 
for multiple, concurrent diagnoses. In addition, the ICD-10-CM codes 
may not reflect the level of diagnostic particularity reflected in either the 
on-label or compendia indications. For example, 
[E]ven if diagnosis information were available on both the prescrip-
tion and the claim, sponsors may not be able to ascertain that the 
prescribed drug was used for a medically accepted indication using 
current coding standards. For example, the drug Zelboraf (vemurafenib) 
is only on-label, on-compendia for a specific type of melanoma (BRAF 
V6003 mutation positive). The diagnosis information would not be 
detailed enough to determine whether the patient has a BRAF V6003 
mutation, as the International Classification of Diseases (ICDlO) does 
not specify that level of granularity (e.g., ICDlO for malignant melano-
ma of trunk is C43.5). Thus the medically-accepted indication in the 
compendia may rely on information below the level of coding in ICDlO. 
56 
Even with its limitations, though, the ICD coding system remains 
the diagnostic coding system for federal health care billing and the 
mandated version will expand the number to around 140,000-adding 
codes that describe precisely what bone was broken, or which artery is 
receiving a stent. It will also have a code for recording that a patient's 
injury occurred in a chicken coop. Indeed, health plans may never again 
wonder where a patient got hurt. There are codes for injuries in opera 
houses, art galleries, squash courts and nine locations in and around a 
mobile home, from the bathroom to the bedroom."). 
54. Health Insurance Reform: Modifications to the Health Insurance 
Portability and Accountability Act (HIPAA) Electronic Transaction 
Standards, 74 Fed. Reg. 3296, 3330 (Jan. 16, 2009) (codified at 45 C.F.R. § 
162). 
55. Some examples provided by the CDC include a combination code that 
includes both ((a chronic condition [and] a current acute manifestation, as 
in ICD-9 code 250.21 Diabetes with hyperosmolarity, type I (juvenile type), 
not stated as uncontrolled , .. a combination code that ... consists of two 
acute conditions found together, as in ICD-10 code R65.21 Severe sepsis 
with septic shock, or a combination code that consists of an acute condition 
and its external cause, as in I-10 code T58.01 Toxic effect of carbon 
monoxide from motor vehicle exhaust, accidental (unintentional)." CTRS. 
FOR DISEASE CONTROL AND PREVENTION' supra note 52, at 3. 
56. OIG PART D REIMBURSE.MENT REPORT, supra note 2, at 8-9. 
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causes of injury, disease, impairment, or other health-related problems.49 
The ICD was initially developed by the World Health Organization 
(WHO) as a means to classify causes of death.50 Relying heavily on the 
WHO's work, the U.S. Centers for Disease Control and Prevention 
(CDC) National Center for Health Statistics developed a clinical modifi-
cation of the classification to include morbidity (or non-fatal disease) 
purposes, the ICD-9-CM (soon to be the ICD-10-CM).51 
The ICD-10-CM is made up of approximately 70,000 diagnosis codes 
comprised of three to seven alphanumeric characters, a significant 
expansion in detail and precision from the approximately 14,500 diagno-
sis codes comprising the ICD-9-CM. 52 This expansion was meant to 
address the ICD-9-CM's inability to accommodate new codes for diagno-
ses and procedures that have been added to the health care repertoire 
since its inception in 1979.53 The ICD-10-CM provides more information 
49. Protecting Access to Medicare Act of 2014, Pub. L. No. 113-93, § 212, 128 
Stat. 1040, 1047 (2014); 45 C.F.R. § 162.1002 (2012); Health Insurance 
Reform: Standards for Electronic Transactions, 65 Fed. Reg. 50,312, 50,324 
(Aug. 17, 2000) (codified as amended at 42 C.F.R. 160, 162); 
Administrative Simplification: Adoption of a Standard for a Unique Health 
Plan Identifier; Addition to the National Provider Identifier Requirements; 
and a Change to the Compliance Date for the International Classification 
of Diseases, 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data 
Code Sets, 77 Fed. Reg. 54,664 (Sept. 5, 2012). Drugs, by contrast, are 
coded pursuant to "the National Drug Codes maintained and distributed 
by the U.S. Department of Health and Human Services, in collaboration 
with drug manufacturers." Health Insurance Reform: Standards for 
Electronic Transactions, 65 Fed. Reg. 50,313, 50,324-25 (Aug. 17, 2000) 
(codified at 45 C.F.R. §§ 160, 162). 
50. "The 11th revision of the classification has already started and will 
continue until 2015." International Classification of Diseases, WORLD 
HEALTH 0RG, http://www.who.int/classifications/icd/en/ (last visited Apr. 
18, 2014). 
51. See Classifications of Diseases, Functioning, and Disability, CTR. FOR 
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/nchs/icd.htm (last 
updated June 19, 2013). 
52. CTRS. FOR DISEASE CONTROL AND PREVENTION, DIAGNOSIS CODE SET 
GENERAL EQUIVALENCE MAPPINGS: ICD-10-CM TO ICD-9-CM AND ICD-9-
CM TO ICD-10-CM (2013), available at 
ftp://ftp.cdc.gov/ pub /Health_Statistics /N CHS /Publications /ICD lOCM/2 
013 / (select guest as username, download zip file). 
53. HIP AA Administrative Simplification: Modifications to Medical Data Code 
Set Standards to Adopt ICD-10-CM and ICD-10-PCS, 74 Fed. Reg. 3328, 
3330 (Jan. 16, 2009) (to be codified at 45 C.F.R § 162). See also Anna 
Wilde Mathews, Walked into a Lamppost? Hurl While Crocheting? Help Is 
on the Way: New Medical-Billing System Provides Precision; Nine Codes 
for Macaw Mishaps, WALL ST. J. (Sept. 13, 2011), 
http://online.wsj.com/article/SB1000142405311190410340457656074274602 
1106.html ("Today, hospitals and doctors use a system of about 18,000 
codes to describe medical services in bills they send to insurers. 
Apparently, that doesn't allow for quite enough nuance. A new federally 
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and detail within the codes than ICD-9-CM, including "more detail on 
socioeconomics, ambulatory care conditions, problems related to lifestyle, 
and the results of screening tests. "54 
Even though diagnostic information is necessary for enforcement of 
the Medicare Part D and Medicaid coverage laws, the ICD-10-CM 
coding system may not be sufficient for all coverage determinations. 
While many of the codes signify a single diagnosis, some codes (known 
as "combination codes") in both the ICD-9-CM and ICD-10-CM contain 
more than one diagnosis. 55 Few, if any, prescription drugs are indicated 
for multiple, concurrent diagnoses. In addition, the ICD-10-CM codes 
may not reflect the level of diagnostic particularity reflected in either the 
on-label or compendia indications. For example, 
[E]ven if diagnosis information were available on both the prescrip-
tion and the claim, sponsors may not be able to ascertain that the 
prescribed drug was used for a medically accepted indication using 
current coding standards. For example, the drug Zelboraf (vemurafenib) 
is only on-label, on-compendia for a specific type of melanoma (BRAF 
V6003 mutation positive). The diagnosis information would not be 
detailed enough to determine whether the patient has a BRAF V6003 
mutation, as the International Classification of Diseases (ICDlO) does 
not specify that level of granularity (e.g., ICDlO for malignant melano-
ma of trunk is C43.5). Thus the medically-accepted indication in the 
compendia may rely on information below the level of coding in ICDlO. 
56 
Even with its limitations, though, the ICD coding system remains 
the diagnostic coding system for federal health care billing and the 
mandated version will expand the number to around 140,000-adding 
codes that describe precisely what bone was broken, or which artery is 
receiving a stent. It will also have a code for recording that a patient's 
injury occurred in a chicken coop. Indeed, health plans may never again 
wonder where a patient got hurt. There are codes for injuries in opera 
houses, art galleries, squash courts and nine locations in and around a 
mobile home, from the bathroom to the bedroom."). 
54. Health Insurance Reform: Modifications to the Health Insurance 
Portability and Accountability Act (HIP AA) Electronic Transaction 
Standards, 74 Fed. Reg. 3296, 3330 (Jan. 16, 2009) (codified at 45 C.F.R. § 
162). 
55. Some examples provided by the CDC include a combination code that 
includes both "a chronic condition [and] a current acute manifestation, as 
in ICD-9 code 250.21 Diabetes with hyperosmolarity, type I (juvenile type), 
not stated as uncontrolled , .. a combination code that ... consists of two 
acute conditions found together, as in ICD-10 code R65.21 Severe sepsis 
with septic shock, or a combination code that consists of an acute condition 
and its external cause, as in I-10 code T58.01 Toxic effect of carbon 
monoxide from motor vehicle exhaust, accidental (unintentional)." CTRS. 
FOR DISEASE CONTROL AND PREVENTION, supra note 52, at 3. 
56. OIG PART D REIMBURSEMENT REPORT, supra note 2, at 8-9. 
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primary data point for determining appropriate coverage in the context 
of Medicare Part B reimbursement of prescription drugs.57 Extending use 
of ICD-10-CM to coverage determinations for Part D and Medicaid 
would be consistent with the existing Part B policy but hardly perfect in 
its ability to communicate accurately the complexity of individualized 
medical practice. 
While a number of studies have found the transition from ICD-9 to 
ICD-10 to be fairly smooth in terms of maintaining data quality,58 these 
studies have been limited to inpatient hospital systems (in Australia and 
Canada) rather than reflective of outpatient coding practices in the 
United States. The new code "represents a significant break from ICD-9-
CM, "59 and the transition to ICD-10-CM will come with a learning curve 
for prescribers and pharmacists alike. Providers in smaller (primarily 
outpatient) practice settings have been slower to adapt to the pending 
transition from ICD-9-CM to ICD-10-CM. 60 It remains to be seen 
whether the transition will go smoothly in the U.S, although a prelimi-
nary study suggests at least a third of initial ICD-10 coding in the U.S. 
will be inaccurate.61 
57. See, e.g., MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.6 
("The Medicare Prescription Drug, Improvement, and Modernization Act 
of 2003 provides coverage of intravenous immune globulin (IVIG) for the 
treatment of primary immune deficiency diseases (ICD-9 diagnosis codes 
219.04, 219.05, 219.06, 219.12, and 219.2) in the home." (emphasis 
added)). 
58. See Toni Henderson et al., Quality of Diagnosis and Procedure Coding in 
ICD-10 Administrative Data, 44 MED. CARE 1011, 1016 (2006); Rude Quan 
et al., Assessing Validity of ICD-9-CM and ICD-10 Administrative Data in 
Recording Clinical Conditions in a Unique Dually Coded Database, 43 
HEALTH SERV. RES. 1424, 1437 (2008). 
59. Steven J. Steindel, Taking ICD-10-CM in Parts, J. AM. HEALTH INFO. 
MGMT. Ass'N. (2011), http:/ /journal.ahima.org/2011/01/01/taking-icd-10-
cm-in-parts/. 
60. Administrative Simplification: Adoption of a Standard for a Unique Health 
Plan Identifier; Addition to the National Provider Identified Requirements; 
and a Change to the Compliance Date for the International Classification 
of Diseases 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data 
Code Sets, 77 Fed. Reg. 54664, 54665 (Sept. 5, 2012) (to be codified at 45 
C.F.R. 162) (citing KETCHUM INC., VERSION 5010 AND ICD-10 READINESS 
ASSESSMENT: CONDUCTED AMONG HEALTH CARE PROVIDERS, PAYER.SAND 
VENDORS FOR. THE CENTERS FOR MEDICARE & MEDICAID SERVICES (2011) 
available at 
http://www.ems.gov/Medicare/ Coding/ICD 10 /Downloads/ReadinessAsses 
smentSummary-.pdf)). 
61. HEALTHCARE INFO. AND MGMT. SYS. Soc'y & W ORKGROUP FOR ELEC. DATA 
INTERCHANGE, ICD-10 NATIONAL PILOT PROGRAM: OUTCOMES REPORT 17 
(2013), available at 
http://www.himss.org/files/HIMSSorg/Content/files/ICD-
lO_NPP _Outcomes_Report.pdf ("The average accuracy of the testing 
facility coders was 63%."). 
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As the critical data point used to determine whether a particular 
prescription is for a "medically accepted indication," any additional 
uncertainty created by the transition to ICD-10-CM will likely increase 
the perceived gap (if not the actual gap) between medical practice and 
"medically accepted indications," especially for prescribers and pharma-
cists working in smaller practices. Even so, the potential public health 
benefits of including the diagnosis codes on outpatient prescriptions 
described in Part III below outweigh the limitations of the coding or 
perceived gap, but only if strict enforcement of the coverage law is 
suspended until prescribers and pharmacists have gotten accustomed to 
and accepted the new coding system. 
C. Incentives for Prescribers and Pharmacists to Misrepresent Patient 
Diagnoses 
With the disconnect between "medical acceptance" and "scientific 
acceptance," as well as the uncertainty inherent in the transition from 
ICD-9-CM to ICD-10-CM, the use of diagnostic information for billing 
and reimbursement of outpatient prescription drugs (or denials thereof) 
may create incentives for prescribers and pharmacists to misrepresent 
patient diagnoses on prescriptions and claims for reimbursement.62 
The role of a third-party payor as the gatekeeper to treatment can 
put health care providers in an ethical dilemma where they are asked to 
choose between truth-telling (i.e., accurately describing the patient 
diagnosis and prescribed treatment when submitting bills for services 
and products) and effectively treating their patients when the effective 
treatment is not covered by the payor (i.e., when the treatment is truly 
medically accepted but still not found on the FDA-approved label or in 
the compendia).63 This dilemma exists especially for providers who treat 
patients living on limited and fixed incomes - a majority of the benefi-
ciaries of Medicare and Medicaid-where out-of-pocket payment is not a 




Peter Jaret, Mining Electronic Records for Revealing Health Data, N.Y. 
TIMES (Jan. 14, 2013), 
http://www.nytimes.com/2013/01/15/health/mining-electronic-records-for-
revealing-health-data.html ("The information entered into a medical record 
may be wrong, and diagnostic codes are notoriously unreliable, according 
to Dr. Tatonetti, partly because they are also used for billing."). 
Off-label use of drugs unsupported by strong clinical evidence is quite 
common in oncology and neuropsychiatry generally, as well as in treating 
the frail elderly, very young children, high-risk pregnant women, and 
patients with extremely rare diseases. Kesselheim, supra note 3, at 234-38. 
Pursuant to the Affordable Care Act's revisions to the Medicaid program, 
Medicaid eligibility is contingent on an annual income of less than 1333 
the federal poverty level - $15,281.70 for an individual or $31,321 for a 
family of four. See Medicaid Program: Eligibility Changes Under the 
Affordable Care Act of 2010, 77 Fed. Reg. 17,143, 17,145 (Mar. 23, 2012) 
(codified at 42 C.F.R. §§ 431, 435, 457); Annual Update of the HHS 
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primary data point for determining appropriate coverage in the context 
of Medicare Part B reimbursement of prescription drugs.57 Extending use 
of ICD-10-CM to coverage determinations for Part D and Medicaid 
would be consistent with the existing Part B policy but hardly perfect in 
its ability to communicate accurately the complexity of individualized 
medical practice. 
While a number of studies have found the transition from ICD-9 to 
ICD~lO to be fairly smooth in terms of maintaining data quality,58 these 
studies have been limited to inpatient hospital systems (in Australia and 
Canada) rather than reflective of outpatient coding practices in the 
United States. The new code "represents a significant break from ICD-9-
CM,"59 and the transition to ICD-10-CM will come with a learning curve 
for prescribers and pharmacists alike. Providers in smaller (primarily 
outpatient) practice settings have been slower to adapt to the pending 
transition from ICD-9-CM to ICD-10-CM.60 It remains to be seen 
whether the transition will go smoothly in the U.S, although a prelimi-
nary study suggests at least a third of initial ICD-10 coding in the U.S. 
will be inaccurate. 61 
57. See, e.g., MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.6 
("The Medicare Prescription Drug, Improvement, and Modernization Act 
of 2003 provides coverage of intravenous immune globulin (IVIG) for the 
treatment of primary immune deficiency diseases (ICD-9 diagnosis codes 
279.04, 279.05, 279.06, 279.12, and 279.2) in the home." (emphasis 
added)). 
58. See Toni Henderson et al., Quality of Diagnosis and Procedure Coding in 
ICD-10 Administrative Data, 44 MED. CARE 1011, 1016 (2006); Rude Quan 
et al., Assessing Validity of ICD-9-CM and ICD-10 Administrative Data in 
Recording Clinical Conditions in a Unique Dually Coded Database, 43 
HEALTH SERV. RES. 1424, 1437 (2008). 
59. Steven J. Steindel, Taking ICD-10-CM in Parts, J. AM. HEALTH INFO. 
MGMT. Ass'N. (2011), http://journal.ahima.org/2011/0l/01/taking-icd-10-
cm-in-parts/. 
60. Administrative Simplification: Adoption of a Standard for a Unique Health 
Plan Identifier; Addition to the National Provider Identified Requirements; 
and a Change to the Compliance Date for the International Classification 
of Diseases 10th Edition (ICD-10-CM and ICD-10-PCS) Medical Data 
Code Sets, 77 Fed. Reg. 54664, 54665 (Sept. 5, 2012) (to be codified at 45 
C.F.R. 162) (citing KETCHUM INC., VERSION 5010 AND ICD-10 READINESS 
ASSESSMENT: CONDUCTED AMONG HEALTH CARE PROVIDERS, PAYERS AND 
VENDORS FOR THE CENTERS FOR MEDICARE & MEDICAID SERVICES (2011) 
available at 
http://www.ems.gov/Medicare/ Coding/ICDlO /Downloads/ReadinessAsses 
smentSummary-.pdf)). 
61. HEALTHCARE INFO. AND MGMT. SYS. Soc'y & WORKGROUP FOR ELEC. DATA 
INTERCHANGE, ICD-10 NATIONAL PILOT PROGRAM: OUTCOMES REPORT 17 
(2013), available at 
http://www.himss.org/files/HIMSSorg/Content/files/ICD-
lO_NPP _Outcomes_Report.pdf ("The average accuracy of the testing 
facility coders was 633."). 
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As the critical data point used to determine whether a particular 
prescription is for a "medically_ ~ccepted indication,''. a~y ad_ditional 
uncertainty created by the trans1t10n to ICD-10-CM will likely mcrease 
the perceived gap (if not the actual gap) between medical practice and 
"medically accepted indications," especially for prescribers and pharma-
cists working in smaller practices. Even so, the potential public health 
benefits of including the diagnosis codes on outpatient prescriptions 
described in Part III below outweigh the limitations of the coding or 
perceived gap, but only if strict enforcement of the coverage law is 
suspended until prescribers and pharmacists have gotten accustomed to 
and accepted the new coding system. 
C. Incentives for Prescribers and Pharmacists to Misrepresent Patient 
Diagnoses 
With the disconnect between "medical acceptance" and "scientific 
acceptance," as well as the uncertainty inherent in the transition from 
ICD-9-CM to ICD-10-CM, the use of diagnostic information for billing 
and reimbursement of outpatient prescription drugs (or denials thereof) 
may create incentives for prescribers and pharmacists to misrepresent 
patient diagnoses on prescriptions and claims for reimbursement.62 
The role of a third-party payor as the gatekeeper to treatment can 
put health care providers in an ethical dilemma where they are asked to 
choose between truth-telling (i.e., accurately describing the patient 
diagnosis and prescribed treatment when submitting bills for services 
and products) and effectively treating their patients when the effective 
treatment is not covered by the payor (i.e., when the treatment is truly 
medically accepted but still not found on the FDA-approved label or in 
the compendia).63 This dilemma exists especially for providers who treat 
patients living on limited and fixed incomes - a majority of the benefi-
ciaries of Medicare and Medicaid - where out-of-pocket payment is not a 




Peter Jaret, Mining Electronic Records for Revealing Health Data, N.Y. 
TIMES (Jan. 14, 2013), 
http://www.nytimes.com/2013/01/15/health/mining-electronic-records-for-
revealing-health-data.html ("The information entered into a medical record 
may be wrong, and diagnostic codes are notoriously unreliable, according 
to Dr. Tatonetti, partly because they are also used for billing."). 
Off-label use of drugs unsupported by strong clinical evidence is quite 
common in oncology and neuropsychiatry generally, as well as in treating 
the frail elderly, very young children, high-risk pregnant women, and 
patients with extremely rare diseases. Kesselheim, supra note 3, at 234-38. 
Pursuant to the Affordable Care Act's revisions to the Medicaid program, 
Medicaid eligibility is contingent on an annual income of less than 1333 
the federal poverty level - $15,281. 70 for an individual or $31,321 for a 
family of four. See Medicaid Program: Eligibility Changes Under the 
Affordable Care Act of 2010, 77 Fed. Reg. 17,143, 17,145 (Mar. 23, 2012) 
(codified at 42 C.F.R. §§ 431, 435, 457); Annual Update of the HHS 
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statute (and many states' Medicaid statutes) would significantly limit 
outpatient prescription drug coverage for the many medically accepted 
uses with little scientific evidence to support them. As a result, many 
patients would no longer be able to access their prescribed medications; 
that is, unless their prescribers or pharmacists decided that the patients' 
best interests were served by using inaccurate, but otherwise covered, 
diagnoses on prescriptions and claims. There are a number of character-
istics of a strict enforcement policy that would make diagnostic 
miscoding more justifiable for prescribers and pharmacists concerned 
about patients' inability to access the most effective treatment. 
First, the most likely immediate outcome of miscoding (as seen from 
the prescriber or pharmacist's perspective) would be better, or at least 
sustained, patient health - a favorable outcome. Decisions resulting in 
favorable outcomes are more likely to be judged as good than those with 
poor outcomes (such as a decline in patient health due to lack of 
treatment). 65 Second, the people most likely to be harmed by accurately 
reporting diagnoses under a strictly enforced Medicare Part D coverage 
law (again, from the prescriber and pharmacist's perspective) will be the 
patients denied treatment - identifiable victims. Identifiable victims are 
more likely to create an empathic response on the part of prescribers and 
pharmacists than the "statistical victims" of miscoding - the taxpayers 
or beneficiaries of other governmental programs denied funding due to 
rising health care costs. 66 Third, coverage denials, especially where a 
Poverty Guidelines, 78 Fed. Reg. 5182, 5183 (Jan. 24, 2013). Likewise, the 
majority of Medicare beneficiaries live on modest incomes, with a median 
annual income of $22,800. JULIETTE CUBANSKI ET AL., KAISER FAMILY 
FOUND., MEDICARE CHARTBOOK 15 (4th ed. 2010), available at 
http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8103.pdf. 
65. When evaluating decisions, a "bad outcome" (the visible result of a 
decision) as a result of a particular decision, such as a decline in health, is 
often attributed to "bad decision making." See Jonathan Baron & John C. 
Hershey, Outcome Bias in Decision Evaluation, 54 J. PERSONALITY AND 
Soc. PSYCHOL. 569, 569-70 (1988). Similarly, to the extent that good 
outcomes are perceived as the result of good decision making and a good 
health outcome is understood to be dependent on a particular treatment, a 
deCision to ensure access to the treatment will likely be considered "good." 
Id. at 569. See also Francesca Gino et al., Nameless + Harmless = 
Blameless: When Seemingly Irrelevant Factors Influence Judgment of 
(Un)ethical Behavior, 111 0RG. BEHAV. & HUM. DECISION PROCESSES 93 
96 (2010) (noting people tend to judge behavior as more unethical whe~ 
the behavior leads to a negative rather than positive outcome). 
66. The most important factor in the disparate treatment between identifiable 
and statistical victims appears to be the perception that a high proportion 
of the identifiable victims "can be saved," as compared to the uncertainty 
of "saving" the unknown number of adversely affected taxpayers or 
beneficiaries of other government programs denied funding. Karen E. Jenni 
& George Lowenstein, Explaining the "Identifiable Victim Effect," 14 J. 
RISK & UNCERTAINTY 235, 254 (1997). See also Gino et al., supra note 65, 
at 96 (noting that people tend to judge behavior as more unethical when 
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treatment was previously paid for (albeit in contravention of the 
coverage law), are inherently perceived as losses to patients and provid-
ers, increasing the likelihood of misrepresentation by providers as a 
means of avoiding the loss.67 Lastly, rationalizations for miscoding are 
especially likely where prescribers and pharmacists see their misrepresen-
tations as beneficial for their patients who, but for their financial 
circumstances, would be able to access the treatment. 68 Prescribers and 
pharmacists will need to see denials of coverage as legitimate or else the 
perceived illegitimacy of the denials may justify misrepresentation of 
diagnostic information in order to secure federal payment for patients 
otherwise unable to pay for their prescriptions.69 
As a result, a federal health care system in which truthful reporting 
of diagnostic information results in a loss of coverage, and accordingly a 
loss of treatment, would likely encourage prescribers and pharmacists to 
identifiable vs. unidentifiable victims are involved). The identifiable victim 
effect may be counteracted, however, where the individual is perceived to 
be responsible for her situation and thus no longer a "victim." Deborah A. 
Small & George A. Lowenstein, Helping a Victim or Helping the Victim: 
Altruism and Identifiability, 26 J. RISK & UNCERTAINTY 5, 14 (2003). 
67. A feeling of falling short of one's potential success, as doctors, physician 
assistants, and nurses may have when their patients' health declines due to 
a perceived arbitrary coverage determination, can motivate cheating. 
Jessica S. Cameron & Dale T. Miller, Ethical Standards in Gain Versus 
Loss Frames, in PSYCHOLOGICAL PERSPECTIVES ON ETHICAL BEHAVIOR AND 
DECISION MAKING 91, 100 (David De Cremer ed., 2009). Similarly, cheating 
may also be prompted by the frustration felt when "honest effort" will not 
achieve what is perceived to be "deserved." Id. 
68. "[P]eople tend to discount the wrongness of dishonest actions when those 
actions restore equity than when they do not." Francesca Gino & Lamar 
Pierce, Lying to Level the Playing Field: Why People May Dishonestly Help 
or Hurt Others to Create Equity, 95 J. Bus. ETHICS 89, 100 (2011). In the 
case where the actor perceives herself to be better situated than another 
person (likely a common situation for prescribers and pharmacists treating 
Medicare and Medicaid patients), she often experiences guilt, which in turn 
motivates her to act dishonestly to help the other person. Id. at 92. See 
also Francesca Gino & Lamar Pierce, Robin Hood Under the Hood: 
Wealth-Based Discrimination in fllicit Customer Help, 21 0RG. SCI. 1176, 
1176 (2010); Francesca Gino & Lamar Pierce, Dishonesty in the Name of 
Equity, 20 PSYCHOL. SCI. 1153, 1159 (2009). 
69. Tyler, supra note 48, at 379 ("Consistent with the longstanding arguments 
of legitimacy theories, recent studies suggest that having legitimacy 
facilitates the ability to gain decision acceptance and to promote rule-
following. "). See also Am. Med. Ass'n, Code of Med. Ethics, Op. 1.02 -
The Relation of Law and Ethics (1994), available at http://www.ama-
assn.org/ ama/ pub/ physician-resources/ medical-ethics/ code-medical-
ethics. page ("In some cases, the law mandates unethical conduct. In 
general, when physicians believe a law is unjust, they should work to 
change the law. In exceptional circumstances of unjust laws, ethical 
responsibilities should supersede legal obligations."). 
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statute (and many states' Medicaid statutes) would significantly limit 
outpatient prescription drug coverage for the many medically accepted 
uses with little scientific evidence to support them. As a result, many 
patients would no longer be able to access their prescribed medications; 
that is, unless their prescribers or pharmacists decided that the patients' 
best interests were served by using inaccurate, but otherwise covered, 
diagnoses on prescriptions and claims. There are a number of character-
istics of a strict enforcement policy that would make diagnostic 
miscoding more justifiable for prescribers and pharmacists concerned 
about patients' inability to access the most effective treatment. 
First, the most likely immediate outcome of miscoding (as seen from 
the prescriber or pharmacist's perspective) would be better, or at least 
sustained, patient health - a favorable outcome. Decisions resulting in 
favorable outcomes are more likely to be judged as good than those with 
poor outcomes (such as a decline in patient health due to lack of 
treatment). 65 Second, the people most likely to be harmed by accurately 
reporting diagnoses under a strictly enforced Medicare Part D coverage 
law (again, from the prescriber and pharmacist's perspective) will be the 
patients denied treatment - identifiable victims. Identifiable victims are 
more likely to create an empathic response on the part of prescribers and 
pharmacists than the "statistical victims" of miscoding - the taxpayers 
or beneficiaries of other governmental programs denied funding due to 
rising health care costs.66 Third, coverage denials, especially where a 
Poverty Guidelines, 78 Fed. Reg. 5182, 5183 (Jan. 24, 2013). Likewise, the 
majority of Medicare beneficiaries live on modest incomes, with a median 
annual income of $22,800. JULIETTE CUBANSKI ET AL., KAISER FAMILY 
FOUND., MEDICARE CHARTBOOK 15 (4th ed. 2010), available at 
http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8103.pdf. 
65. When evaluating decisions, a "bad outcome" (the visible result of a 
decision) as a result of a particular decision, such as a decline in health, is 
often attributed to "bad decision making." See Jonathan Baron & John C. 
Hershey, Outcome Bias in Decision Evaluation, 54 J. PERSONALITY AND 
Soc. PSYCHOL. 569, 569-70 (1988). Similarly, to the extent that good 
outcomes. are perceived as the result of good decision making and a good 
health outcome is understood to be dependent on a particular treatment, a 
dedsion to ensure access to the treatment will likely be considered "good." 
Id. at 569. See also Francesca Gino et al., Nameless + Harmless = 
Blameless: When Seemingly Irrelevant Factors Influence Judgment of 
(Un)ethical Behavior, 111 0RG. BEHAV. & HUM. DECISION PROCESSES 93 
96 (2010) (noting people tend to judge behavior as more unethical whe~ 
the behavior leads to a negative rather than positive outcome). 
66. The most important factor in the disparate treatment between identifiable 
and statistical victims appears to be the perception that a high proportion 
of the identifiable victims "can be saved," as compared to the uncertainty 
of "saving" the unknown number of adversely affected taxpayers or 
beneficiaries of other government programs denied funding. Karen E. Jenni 
& George Lowenstein, Explaining the "Identifiable Victim Effect," 14 J. 
RISK & UNCERTAINTY 235, 254 (1997). See also Gino et al., supra note 65, 
at 96 (noting that people tend to judge behavior as more unethical when 
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treatment was previously paid for (albeit in contravention of the 
coverage law), are inherently perceived as losses to patients and provid-
ers, increasing the likelihood of misrepresentation by providers as a 
means of avoiding the loss.67 Lastly, rationalizations for miscoding are 
especially likely where prescribers and pharmacists see their misrepresen-
tations as beneficial for their patients who, but for their financial 
circumstances, would be able to access the treatment. 68 Prescribers and 
pharmacists will need to see denials of coverage as legitimate or else the 
perceived illegitimacy of the denials may justify misrepresentation of 
diagnostic information in order to secure federal payment for patients 
otherwise unable to pay for their prescriptions.69 
As a result, a federal health care system in which truthful reporting 
of diagnostic information results in a loss of coverage, and accordingly a 
loss of treatment, would likely encourage prescribers and pharmacists to 
identifiable vs. unidentifiable victims are involved). The identifiable victim 
effect may be counteracted, however, where the individual is perceived to 
be responsible for her situation and thus no longer a "victim." Deborah A. 
Small & George A. Lowenstein, Helping a Victim or Helping the Victim: 
Altruism and Identifiability, 26 J. RISK & UNCERTAINTY 5, 14 (2003). 
67. A feeling of falling short of one's potential success, as doctors, physician 
assistants, and nurses may have when their patients' health declines due to 
a perceived arbitrary coverage determination, can motivate cheating. 
Jessica S. Cameron & Dale T. Miller, Ethical Standards in Gain Versus 
Loss Frames, in PSYCHOLOGICAL PERSPECTIVES ON ETHICAL BEHAVIOR AND 
DECISION MAKING 91, 100 (David De Cremer ed., 2009). Similarly, cheating 
may also be prompted by the frustration felt when "honest effort" will not 
achieve what is perceived to be "deserved." Id. 
68. "[P]eople tend to discount the wrongness of dishonest actions when those 
actions restore equity than when they do not." Francesca Gino & Lamar 
Pierce, Lying to Level the Playing Field: Why People May Dishonestly Help 
or Hurt Others to Create Equity, 95 J. Bus. ETHICS 89, 100 (2011). In the 
case where the actor perceives herself to be better situated than another 
person (likely a common situation for prescribers and pharmacists treating 
Medicare and Medicaid patients), she often experiences guilt, which in turn 
motivates her to act dishonestly to help the other person. Id. at 92. See 
also Francesca Gino & Lamar Pierce, Robin Hood Under the Hood: 
Wealth-Based Discrimination in fllicit Customer Help, 21 ORG. Sc1. 1176, 
1176 (2010); Francesca Gino & Lamar Pierce, Dishonesty in the Name of 
Equity, 20 PSYCHOL. Ser. 1153, 1159 (2009). 
69. Tyler, supra note 48, at 379 ("Consistent with the longstanding arguments 
of legitimacy theories, recent studies suggest that having legitimacy 
facilitates the ability to gain decision acceptance and to promote rule-
following. "). See also Am. Med. Ass'n, Code of Med. Ethics, Op. 1.02 -
The Relation of Law and Ethics (1994), available at http://www.ama-
assn.org/ ama/ pub /physician-resources/ medical-ethics/ code-medical-
ethics. page ("In some cases, the law mandates unethical conduct. In 
general, when physicians believe a law is unjust, they should work to 
change the law. In exceptional circumstances of unjust laws, ethical 
responsibilities should supersede legal obligations."). 
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tailor diagnoses for payment purposes rather than treatment purposes or 
at least make justification of miscoding easier for individual prescribers 
or pharmacists. Systemic miscoding would, in turn, significantly under-
mine the public safety benefits potentially gained through the more 
thorough pharmacist review of outpatient prescriptions for medication 
errors and increased drug safety surveillance efforts described in Part III. 
III. How INCREMENTAL IMPLEMENTATION OF THE LAW 
WOULD SUPPORT BOTH PATIENT SAFETY AND BETTER 
MANAGEMENT OF FEDERAL HEALTH CARE FUNDS 
Instead of relying, as suggested by CMS Administrator Donald Ber-
wick, primarily on prior authorization strategies for drugs that are at 
high risk for prescription without a medically accepted indication (or the 
nearly impossible retrospective review), 70 I propose that CMS require 
submission of ICD-10-CM codes for reimbursement of outpatient 
prescription drug claims, but limit the current use of those codes for 
pharmacist prescription review, not coverage denials. In doing so, CMS 
would encourage more thorough real-time pharmacist review of prescrip-
tions for patient safety purposes as well as truthful reporting of 
diagnostic and prescribing habits for future pharmacosurveillance and 
comparative effectiveness efforts. 71 
A. Role of Diagnosis in Pharmacists' Standard of Care 
With the increasingly commercial nature of drug store chains and 
grocery store pharmacy counters in the second half of the twentieth 
century, pharmacists are often misunderstood to be glorified sales clerks 
who merely count pills, but that understanding is simply not accurate. 72 
70. OIG PART D REIMBURSEMENT REPORT, supra note 2, at 9. 
71. By reframing the goal of accurate diagnostic coding from a mere billing 
necessity to a critical step in preventing medication errors (a negative 
outcome that can be avoided), this subtle change may significantly 
influence truthful prescriber and pharmacist reporting behavior. Francesca 
Gino & Joshua D. Margolis, Bringing Ethics Into Focus: How Regulatory 
Focus and Risk Preferences Influence (Un)ethical Behavior, 115 ORG. 
BEHAV. & HUM. DECISION PROCESSES 145, 154 (2011). 
72. Anonymous v. CVS Corp., 728 N.Y.S.2d 333, 337 (N.Y. Sup. Ct. 2001) 
("Unlike in a traditional commercial transaction, pharmacists are required 
to collect otherwise confidential medical information, and are obligated to 
review that information before each prescription is dispensed." (citations 
omitted)). Horner v. Spalitto, 1 S.W.3d 519, 524 (Mo. Ct. App. 1999) 
("We agree that a physician typically is in a superior position to judge the 
propriety of a particular patient's drug regimen, but this should not 
relegate the pharmacist to the role of being merely an order filler."); Jones 
v. Irvin, 602 F. Supp. 399, 400 (S.D. Ill. 1985) (citations omitted) (noting 
"a pharmacist is not strictly liable under a products liability theory since 
he is not a retailer"). 
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Historically, the practice of pharmacy was limited to the making 
(through a practice called compoun~i~g) and_ dispensing _of drugs V:ith 
prescribers solely responsible for adv1smg patients on their appropriate 
use.73 More recently, pharmacists have become, and continue to be, 
recognized as highly educated, licensed professionals entrusted with 
evaluating confidential patient information in order to dispense medica-
tions with both great treatment potential and great (even fatal) risk if 
misused.74 
The practice of pharmacy, like the practices of medicine, nursing, 
and law, is primarily governed by state law and includes not only 
dispensing drugs and custom compounding medications for patients 
contraindicated for commercially prepared products, but also consulting 
(with both patients and prescribers) about the contents, therapeutic 
values, interactions, and uses of any prescription drug; the review and 
monitoring of a patient's drug therapy regimen; assisting the patient in 
managing his or her drug therapy; and communicating with the patient's 
prescribing health care provider in the event that the pharmacist or 
patient has a question about a treatment regimen. 75 Indeed, the increas-
73. RICHARD R. ABOOD, PHARMACY PRACTICE AND THE LAW 324 (Jack 
Bruggeman et al. eds., 4th ed. 2005). 
74. Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1123 (Ill. 2002) 
(quoting Kirby v. Gen. Paving Co., 229 N.E.2d 777, 779 (Ill. App. Ct. 
1967)) ("A duty to warn exists where there is unequal knowledge, actual or 
constructive [of a dangerous condition], and the defendant[,] possessed of 
such knowledge, knows or should know that harm might or could occur if 
no warning is given."); Anonymous, 728 N .Y.S.2d at 338 (citing Lutz v. 
Houck, 188 N.E. 274 (N.Y. 1933)) ("While the role of a pharmacist may 
not equal that of a physician treating a patient, surely access and the right 
to collect private medical information on one's customers does not make a 
pharmacist merely 'the dispenser of a commercial product."'); Morgan v. 
Wal-Mart Stores, Inc., 30 S.W.3d 455, 469 (Tex. Ct. App. 2000) ("[T]he 
pharmacist's role has changed in the last few decades from a mere 
dispenser of medication to a trusted professional who plays a vital role in 
patient treatment."); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa. 
Super. Ct. 1986) (rejecting the argument that a pharmacy is strictly a 
warehouse of drugs and that a pharmacist should unquestionably obey the 
written orders of physicians). 
75. The following state statutes define "practice of pharmacy," "practice of the 
profession of pharmacy," and/or the scope of the practice of pharmacy. 
ARIZ. REV. STAT. ANN. § 32-1901(69) (2012); ARK. CODE ANN. § 17-92-
101(16)(A) (West 2012); CAL. Bus. & PROF. CODE § 4052 (West 2013); 
CONN. GEN. STAT. § 20-571(21) (2012); COLO. REV. STAT. ANN. § 12-42.5-
102(31) (West 2012); DEL. CODE ANN. tit. 24, § 2502(19) (2012); D.C. CODE 
§ 3-1201.02(11)(A) (2012); FLA. STAT. ANN. § 465.003(13) (2012); GA. 
CODE ANN. § 26-4-4 (2012); HAW. REV. STAT.§ 461-1 (2012); IDAHO CODE 
ANN.§ 54-1704 (2012) (as amended by 2013 Idaho Laws Ch. 28 (H.B. 17), 
2013 Idaho Laws Ch. 28 (H.B. 17)); 225 ILL. COMP. STAT. ANN. 85/3(d) 
(2012); IND. CODE ANN. § 25-26-13-2 (West 2010 & Supp. 2012); IOWA 
CODE ANN. § 155A.3(34) (West 2005 & Supp. 2013); KAN. STAT. ANN. § 
65-1626a(b) (2002); KY. REV. STAT. ANN. § 315.010(19) (2011); LA. REV. 
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tailor diagnoses for payment purposes rather than treatment purposes or 
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Instead of relying, as suggested by CMS Administrator Donald Ber-
wick, primarily on prior authorization strategies for drugs that are at 
high risk for prescription without a medically accepted indication (or the 
nearly impossible retrospective review), 70 I propose that CMS require 
submission of ICD-10-CM codes for reimbursement of outpatient 
prescription drug claims, but limit the current use of those codes for 
pharmacist prescription review, not coverage denials. In doing so, CMS 
would encourage more thorough real-time pharmacist review of prescrip-
tions for patient safety purposes as well as truthful reporting of 
diagnostic and prescribing habits for future pharmacosurveillance and 
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necessity to a critical step in preventing medication errors (a negative 
outcome that can be avoided), this subtle change may significantly 
influence truthful prescriber and pharmacist reporting behavior. Francesca 
Gino & Joshua D. Margolis, Bringing Ethics Into Focus: How Regulatory 
Focus and Risk Preferences Influence (Un)ethical Behavior, 115 ORG. 
BEHAV. & HUM. DECISION PROCESSES 145, 154 (2011). 
72. Anonymous v. CVS Corp., 728 N.Y.S.2d 333, 337 (N.Y. Sup. Ct. 2001) 
("Unlike in a traditional commercial transaction, pharmacists are required 
to collect otherwise confidential medical information, and are obligated to 
review that information before each prescription is dispensed." (citations 
omitted)). Horner v. Spalitto, 1 S.W.3d 519, 524 (Mo. Ct. App. 1999) 
("We agree that a physician typically is in a superior position to judge the 
propriety of a particular patient's drug regimen, but this should not 
relegate the pharmacist to the role of being merely an order filler."); Jones 
v. Irvin, 602 F. Supp. 399, 400 (S.D. Ill. 1985) (citations omitted) (noting 
"a pharmacist is not strictly liable under a products liability theory since 
he is not a retailer"). 
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contraindicated for commercially prepared products, but also consulting 
(with both patients and prescribers) about the contents, therapeutic 
values, interactions, and uses of any prescription drug; the review and 
monitoring of a patient's drug therapy regimen; assisting the patient in 
managing his or her drug therapy; and communicating with the patient's 
prescribing health care provider in the event that the pharmacist or 
patient has a question about a treatment regimen.75 Indeed, the increas-
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constructive [of a dangerous condition], and the defendant[,] possessed of 
such knowledge, knows or should know that harm might or could occur if 
no warning is given."); Anonymous, 728 N.Y.S.2d at 338 (citing Lutz v. 
Houck, 188 N.E. 274 (N.Y. 1933)) ("While the role of a pharmacist may 
not equal that of a physician treating a patient, surely access and the right 
to collect private medical information on one's customers does not make a 
pharmacist merely 'the dispenser of a commercial product.'"); Morgan v. 
Wal-Mart Stores, Inc., 30 S.W.3d 455, 469 (Tex. Ct. App. 2000) ("[T]he 
pharmacist's role has changed in the last few decades from a mere 
dispenser of medication to a trusted professional who plays a vital role in 
patient treatment."); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1251 (Pa. 
Super. Ct. 1986) (rejecting the argument that a pharmacy is strictly a 
warehouse of drugs and that a pharmacist should unquestionably obey the 
written orders of physicians). 
75. The following state statutes define "practice of pharmacy," "practice of the 
profession of pharmacy," and/or the scope of the practice of pharmacy. 
ARIZ. REV. STAT. ANN. § 32-1901(69) (2012); ARK. CODE ANN. § 17-92-
101(16)(A) (West 2012); CAL. Bus. & PR.OF. CODE § 4052 (West 2013); 
CONN. GEN. STAT. § 20-571(21) (2012); COLO. REV. STAT. ANN. § 12-42.5-
102(31) (West 2012); DEL. CODE ANN. tit. 24, § 2502(19) (2012); D.C. CODE 
§ 3-1201.02(11)(A) (2012); FLA. STAT. ANN. § 465.003(13) (2012); GA. 
CODE ANN. § 26-4-4 (2012); HAW. REV. STAT.§ 461-1 (2012); IDAHO CODE 
ANN.§ 54-1704 (2012) (as amended by 2013 Idaho Laws Ch. 28 (H.B. 17), 
2013 Idaho Laws Ch. 28 (H.B. 17)); 225 ILL. COMP. STAT. ANN. 85/3(d) 
(2012); IND. CODE ANN. § 25-26-13-2 (West 2010 & Supp. 2012); IOWA 
CODE ANN. § 155A.3(34) (West 2005 & Supp. 2013); KAN. STAT. ANN. § 
65-1626a(b) (2002); KY. REV. STAT. ANN. § 315.010(19) (2011); LA. REV. 
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ing reliance on prescription drugs, and increasing number of prescription 
drugs available for use has led many pharmacists to play a greater role 
in coordinating drug therapy for patients than ever before. 
In addition to the state laws regulating the practice of pharmacy, 
federal law has relied heavily on pharmacists' professional standards in 
structuring the federal health care delivery system (specifically in the 
l~ws governing both Medicaid76 and Medicare77) and regulation of drugs 
(m the context of the federal Food, Drug and Cosmetic Act (FDCA)7s 
STAT. ANN. § 37:1164(41) (2007); ME. REV. STAT. tit. 32, § 13702-A (28) 
(2012); MD. CODE ANN., HEALTH Occ. § 12-lOl(t)(l) (Supp. 2012); MICH. 
COMP. LAWS ANN. § 333.17707(5) (West 2008); MINN. STAT. ANN. § 
151.01(27) (West 2011 & Supp. 2013); Mrss. CODE ANN. § 73-21-73(bb) 
(2012); Mo. ANN. STAT. § 338.010(1) (2012); 2013 Montana Laws 220 
(codified with some differences in language at MONT. CODE ANN. § 37-7-
101(34) (2012)); NEB. REV. STAT. § 38-2837(1) (2012); NEV. REV. STAT. 
ANN. § 639.0124 (West 2012); N.H. REV. STAT. ANN.§ 318:1(XIV) (2013); 
N.J. REV. STAT.§ 45:14-41 (2013); N.M. STAT. ANN. § 61-ll-2(BB) (2012); 
N.Y. EDUC. LAW § 6801(1) (2012); N.C. GEN. STAT. ANN. § 90-85.3(r) 
(2012); N.D. CENT. CODE ANN. § 43-15-01(24) (2012); Omo REV. CODE 
ANN.§ 4729.0l(B) (LexisNexis 2012); OKLA. STAT. ANN. tit. 59, § 353.1(28) 
(West 2012); OR. REV. STAT. § 689.005(28) (2012); 63 PA. STAT. ANN.§ 
390-2(11) (West 2012); R.I. GEN. LAWS § 5-19.1-2 (2009 & Supp. 2012); 
S.C. CODE ANN. § 40-43-30(44) (2012); S.D. CODIFIED LAWS § 36-11-2.2 
(2012); TENN. CODE ANN. § 63-10-204(35)(A) (2010 & Supp. 2012); TEX. 
Occ. CODE ANN. § 551.003(33) (West 2012); UTAH CODE ANN. § 58-17b-
102(54) (LexisNexis 2012 & Supp. 2013); VT. STAT. ANN. tit. 26, § 2022(14) 
(2012); VA. CODE ANN.§ 54.1-3300 (West 2012); WASH. REV. CODE ANN.§ 
18.64.011(23) (2012); W. VA. CODE ANN.§ 30-5-3 (2012) (amended 2013); 
Wrs. STAT. ANN.§ 450.01(16) (2012); WYO. STAT. ANN.§ 33-24-124 (2012). 
76. See,. e.g., 42 U.~·~· § 1396r-8(g)(2)(A)(ii) (2012) (conditioning federal 
fund~n~ for Med~ca~d on states' establishing standards for counseling of 
Medicaid beneficianes by pharmacists). 
77. See, e.g., 42_ U.S.C. § 1395w-104(c)(2)(C)(i) (2012) (requiring "an annual 
~omp:ehensive medication review" for each Medicare Part D beneficiary 
.furmshed perso~-to-person or using telehealth technologies . . . by a 
licensed pharmacist or other qualified provider"). 
78. The entire prescription drug regulatory system dating back to the Food 
D:ug and Co~metic Act of 1938 depends squarely on pharmacists t~ 
withhold certam products until receipt of a valid prescription. 21 U.S.C. § 
353 (2012). See also PETER BARTON HUTT ET AL., FOOD & DRUG LAW 490 
(3d ed: 2007) ("[This section of the FDCA] relies upon state law to 
determme what professional training is required for licensure to administer 
prescription drugs."). More recently, however, the Food and Drug 
Amend~ents Act of 2007 (FDAAA) also contemplates pharmacists' 
~derl?omg product-specific certification and further limiting dispensing of 
high-nsk products only in response to a valid prescription plus "evidence or 
other documentation of safe-use conditions, such as laboratory test 
results," or checking a product-specific registry as part of the Risk 
Evaluation and Mitigation Strategies (REMS) system created by FDAAA. 
Food&: Drug Amendments Act of 2007, 21U.S.C.§355-l(f)(3) (2012). See 
also Dima M. Qato & G. Caleb Alexander, Improving the Food and Drug 
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and Controlled Substances Act). 79 To the extent that state laws govern-
ing the practice of pharmacy are not as rigorous as the federal 
expectations, the federal statutes have created both regulatory and 
statutory consequences for pharmacists who fall short of the federal 
standards.80 
Despite the myriad state and federal laws governing the pharmacist-
patient relationship, pharmacists have never had a general duty to warn 
patients about the risks associated with prescription drugs; this duty to 
warn has traditionally fallen instead into the realm of medicine (and 
more recently nursing) than pharmacy. Like all professionals, though, 
pharmacists are responsible for exercising due care in the course of their 
practice. As explained below, adding diagnosis codes to prescriptions 
would not affect the existing boundaries between the practices of 
medicine, nursing, and pharmacy, but would likely increase the level of 
care expected of pharmacists. 
1. The Duty to W am Patients about Risks Generally Associated with 
Prescription Drugs Would Remain with Prescribers, Not Pharmacists 
State courts have traditionally, and quite consistently, held that a 
pharmacist has no general duty to warn a customer of the risk of harm 
that might be encountered from drugs which are accurately dispensed 




Administration's Mandate to Ensure Postmarketing Drug Safety, 306 
JAMA 1595, 1595 (2011). 
As part of the Controlled Substances Act, "a pharmacist may not fill a 
written order from a practitioner, appearing on its face to be a prescription 
[for a controlled substance], if he knows the practitioner issued it in other 
than the usual course of medical treatment." United States v. Hayes, 595 
F.2d 258, 260 (5th Cir. 1979) (construing 21C.F.R§1306.04(a)). See also 
21 U.S.C. § 829(e)(2) (2012) (noting a "valid prescription" is "a 
prescription that is issued for a legitimate medical purpose in the usual 
course of professional practice ... "). 
For example, it was a piece of federal legislation ( 0 BRA-90) 's articulating 
conditions for state receipt of Medicaid funds that prompted widespread 
adoption of prospective drug utilization review software by pharmaci~ts 
nationwide. See Thomas R. Fulda et al., Current Status of Prospective 
Drug Utilization Review, 10 J. OF MANAGED CARE PHARMACY 433 (2004); 
see also United States v. Jae Gab Kim, 449 F.3d 933, 937 (9th Cir. 2006) 
(sentencing a pharmacist to five months inc~rceration, three . yea:s 
supervised release, and a $15,000 fine for sellmg pseudoephedrme m 
violation of federal Controlled Substances Act and state law); United 
States v. Munoz, 430 F.3d 1357, 1364 (11th Cir. 2005) (sentencing 
defendant to ten months' imprisonment and a $10,000 fine for dispensing 
drugs without a valid prescription in violation of FDCA). 
See Downing v. Hyland Pharmacy, 194 P.3d 944, 946 (Utah 2008) (quoting 
Schaerrer v. Stewart's Plaza Pharmacy, 79 P .3d 922, 929 (Utah 2003)) 
("So long as a pharmacist's ability to distribute prescription drugs is 
limited by the highly restricted, FDA-regulated drug distribution system in 
this country, and a pharmacist cannot supply a patient with prescription 
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ing reliance on prescription drugs, and increasing number of prescription 
drugs available for use has led many pharmacists to play a greater role 
in coordinating drug therapy for patients than ever before. 
In addition to the state laws regulating the practice of pharmacy, 
federal law has relied heavily on pharmacists' professional standards in 
structuring the federal health care delivery system (specifically in the 
l~ws governing both Medicaid76 and Medicare77) and regulation of drugs 
(m the context of the federal Food, Drug and Cosmetic Act (FDCA)?s 
STAT. ANN. § 37:1164(41) (2007); ME. REV. STAT. tit. 32, § 13702-A (28) 
(2012); MD. CODE ANN., HEALTH Occ. § 12-lOl(t)(l) (Supp. 2012); MICH. 
COMP. LAWS ANN. § 333.17707(5) (West 2008); MINN. STAT. ANN. § 
151.01(27) (West 2011 & Supp. 2013); MISS. CODE ANN. § 73-21-73(bb) 
(2012); Mo. ANN. STAT. § 338.010(1) (2012); 2013 Montana Laws 220 
(codified with some differences in language at MONT. CODE ANN. § 37-7-
101(34) (2012)); NEB. REV. STAT. § 38-2837(1) (2012); NEV. REV. STAT. 
ANN. § 639.0124 (West 2012); N.H. REV. STAT. ANN.§ 318:l(XIV) (2013); 
N.J. REV. STAT.§ 45:14-41 (2013); N.M. STAT. ANN.§ 61-11-2(BB) (2012); 
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(2012); TENN. CODE ANN. § 63-10-204(35)(A) (2010 & Supp. 2012); TEX. 
Occ. CODE ANN. § 551.003(33) (West 2012); UTAH CODE ANN. § 58-17b-
102(54) (LexisNexis 2012 & Supp. 2013); VT. STAT. ANN. tit. 26, § 2022(14) 
(2012); VA. CODE ANN.§ 54.1-3300 (West 2012); WASH. REV. CODE ANN.§ 
18.64.011(23) (2012); W. VA. CODE ANN.§ 30-5-3 (2012) (amended 2013); 
WIS. STAT. ANN.§ 450.01(16) (2012); WYO. STAT. ANN.§ 33-24-124 (2012). 
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withhold certam products until receipt of a valid prescription. 21 U.S.C. § 
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and Controlled Substances Act). 79 To the extent that state laws govern-
ing the practice of pharmacy are not as rigorous as the federal 
expectations, the federal statutes have created both regulatory and 
statutory consequences for pharmacists who fall short of the federal 
standards.80 
Despite the myriad state and federal laws governing the pharmacist-
patient relationship, pharmacists have never had a general duty to warn 
patients about the risks associated with prescription drugs; this duty to 
warn has traditionally fallen instead into the realm of medicine (and 
more recently nursing) than pharmacy. Like all professionals, though, 
pharmacists are responsible for exercising due care in the course of their 
practice. As explained below, adding diagnosis codes to prescriptions 
would not affect the existing boundaries between the practices of 
medicine, nursing, and pharmacy, but would likely increase the level of 
care expected of pharmacists. 
I. The Duty to Warn Patients about Risks Generally Associated with 
Prescription Drugs Would Remain with Prescribers, Not Pharmacists 
State courts have traditionally, and quite consistently, held that a 
pharmacist has no general duty to warn a customer of the risk of harm 
that might be encountered from drugs which are accurately dispensed 
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JAMA 1595, 1595 (2011). 
As part of the Controlled Substances Act, "a pharmacist may not fill a 
written order from a practitioner, appearing on its face to be a prescription 
[for a controlled substance], if he knows the practitioner issued it in other 
than the usual course of medical treatment." United States v. Hayes, 595 
F.2d 258, 260 (5th Cir. 1979) (construing 21C.F.R§1306.04(a)). See also 
21 U.S.C. § 829(e)(2) (2012) (noting a "valid prescription" is "a 
prescription that is issued for a legitimate medical purpose in the usual 
course of professional practice . . . "). 
For example, it was a piece of federal legislation (OBRA-90)'s articulating 
conditions for state receipt of Medicaid funds that prompted widespread 
adoption of prospective drug utilization review software by pharmaci~ts 
nationwide. See Thomas R. Fulda et al., Current Status of Prospective 
Drug Utilization Review, 10 J. OF MANAGED CARE PHARMACY 433 (2004); 
see also United States v. Jae Gab Kim, 449 F.3d 933, 937 (9th Cir. 2006) 
(sentencing a pharmacist to five months inc~rceration, three. yea:s 
supervised release, and a $15,000 fine for sellmg pseudoephedrme m 
violation of federal Controlled Substances Act and state law); United 
States v. Mufi.oz, 430 F.3d 1357, 1364 (11th Cir. 2005) (sentencing 
defendant to ten months' imprisonment and a $10,000 fine for dispensing 
drugs without a valid prescription in violation of FDCA). 
See Downing v. Hyland Pharmacy, 194 P.3d 944, 946 (Utah 2008) (quoting 
Schaerrer v. Stewart's Plaza Pharmacy, 79 P .3d 922, 929 (Utah 2003)) 
("So long as a pharmacist's ability to distribute prescription drugs is 
limited by the highly restricted, FDA-regulated drug distribution system in 
this country, and a pharmacist cannot supply a patient with prescription 
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contains "patent, clear, or obvious errors" or (2) the pharmacist has 
knowledge of patient-specific information that would indicate that a 
particular patient has a higher risk profile for a particular drug. 82 
Pharmacies and pharmacists have been exempted from a duty to warn 
due to the learned intermediary doctrine.83 As articulated by courts, the 
drugs without an intervening physician's prescription, we will not impose a 
duty upon the pharmacist to warn of the risks associated with the use of 
prescription drugs."); Pysz v. Henry's Drug Store, 457 So. 2d 561, 562 (Fla. 
Dist. Ct. App. 4th 1984) (holding that it is the physician, not the 
pharmacist, who has the duty to know the drug that he is prescribing and 
to warn and monitor the patient properly); Adkins v. Mong, 425 N.W.2d 
151, 154 (Mich. Ct. App. 1988) (dismissing negligence claim against 
pharmacy because "there exists no legal duty on the part of a pharmacist 
to monitor and intervene with a customer's reliance on drugs prescribed by 
a licensed treating physician"); Morgan v. Wal-Mart Stores, Inc., 30 
S.W.3d 455, 467 (Tex. Ct. App. 2000) (cautioning that imposing a 
generalized duty to warn would unnecessarily interfere in the physician and 
patient relationship); Allberry v. Parkmor Drug, Inc., 834 N.E.2d 199, 203 
(Ind. Ct. App. 2005) (holding that a pharmacist had no duty to give 
patient the manufacturer's product information, which contained certain 
warnings about the use of the drug, as such information was not included 
in the prescription itself); Cottam v. CVS Pharmacy, Inc., 764 N.E.2d 814, 
821 (Mass. 2002) (holding that in the absence of a voluntarily assumed 
duty "where the pharmacist has no specific knowledge of an increased 
danger to a particular customer, the pharmacist has no duty to warn that 
customer of potential side effects"). 
82. Morgan, 30 S.W.3d at 467 (noting that the action does not claim either 
that the pharmacy had any knowledge of the patient's medical history or 
should have known of contraindications that would impose upon the 
pharmacy an additional duty to warn the patient); Deed v. Walgreen Co., 
927 A.2d 1001, 1002-03 (Conn. Super. Ct. 2007) (holding that pharmacists 
did not have "specific knowledge of potential harm" sufficient to trigger 
duty to warn where patient's primary care physician had written majority 
of 149 prescriptions filled by pharmacy). But see McKee v. Am. Home 
Prods., Corp., 782 P.2d 1045, 1050 (Wash. 1989) ("[T]he patient must look 
to the physician [for information on the potential adverse effects of a 
prescription drug], for it is only the physician who can relate the 
propensities of the drug to the physical idiosyncrasies of the patient."). See 
generally David J. Marchitelli, Liability of Pharmacist Who Accurately 
Fills Prescription for Harm Resulting to User, 44 A.L.R.5th 393, at § 2[a] 
(2011). 
83. Morgan, 30 S.W.3d at 469 (holding that the learned intermediary doctrine 
does not impose on pharmacists a generalized duty to warn patients of 
potential adverse reactions absent special circumstances); Moore v. Mem'l 
Hosp., 825 So.2d 658, 664 (Miss. 2002) (extending the "learned 
intermediary" doctrine to pharmacists in Mississippi). See, e.g., Cottam, 
764 N.E.2d at 821 ("This court has already recognized the learned 
intermediary doctrine in the context of prescription drug manufacturers. 
Because the physician is the appropriate person to perform the duty of 
warning a patient of the possible side effects of prescription drugs, we now 
extend this doctrine to pharmacies." (citations omitted)). See also 
Fakhouri v. Taylor, 618 N.E.2d 518, 519 (Ill. App. Ct. 1993); Leesley v. 
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learned intermediary doctrine prevents pharmacists from interfering with 
the doctor-patient relationship because it "prevents pharmacists from 
constantly second-guessing a prescribing doctor's judgment simply in 
order to avoid his or her own liability to the customer. "84 
Even where courts have decided that the learned intermediary doc-
trine protects pharmacists from a duty to warn, the decisions have been 
qualified because the foreseeability of injury to an individual consumer 
"varies greatly depending on the medical history and condition of the 
individual - facts which we cannot reasonably expect the pharmacist to 
know."85 But when in fact a pharmacist is aware of a patient's individual 
allergies or diagnoses, the learned intermediary doctrine does not 
foreclose a pharmacist's potential for liability because the pharmacist has 
knowledge of a customer-specific risk.86 At a minimum, pharmacists have 
a duty to warn physicians and patients when a prescription drug is 
contraindicated for a specific patient or when a patient is concurrently 
taking two drugs which are known to cause serious adverse effects in 
some patients when taken together,87 but there remains a disagreement 
West, 518 N.E.2d 758, 760 (Ill. App. Ct. 1988); Eldridge v. Eli Lilly & Co., 
485 N.E.2d 551, 551 (Ill. App. Ct. 1985). 
84. Klasch v. Walgreen Co., 264 P.3d 1155, 1159 (Nev. 2011). 
85. Leesley, 518 N.E.2d at 762 (citing Eldridge, 485 N.E.2d 551). 
86. Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1129 (Ill. 2002) ("For 
the reasons set forth above, we hold that a narrow duty to warn exists 
where, as in the instant case, a pharmacy has patient-specific information 
about drug allergies, and knows that the drug being prescribed is 
contraindicated for the individual patient. In such instances, a pharmacy 
has a duty to warn either the prescribing physician or the patient of the 
potential danger."); Lasley v. Shrake's Country Club Pharmacy, Inc., 880 
P.2d 1129, 1132-34 (Ariz. Ct. App. 1994) (imposing a duty for failing to 
warn the customer when filling two prescriptions that adversely interacted 
with one another); Klasch, 264 P.3d at 1156 ("We conclude that when a 
pharmacist has knowledge of a customer-specific risk with respect to a 
prescribed medication, the pharmacist has a duty to exercise reasonable 
care in warning the. customer or notifying the prescribing doctor of this 
risk."); Walton v. Bayer Corp., 643 F.3d 994, 1000 (7th Cir. 2011) ("What 
a pharmacy sometimes knows, however, without investigation, and the 
manufacturer will not know and even a treating physician may not know, 
is susceptibilities of particular customers of the pharmacy to the side 
effects of a drug that it sells them - susceptibilities because of other drugs 
that the pharmacy knows the customer is taking, or a pre-existing physical 
or mental condition (again known to it) that makes the drug 
contraindicated for the customer - and then it must warn either the 
customer or his physician. But not otherwise." (citations omitted)). 
87. Keffer v. Lorzenz, 2012 WL 3235398, at ~ 17 (D.C. Super. Ct. 2012) 
(noting pharmacists likely had a duty to warn because patient was "at risk 
of a specific, defined, and foreseeable harm of which the pharmacists knew 
or should have known," specifically the concurrent use of two drugs known 
to cause serious adverse events when taken together). 
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contains "patent, clear, or obvious errors" or (2) the pharmacist has 
knowledge of patient-specific information that would indicate that a 
particular patient has a higher risk profile for a particular drug. 82 
Pharmacies and pharmacists have been exempted from a duty to warn 
due to the learned intermediary doctrine.83 As articulated by courts, the 
drugs without an intervening physician's prescription, we will not impose a 
duty upon the pharmacist to warn of the risks associated with the use of 
prescription drugs."); Pysz v. Henry's Drug Store, 457 So. 2d 561, 562 (Fla. 
Dist. Ct. App. 4th 1984) (holding that it is the physician, not the 
pharmacist, who has the duty to know the drug that he is prescribing and 
to warn and monitor the patient properly); Adkins v. Mong, 425 N.W.2d 
151, 154 (Mich. Ct. App. 1988) (dismissing negligence claim against 
pharmacy because "there exists no legal duty on the part of a pharmacist 
to monitor and intervene with a customer's reliance on drugs prescribed by 
a licensed treating physician"); Morgan v. Wal-Mart Stores, Inc., 30 
S.W.3d 455, 467 (Tex. Ct. App. 2000) (cautioning that imposing a 
generalized duty to warn would unnecessarily interfere in the physician and 
patient relationship); Allberry v. Parkmor Drug, Inc., 834 N.E.2d 199, 203 
(Ind. Ct. App. 2005) (holding that a pharmacist had no duty to give 
patient the manufacturer's product information, which contained certain 
warnings about the use of the drug, as such information was not included 
in the prescription itself); Cottam v. CVS Pharmacy, Inc., 764 N.E.2d 814, 
821 (Mass. 2002) (holding that in the absence of a voluntarily assumed 
duty "where the pharmacist has no specific knowledge of an increased 
danger to a particular customer, the pharmacist has no duty to warn that 
customer of potential side effects"). 
82. Morgan, 30 S.W.3d at 467 (noting that the action does not claim either 
that the pharmacy had any knowledge of the patient's medical history or 
should have known of contraindications that would impose upon the 
pharmacy an additional duty to warn the patient); Deed v. Walgreen Co., 
927 A.2d 1001, 1002-03 (Conn. Super. Ct. 2007) (holding that pharmacists 
did not have "specific knowledge of potential harm" sufficient to trigger 
duty to warn where patient's primary care physician had written majority 
of 149 prescriptions filled by pharmacy). But see McKee v. Am. Home 
Prods., Corp., 782P.2d1045, 1050 (Wash. 1989) ("[T]he patient must look 
to the physician [for information on the potential adverse effects of a 
prescription drug], for it is only the physician who can relate the 
propensities of the drug to the physical idiosyncrasies of the patient."). See 
generally David J. Marchitelli, Liability of Pharmacist VVho Accurately 
Fills Prescription for Harm Resulting to User, 44 A.L.R.5th 393, at § 2[a] 
(2011). 
83. Morgan, 30 S.W.3d at 469 (holding that the learned intermediary doctrine 
does not impose on pharmacists a generalized duty to warn patients of 
potential adverse reactions absent special circumstances); Moore v. Mem'l 
Hosp., 825 So.2d 658, 664 (Miss. 2002) (extending the "learned 
intermediary" doctrine to pharmacists in Mississippi). See1 e.g., Cottam, 
764 N.E.2d at 821 ("This court has already recognized the learned 
intermediary doctrine in the context of prescription drug manufacturers. 
Because the physician is the appropriate person to perform the duty of 
warning a patient of the possible side effects of prescription drugs, we now 
extend this doctrine to pharmacies." (citations omitted)). See also 
Fakhouri v. Taylor, 618 N.E.2d 518, 519 (Ill. App. Ct. 1993); Leesley v. 
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learned intermediary doctrine prevents pharmacists from interfering with 
the doctor-patient relationship because it "prevents pharmacists from 
constantly second-guessing a prescribing doctor's judgment simply in 
order to avoid his or her own liability to the customer. "84 
Even where courts have decided that the learned intermediary doc-
trine protects pharmacists from a duty to warn, the decisions have been 
qualified because the foreseeability of injury to an individual consumer 
"varies greatly depending on the medical history and condition of the 
individual - facts which we cannot reasonably expect the pharmacist to 
know."85 But when in fact a pharmacist is aware of a patient's individual 
allergies or diagnoses, the learned intermediary doctrine does not 
foreclose a pharmacist's potential for liability because the pharmacist has 
knowledge of a customer-specific risk.86 At a minimum, pharmacists have 
a duty to warn physicians and patients when a prescription drug is 
contraindicated for a specific patient or when a patient is concurrently 
taking two drugs which are known to cause serious adverse effects in 
some patients when taken together ,87 but there remains a disagreement 
West, 518 N.E.2d 758, 760 (Ill. App. Ct. 1988); Eldridge v. Eli Lilly & Co., 
485 N.E.2d 551, 551 (Ill. App. Ct. 1985). 
84. Klasch v. Walgreen Co., 264 P.3d 1155, 1159 (Nev. 2011). 
85. Leesley, 518 N.E.2d at 762 (citing Eldridge, 485 N.E.2d 551). 
86. Happel v. Wal-Mart Stores, Inc., 766 N.E.2d 1118, 1129 (Ill. 2002) ("For 
the reasons set forth above, we hold that a narrow duty to warn exists 
where, as in the instant case, a pharmacy has patient-specific information 
about drug allergies, and knows that the drug being prescribed is 
contraindicated for the individual patient. In such instances, a pharmacy 
has a duty to warn either the prescribing physician or the patient of the 
potential danger."); Lasley v. Shrake's Country Club Pharmacy, Inc., 880 
P.2d 1129, 1132-34 (Ariz. Ct. App. 1994) (imposing a duty for failing to 
warn the customer when filling two prescriptions that adversely interacted 
with one another); Klasch, 264 P.3d at 1156 ("We conclude that when a 
pharmacist has knowledge of a customer-specific risk with respect to a 
prescribed medication, the pharmacist has a duty to exercise reasonab~e 
care in warning the. customer or notifying the prescribing doctor of this 
risk."); Walton v. Bayer Corp., 643 F.3d 994, 1000 (7th Cir. 2011) ("What 
a pharmacy sometimes knows, however, without investigation, and the 
manufacturer will not know and even a treating physician may not know, 
is susceptibilities of particular customers of the pharmacy to the side 
effects of a drug that it sells them - susceptibilities because of other drugs 
that the pharmacy knows the customer is taking, or a pre-existing physical 
or mental condition (again known to it) that makes the drug 
contraindicated for the customer - and then it must warn either the 
customer or his physician. But not otherwise." (citations omitted)). 
87. Keffer v. Lorzenz, 2012 WL 3235398, at ~ 17 (D.C. Super. Ct. 2012) 
(noting pharmacists likely had a duty to wa.rn because patient was "at risk 
of a specific, defined, and foreseeable harm of which the pharmacists knew 
or should have known," specifically the concurrent use of two drugs known 
to cause serious adverse events when taken together). 
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between jurisdictions whether pharmacists have a duty to warn physi-
cians or patients when a dose in excess of the manufacturer's recommen-
recommendation (and FDA approval) has been prescribed.88 While 
contraindications are seen as straightforward warnings that do not 
require a pharmacist to make an independent medical judgment, 89 dosage 
decisions appear to cross the line from the practice of pharmacy into the 
practice of medicine. 90 
88. See Horner v. Spalitto, 1 S.W.3d 519, 523 (Mo. Ct. App. 1999) (finding 
that the pharmacist is "in the best position" to contact the patient's 
physician to discuss any potential problems with the patient's 
prescription); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1250 (Pa. Super. 
Ct. 1986) ("Pharmacists and a pharmacologist testified that a pharmacist 
who receives a prescription which has inadequate instructions as to 
maximum dosage has a duty to either ascertain if the patient is aware of 
the limitation concerning the use of the medication or to contact the 
prescribing physician to call the inadequacy of the prescription to the 
doctor's attention. Experts testified further that under the facts of this case 
a reasonably prudent pharmacist would have taken steps to correct the 
error of the prescribing physician."). See also McKee v. Am. Home Prods., 
Corp., 782 P.2d 1045, 1053 (Wash. 1989) ("We agree pharmacists should 
have a duty to be alert for patent errors in a prescription, for example: 
obvious lethal dosages, inadequacies in the instructions, known 
contraindications, or incompatible prescriptions, and to take corrective 
measures."). But see Fakhouri, 618 N.E.2d at 519 (denying request to 
impose upon pharmacists a duty to warn their customers of prescribed 
dosages of medication in excess of the manufacturer's recommended limits). 
89. '.'A c~ntraindication is a serious limitation on a drug's use, necessarily 
rmplymg grave consequences if it is ignored. As one court has noted a 
contraindication refers to 'a circumstance under which the drug must ne~er 
be given."' Happel, 766 N.E.2d at 1128 (quoting Hand v. Krakowski, 453 
N.Y.S.2d 121, 123 (N.Y. App. Div. 1982)). "It requires no medical 
judgment simply to notify a physician or a patient of such a 
contraindication." Happel, 766 N.E.2d at 1128. 
90. See Eldridge v. Eli Lilly & Co., 485 N.E.2d 551, 553 (Ill. App. Ct. 1985) 
("A prescription which is excessive for one patient may be entirely 
reasonable for the treatment of another. To fulfill the duty which the 
plaintiff urges us to impose would require the pharmacist to learn the 
customer's condition and monitor his drug usage. To accomplish this, the 
pharmacist would have to interject himself into the doctor-patient 
relationship and practice medicine without a license."). See also 
~,rumag~im v. Eckel, 94 A.D.3~ 1391, 1393 (N.Y. Sup. Ct. 2012) 
( Imposmg a duty upon a pharmacist to contact the prescribing physician 
whenever there has been a change in dosage - within medically acceptable 
ranges - of a particular patient's medication would, in essence, require the 
pharma~ist to question the physician's judgment regarding the 
appropriateness of each customer's prescription. Sound policy reasons exist 
for not imposing such a duty."); McKee, 782 P.2d at 1051 ("Neither 
manufacturer nor pharmacist has the medical education or knowledge of 
the medical history of the patient which would justify a judicial imposition 
of a duty to intrude into the physician-patient relationship."). But see Riff, 
508 A.2d at 1253 ("Expert testimony established that the 'reasonable 
pharmacist' has an affirmative duty to read the prescription and to be 
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The addition of diagnostic information to outpatient prescriptions 
would do nothing to shift the burden of the general duty to warn from 
prescribers to pharmacists; it would, however, ~ik~ly increase the nur~ber 
of situations where pharmacists detect prescription errors and patient-
specific risks, situations which would trigger pharmacists' professional 
duty of due care. 
2. Pharmacists' Duty of Due Care Would Be Heightened with Addition of 
Diagnosis Codes for Medicare and Medicaid Reimbursement 
Given the "poisonous character" of prescription medications, phar-
macists are generally required to exercise a "duty of care and caution" 
when dispensing drugs.91 As part of this duty, pharmacists are expected 
to review a prescription before it is dispensed to identify: (1) apparent 
errors with the prescription and clarify any questions with the pre-
scriber, 92 and (2) potential drug-drug interactions, drug-disease contrain-
dications, therapeutic duplication, or other potential patient-specific 




aware of patent inadequacies in the instructions as to maximum safe 
dosage of known toxic drugs and medicines."). 
Eldridge, 485 N.E.2d at 552 ("A pharmacist owes a duty of ordinary care 
in practicing his profession, but such care requires the highest degree of 
prudence, thoughtfulness and diligence, and it is prop.orti.oned to the 
danger involved." (emphasis added)). See generally March1telh, supra note 
82, at § 2[a]. 
Despite the increased adoption of electronic prescribing as part of their role 
in "interpret [ing]" and "evaluat[ing]" prescriptions pharmacists still 
encounter sloppy writing and inappropriate directions, which can lead to 
adverse drug events. Randall Stross, Chicken Scratches v. Electronic 
Prescriptions, N.Y. TIMES (Apr. 28, 2012), 
http://www.nytimes.com/2012/04/29/business/e-~r~scriptions-red~ce~ 
errors-but-their-adoption-is-slow.html? _r=O. Add1t10nally, prescnpt10n 
errors are a known reality in our health care system. See Riff, 508 A.2d at 
1253 ("Fallibility is a condition of the human existence. Doctors, like other 
mortals, will from time to time err through ignorance or inadvertence. An 
error in the practice of medicine can be fatal; and so it is reasonable that 
the medical community including physicians, pharmacists, 
anesthesiologists, nurses and support staff have established profes~ional 
standards which require vigilance not only with respect to primary 
functions, but also regarding the acts and omissions of the other 
professionals and support personnel in the health care team. Each has an 
affirmative duty to be, to a limited extent, his brother's keeper."). 
42 U.S.C. § 1396r-8(g)(2)(A)(i) (2012). Physicians may not be aware of all 
contraindications associated with the drugs they prescribe. See, e.g., 
Happel, 766 N.E.2d at 1121 (Ill. 2002) (noting the physicia1: did not ~ow 
that Toradol was contraindicated for patients with allergies to aspmn). 
But, at present, pharmacists may similarly be unaware of all of a patient's 
conditions. See Fulda et al., supra note 80 (recognizing that drug-disease 
contraindications may only be identified "when disease information is 
available or using surrogate indicators"). 
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between jurisdictions whether pharmacists have a duty to warn physi-
cians or patients when a dose in excess of the manufacturer's recommen-
recommendation (and FDA approval) has been prescribed.88 While 
contraindications are seen as straightforward warnings that do not 
require a pharmacist to make an independent medical judgment,89 dosage 
decisions appear to cross the line from the practice of pharmacy into the 
practice of medicine. 90 
88. See Homer v. Spalitto, 1 S.W.3d 519, 523 (Mo. Ct. App. 1999) (finding 
that the pharmacist is "in the best position" to contact the patient's 
physician to discuss any potential problems with the patient's 
prescription); Riff v. Morgan Pharmacy, 508 A.2d 1247, 1250 (Pa. Super. 
Ct. 1986) ("Pharmacists and a pharmacologist testified that a pharmacist 
who receives a prescription which has inadequate instructions as to 
maximum dosage has a duty to either ascertain if the patient is aware of 
the limitation concerning the use of the medication or to contact the 
prescribing physician to call the inadequacy of the prescription to the 
doctor's attention. Experts testified further that under the facts of this case 
a reasonably prudent pharmacist would have taken steps to correct the 
error of the prescribing physician."). See also McKee v. Am. Home Prods., 
Corp., 782 P.2d 1045, 1053 (Wash. 1989) ("We agree pharmacists should 
have a duty to be alert for patent errors in a prescription, for example: 
obvious lethal dosages, inadequacies in the instructions, known 
contraindications, or incompatible prescriptions, and to take corrective 
measures."). But see Fakhouri, 618 N.E.2d at 519 (denying request to 
impose upon pharmacists a duty to warn their customers of prescribed 
dosages of medication in excess of the manufacturer's recommended limits). 
89. '.'A c~ntraindication is a serious limitation on a drug's use, necessarily 
implymg grave consequences if it is ignored. As one court has noted a 
contraindication refers to 'a circumstance under which the drug must ne~er 
be given."' Happel, 766 N.E.2d at 1128 (quoting Hand v. Krakowski, 453 
N.Y.S.2d 121, 123 (N.Y. App. Div. 1982)). "It requires no medical 
judgment simply to notify a physician or a patient of such a 
contraindication." Happel, 766 N.E.2d at 1128. 
90. ~:e Eldrid~e :· Eli L~lly 8: Co., 48.5 N.E.2d 551, 553 (Ill. App. Ct. 1985) 
( A prescription which is excessive for one patient may be entirely 
reasonable for the treatment of another. To fulfill the duty which the 
plaintiff urges us to impose would require the pharmacist to learn the 
customer's condition and monitor his drug usage. To accomplish this, the 
pharmacist would have to interject himself into the doctor-patient 
relationship and practice medicine without a license."). See also 
~,rumag~im v. Eckel, 94 A.D.3~ 1391, 1393 (N.Y. Sup. Ct. 2012) 
( Imposmg a duty upon a pharmacist to contact the prescribing physician 
whenever there has been a change in dosage - within medically acceptable 
ranges - of a particular patient's medication would, in essence, require the 
pharma~ist to question the physician's judgment regarding the 
appropriateness of each customer's prescription. Sound policy reasons exist 
for not imposing such a duty."); McKee, 782 P.2d at 1051 ("Neither 
manufacturer nor pharmacist has the medical education or knowledge of 
the medical history of the patient which would justify a judicial imposition 
of a duty to intrude into the physician-patient relationship."). But see Riff, 
508 A.2d at 1253 ("Expert testimony established that the 'reasonable 
pharmacist' has an affirmative duty to read the prescription and to be 
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The addition of diagnostic information to outpatient prescriptions 
would do nothing to shift the burden of the general duty to warn from 
prescribers to pharmacists; it would, however, likely increase the nur~ber 
of situations where pharmacists detect prescription errors and pat1ent-
specific risks, situations which would trigger pharmacists' professional 
duty of due care. 
2. Pharmacists' Duty of Due Care Would Be Heightened with Addition of 
Diagnosis Codes for Medicare and Medicaid Reimbursement 
Given the "poisonous character" of prescription medications, phar-
macists are generally required to exercise a "duty of care and caution" 
when dispensing drugs. 91 As part of this duty, pharmacists are expected 
to review a prescription before it is dispensed to identify: (1) apparent 
errors with the prescription and clarify any questions with the pre-
scriber, 92 and (2) potential drug-drug interactions, drug-disease contrain-
dications, therapeutic duplication, or other potential patient-specific 




aware of patent inadequacies in the instructions as to maximum safe 
dosage of known toxic drugs and medicines."). 
Eldridge, 485 N.E.2d at 552 ("A pharmacist owes a duty of ordinary care 
in practicing his profession, but such care requires the highest degree of 
prudence, thoughtfulness and diligence, and it is prop.orti?ned to the 
danger involved." (emphasis added)). See generally March1telh, supra note 
82, at § 2[a]. 
Despite the increased adoption of electronic prescribing as part of their role 
in "interpret [ing]" and "evaluat[ing]" prescriptions pharmacists still 
encounter sloppy writing and inappropriate directions, which can lead to 
adverse drug events. Randall Stross, Chicken Scratches v. Electronic 
Prescriptions, N.Y. TIMES (Apr. 28, 2012), 
http://www.nytimes.com/2012/04/29/business/e-~r~scriptions-red~ce~ 
errors-but-their-adoption-is-slow .html? _r=O. Add1t10nally, prescnption 
errors are a known reality in our health care system. See Riff, 508 A.2d at 
1253 ("Fallibility is a condition of the human existence. Doctors, like other 
mortals, will from time to time err through ignorance or inadvertence. An 
error in the practice of medicine can be fatal; and so it is reasonable that 
the medical community including physicians, pharmacists, 
anesthesiologists, nurses and support staff have established profes~ional 
standards which require vigilance not only with respect to pnmary 
functions, but also regarding the acts and omissions of the other 
professionals and support personnel in the health care team. Each has an 
affirmative duty to be, to a limited extent, his brother's keeper."). 
42 U.S.C. § 1396r-8(g)(2)(A)(i) (2012). Physicians may not be aware of all 
contraindications associated with the drugs they prescribe. See, e.g., 
Happel, 766 N.E.2d at 1121 (Ill. 2002) (noting the physicia1: did not ~ow 
that Toradol was contraindicated for patients with allergies to aspmn). 
But, at present, pharmacists may similarly be unaware of all of a patient's 
conditions. See Fulda et al., supra note 80 (recognizing that drug-disease 
contraindications may only be identified "when disease information is 
available or using surrogate indicators"). 
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use diagnostic infor~ation (at this point provided entirely by patients, 
unle~s they are takmg one of the few outpatient drugs reimbursed by 
Medicare Part B) to warn them about contraindications for specific 
t . 94 E pa rents. ven so, at least one long-term (twenty-month) study has 
f~und that nearly 50 percent of drug problem interventions by pharma-
CISts ~ere _problems that required the pharmacist's independent 
profess10nal Judgment as opposed to problems flagged by drug utilization 
r~view softwar~. 95 Once the validity and appropriateness of the prescrip-
tion are established, the pharmacist is then expected to (3) dispense the 
cor~ect medic~tion in the dosage and quantity prescribed, ( 4) offer each 
patient or designated caregiver counseling on safe and appropriate use of 
the_ medication_ as prescribed (an offer which may be refused by the 
patient or caregiver),96 and (5) maintain records with patient information 
to facilitate future counseling.97 While these standards are technically a 
~atter of state law, the state laws governing them have been heavily 
mfluenced by the federal Medicaid funds conditioned on states' adoption 





See, e.g., Keffer v. Lorzenz, 2012 WL 3235398, at , 2 (D.C. Super. Ct. 
2012) ("CVS's pharmacy personnel used a computerized prescription 
s~stem (the 'CVS system') that informed them of Mr. Keffer's prescription 
history, t~~t he had been prescribed both Cymbalta and Vyvanse, and that 
he was fillrng both medications simultaneously. In addition the CVS 
system notified CVS 's personnel that they should not fill the two 
prescriptions without first contacting Mr. Keffer's physicians to confirm 
that they wanted him to take both medications at the same time."); 
Happel, 766 N.E.2d at 1121 (noting a "'drug interaction' warning would 
have flashed across the [pharmacist's] screen, halting the prescription 
process for customers" for whom the drug was contraindicated until the 
pharmacist had consulted with the patient's physician); Morgan, 30 
S.W.3d at 469 (encouraging the use of computer systems to assist 
pharmacists in "p~~venting the s~le o_f potenti~lly fatal drugs"); Klasch, 
264 P.3d at 1157 ( Walgreens mamtarns a 'patient profile' for each of its 
custo_mers, which i~s phar~acists_ use to identify any potential allergic 
react10ns, harmful rnteract10ns with other medications, or adverse side 
effects that a customer may have to a particular medication."). 
Fulda et al., supra note 80, at 437 ("Approximately one half of the 
documented medication problems would not have been detected by 
compute~-generated alerts available at that time. This suggests that 
[prospective Drug Utilization Review] systems can assist pharmacists but 
cannot identify all of the problems that must be addressed to assure 
appropriate drug use."). 
See Jesse C. Vivian & Joseph L. Fink, OBRA '90 at Sweet Sixteen: A 
Retrospective Review, . 33 U.S. PHARMACIST 59 (?.008), available at 
http://www.uspharmacist.com/content/d/feature/c/10126. 
~~-U.S.C. § 1396r-8(g)(2)(A)(ii)(II)(bb) (2012); Vivian & Fink, supra note 
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1990 (OBRA-90). 98 Inclusion of diagnosis information as part of the 
Medicare and Medicaid programs would better inform four of these five 
practices (i.e., all but the correct dispensation of the product) and, as a 
result, likely heighten the standard of care pursuant to each of these 
practices. 
As observed by one court, the burden of warning a single physician 
or patient may be small,99 but in the aggregate (especially with the 
increasing number of insured patients due to the Supreme Court's 
decision upholding the Affordable Care Act) 100 the increased resources 
necessary to satisfy the augmented duty to warn created by the addition 
of diagnostic information to all outpatient prescriptions may be signifi-
cant. io1 The burden on pharmacists may be heightened, too, where 
patient care for comorbid conditions remains fragmented among special-
ists and no one prescriber is aware of all of a patient's diagnoses or 
medications. 102 To the extent, though, that the practice of pharmacy 







Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104 
Stat. 1388 (1990) (codified as amended at 42 U.S.C. § 1396r-8g (1994)). 
See also Vivian & Fink, supra note 96. 
Happel, 766 N.E.2d at 1124 ("The burden on defendant of imposing this 
duty [to warn] is minimal. All that is required is that the pharmacist 
telephone the physician and inform him or her of the contraindication. 
Alternatively, the pharmacist could provide the same information to the 
patient. Since this burden of warning about a contraindication is extremely 
small, this factor also favors the imposition of a duty here."). 
The Robert Wood Johnson Foundation estimates that the health care 
system will have thirty million newly insured patients once the Patient 
Protection and Affordable Care Act is fully implemented. See CATHERINE 
DOWER & EDWARD O'NEIL, ROBERT WOOD JOHNSON FOUND., PRIMARY 




See Leesley v. West, 518 N.E.2d 758, 763 (Ill. App. Ct. 1988) (explaining 
that the burden of conveying the warnings pharmacies receive from drug 
manufacturers to its customers would be very burdensome because it may 
well mean that pharmacists must bear the additional costs of reproducing 
the material they receive); McKee v. Am. Home Prods., Corp., 782 P.2d 
1045, 1053 (Wash. 1989) (noting that requiring pharmacists to warn 
patients of risks of off-label use "would result in the pharmacist second 
guessing numerous prescriptions to avoid liability. This would not only 
place an undue burden on pharmacists, but would likely create antagonistic 
relations between pharmacists and physicians."). 
Mary E. Tinetti et al., Designing Health Care for the Most Common 
Chronic Condition-Multimorbidity, 307 JAMA 2493, 2493 (2012). 
Horner v. Spalitto, 1 S.W.3d 519, 523-24 (Mo. Ct. App. 1999) (relying on 
Kenneth R. Baker, The OBRA 90 Mandate and Its Developing Impact on 
the Pharmacist7s Standard of Care, 44 DRAKE L. REV. 503, 517 (1996)). 
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use diagnostic information (at this point provided entirely by patients 
unle~s they are taking one of the few outpatient drugs reimbursed b; 
Medicare Part B) to warn them about contraindications for specific 
patients.94 Even so, at least one long-term (twenty-month) study has 
f~und that nearly 50 percent of drug problem interventions by pharma-
cists were problems that required the pharmacist's independent 
professional judgment as opposed to problems flagged by drug utilization 
r~view softwar~. 95 Once the validity and appropriateness of the prescrip-
t10n are est~bhs~ed; the pharmacist is then expected to (3) dispense the 
cor~ect med1cat10n m the dosage and quantity prescribed, ( 4) offer each 
patient or designated caregiver counseling on safe and appropriate use of 
the. medication. as prescribed (an offer which may be refused by the 
patient or caregiver),96 and (5) maintain records with patient information 
to facilitate future counseling.97 While these standards are technically a 
-:natter of state law, the state laws governing them have been heavily 
mfluenced by the federal Medicaid funds conditioned on states' adoption 
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2012) ("CVS's pharmacy personnel used a computerized prescription 
s~stem (the 'CVS system') that informed them of Mr. Keffer's prescription 
history, t?~t he had been prescribed both Cyrnbalta and Vyvanse, and that 
he was fillmg both medications simultaneously. In addition the CVS 
system notified CVS's personnel that they should not fil1 the two 
prescriptions without first contacting Mr. Keffer's physicians to confirm 
that they wanted him to take both medications at the same time."); 
Happel, 766 N.E.2d at 1121 (noting a "'drug interaction' warning would 
have flashed across the [pharmacist's] screen, halting the prescription 
process for customers" for whom the drug was contraindicated until the 
pharmacist had consulted with the patient's physician); Morgan, 30 
S.W.3d at 469 (encouraging the use of computer systems to assist 
pharmacists in "p~~venting the s~le o.f potenti~lly fatal drugs"); Klasch, 
264 P.3d at 1157 ( Walgreens mamtarns a 'patient profile' for each of its 
custo_mers, which i~s phar~acists_ use to identify any potential allergic 
react10ns, harmful rnteract1ons with other medications, or adverse side 
effects that a customer may have to a particular medication."). 
Fulda et al., supra note 80, at 437 ("Approximately one half of the 
documented medication problems would not have been detected by 
compute~-generated alerts available at that time. This suggests that 
[prospective Drug Utilization Review] systems can assist pharmacists but 
cannot identify all of the problems that must be addressed to assure 
appropriate drug use."). 
See Jesse C. Vivian & Joseph L. Fink, OBRA '90 at Sweet Sixteen: A 
Retrospective Review, . 33 U.S. PHARMACIST 59 (?.008), available at 
http://www.uspharmac1st.com/content/d/feature/c/10126. 
~~.U.S.C. § 1396r-8(g)(2)(A)(ii)(II)(bb) (2012); Vivian & Fink, supra note 
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1990 (OBRA-90).98 Inclusion of diagnosis information as part of the 
Medicare and Medicaid programs would better inform four of these five 
practices (i.e., all but the correct dispensation of the product) and, as a 
result, likely heighten the standard of care pursuant to each of these 
practices. 
As observed by one court, the burden of warning a single physician 
or patient may be small, 00 but in the aggregate (especially with the 
increasing number of insured patients due to the Supreme Court's 
decision upholding the Affordable Care Act) 100 the increased resources 
necessary to satisfy the augmented duty to warn created by the addition 
of diagnostic information to all outpatient prescriptions may be signifi-
cant. 101 The burden on pharmacists may be heightened, too, where 
patient care for comorbid conditions remains fragmented among special-
ists and no one prescriber is aware of all of a patient's diagnoses or 
medications. 102 To the extent, though, that the practice of pharmacy 







Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104 
Stat. 1388 (1990) (codified as amended at 42 U.S.C. § 1396r-8g (1994)). 
See also Vivian & Fink, supra note 96. 
Happel, 766 N.E.2d at 1124 ("The burden on defendant of imposing this 
duty [to warn] is minimal. All that is required is that the ~ha~ma~ist 
telephone the physician and inform him or her of the contrarnd1cat10n. 
Alternatively, the pharmacist could provide the same information to the 
patient. Since this burden of warning about a contraindication is extremely 
small, this factor also favors the imposition of a duty here."). 
The Robert Wood Johnson Foundation estimates that the health care 
system will have thirty million newly insured patients once the Patient 
Protection and Affordable Care Act is fully implemented. See CATHERlNE 
DOWER & EDWARD O'NEIL, ROBERT WOOD JOHNSON FOUND., PRIMARY 




See Leesley v. West, 518 N.E.2d 758, 763 (Ill. App. Ct. 1988) (explaining 
that the burden of conveying the warnings pharmacies receive from drug 
manufacturers to its customers would be very burdensome because it may 
well mean that pharmacists must bear the additional costs of reproducing 
the material they receive); McKee v. Am. Home Prods., Corp., 782 P.2d 
1045, 1053 (Wash. 1989) (noting that requiring pharmacists to warn 
patients of risks of off-label use "would result in the pharmacist second 
guessing numerous prescriptions to avoid liability. This would not only 
place an undue burden on pharmacists, but would likely create antagonistic 
relations between pharmacists and physicians."). 
Mary E. Tinetti et al., Designing Health Care for the Most Common 
Chronic Condition-Multimorbidity, 307 JAMA 2493, 2493 (2012). 
Horner v. Spalitto, 1 S.W.3d 519, 523-24 (Mo. Ct. App. 1999) (relying on 
Kenneth R. Baker, The OBRA 90 Mandate and Its Developing Impact on 
the Pharmacist's Standard of Care, 44 DRAKE L. REV. 503, 517 (1996)). 
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diagn.ostic i1:1formation on prescriptions seems a logical next step, 104 
especially with the added potential that the claims database would 
provide for even greater drug safety surveillance and comparative 
effectiveness research. 
B. Potential Role of Outpatient Prescription Drug Database in Informing 
FDA Drug Safety Surveillance 
Use of patient-specific information gathered in the context of health 
care treatment relationships for purposes other than patient treatment is 
always accompanied by privacy concerns - prescription drug information 
is no exception. 105 To the extent that individual patient privacy concerns 
have been weighed against the informational needs of a functional 
federal healt~ care sy~tem (including a drug safety surveillance system), 
the balance IS found m the HIP AA Privacy Rule106 and the Food and 
Drug. A~~nistratio~ Amendments Act of 2007 (FDAAA). 107 Reflecting 
the s1gmficant public health interest in drug safety surveillance, 10s the 
HIP ~A an~ FDAAA standards expressly allow pharmacists and phar-
macies to disclose otherwise-protected health information to the FDA to 
report adverse events or engage in post-marketing surveillance without 
patient consent.109 
104. Marc A. Rodwin, Rooting Out Institutional Corruption to Manage ~~appropriate Off-Label Drug Use, 4_1 J_. L. MED. & ETHICS 654, 659 (2013) 
( Data from tracked off-label prescnpt10ns would help to set priorities for 
the evaluation of the risks and benefits of off-label use, target education 
about drug therapy to physicians, and - where appropriate - warn the 
public. Physicians should be required to indicate on each prescription the 
purpose for which the drug is prescribed."). 
105. For an excellent summary of these concerns, as well as the state and ~ederal :privacy law that governs protection of prescription health mforma~10n, see generally Christopher R. Smith, Somebody's Watching Me: 
Protecting Patient Privacy in Prescription Health Information, 36 VT. L. 
REv. 931 (2012). In addition to the privacy concerns there are also cost 
and quality of care concerns that may accompany 'data breaches that 
co~promise Medicare and Medicaid beneficiary numbers. Julie K. 
Taitsman et al., Protecting Patient Privacy and Data Security, 368 NEW 
ENG. J. MED. 977, 977 (2013). 
106. See generally 45 C.F.R. §§ 160, 164 (2012). 
107. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-
85, 121 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.). 
108. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The 
Food, Drug, and Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME 
L. REV. 419, 482 (2010) ("In effect, Congress determined that the public he~lth benefits of having [an active drug safety surveillance] system are 
weighty enough to override individuals' interest in keeping their data out 
of it."). 
109. Kristen ~~sati, Using Electronic Health Information for 
Pharmacovzgzlance: The Promise and the Pitfalls, 2 J. HEALTH & LIFE Ser. 
L. 171 (2009); LISA M. BOYLE & DAVID M. MACK, HIP AA: A GUIDE TO 
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Pursuant to the authority granted in FDAAA (and in compliance 
with HIP AA), 110 the FDA is building an active post-market risk iden~ifi­
cation and analysis system. 111 This system, known as the Sentmel 
system, relies heavily on claims data112 from both government and 
private health insurance programs to actively track adverse events, 
identify treatment trends and patterns, and export data in a form 
appropriate for further aggregation, statistical analysis, and rep?rting. 113 
While the FDA may have the authority to access the Medicare da-
tabases access alone does nothing to facilitate the cross-linking of the existin~ Part D pharmacy-generated outpatient pre~crip~i?n dr:1g claim 
databases with the Part B physician-generated office vIS1t claim data-
bases necessary to link outpatient prescriptions to patient diagnoses, a 
significant weakness of the current Medicare ?ataba~e sy~tem. 114 Furt~er, 
patient information that does not have an immediate impact on reim-
bursement is often omitted from these systems.115 Inclusion of ICD-10-
CM codes on Medicare Part D claims for outpatient prescription drugs 
as a condition of reimbursement would take care of both of these 
weaknesses in the current Sentinel system and significantly strengthen 
FDA's ability to track adverse events and the trends _and patt.erns of 
prescription drug use in patient populations di~propor~10nately msured 
through Medicare (i.e., the elderly and chromcally disabled) and un-
derrepresented in the FDA pre-market approval process and most post-





HEALTH CARE PRIVACY AND SECURITY LAW 3:26-3:27 (2003) (citing 45 
C.F.R. § 164.512(b)(l)(iii) (2012)); HIPAA Compliance for Reporters to 
FDA . Med Watch, FDA.Gov, 
http://www.fda.gov/Safety /MedWatch/HowToReport/uc.:0:085589.htn:i 
(last updated Jun. 25, 2009) (" [T]he Privacy Rule spec~fically permits 
covered entities (such as pharmacists, physicians or hospitals) to. report 
adverse events and other information related to the quality, effectiveness 
and safety of FDA-regulated products both to the manufacturers and 
directly to FDA."). 
21 U.S.C. § 355(k)(3)(C)(i)(I) (2012) (referencing the HIPAA Privacy 
Rule). 
§ 355(k)(3)(C) (2012). 
§ 355(k)(3)(A) (2012) (providing a definition of "data" for purposes of 
active post-market risk identification). 
§ 355(k)(3)(C)(i). For an example of how d~t~bases are used to identify 
off-label prescribing habits in children, see Mmam C. J.M. Sturkenbo?m 
et al., Drug Use in Children: Cohort Study in Three European Countr~es, 
337 BRIT. MED. J. 1338, 1339 (2008) (recognizing that this study, which 
relied upon physician-generated data from electronic medical r~c~rd 
databases from three different European countries, reflects prescnbmg 
habits and not patient adherence). 
114. See OIG PART D REIMBURSEMENT REPORT, supra note 2. 
115. Roos et al., supra note 45, at 48. 
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diagn.ostic ir:formation on prescriptions seems a logical next step, 104 
especially with the added potential that the claims database would 
provide for even greater drug safety surveillance and comparative 
effectiveness research. 
B. Potential Role of Outpatient Prescription Drug Database in Informing 
FDA Drug Safety Surveillance 
Use of patient-specific information gathered in the context of health 
care treatment relationships for purposes other than patient treatment is 
always accompanied by privacy concerns - prescription drug information 
is no exception. 105 To the extent that individual patient privacy concerns 
have been weighed against the informational needs of a functional 
federal healt~ care sy~tem (including a drug safety surveillance system), 
the balance IS found m the HIP AA Privacy Rule106 and the Food and 
Drug. A~~nistratio~ Amendments Act of 2007 (FDAAA). 107 Reflecting 
the s1gmficant public health interest in drug safety surveillance, 10s the 
HIP AA and FDAAA standards expressly allow pharmacists and phar-
macies to disclose otherwise-protected health information to the FDA to 
report adverse events or engage in post-marketing surveillance without 
patient consent.109 
104. Marc A. Rodwin, Rooting Out Institutional Corruption to Manage ~~appropriate Off-Label Drug Use, 4.1 J: L. MED. & ETHICS 654, 659 (2013) 
( Data from tracked off-label prescnpt10ns would help to set priorities for 
the evaluation of the risks and benefits of off-label use, target education 
about drug therapy to physicians, and - where appropriate - warn the 
public. Physicians should be required to indicate on each prescription the 
purpose for which the drug is prescribed."). 
105. For an excellent summary of these concerns, as well as the state and ~ederal :privacy law that governs protection of prescription health mforma~1on, se~ generally Christopher R. Smith, Somebody's Watching Me: 
Protecting Patient Privacy in Prescription Health Information, 36 VT. L. 
REV. 931 (2012). In addition to the privacy concerns there are also cost 
and quality of care concerns that may accompany 'data breaches that 
co~promise Medicare and Medicaid beneficiary numbers. Julie K. 
Ta1tsman et al., Protecting Patient Privacy and Data Security, 368 NEW 
ENG. J. MED. 977, 977 (2013). 
106. See generally 45 C.F.R. §§ 160, 164 (2012). 
107. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-
85, 121 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.). 
108. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The 
Food, Drug, and Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME 
L. REV. 419, 482 (2010) ("In effect, Congress determined that the public he~lth benefits of having [an active drug safety surveillance] system are 
weighty enough to override individuals' interest in keeping their data out 
of it."). 
109. Kristen 1'.l~sati, Using Electronic Health Information for 
Pharmacovzgzlance: The Promise and the Pitfalls, 2 J. HEALTH & LIFE Ser. 
L. 171 (2009); LISA M. BOYLE & DAVID M. MACK, HIP AA: A GUIDE TO 
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Pursuant to the authority granted in FDAAA (and in compliance 
'th HIP AA) 110 the FDA is building an active post-market risk identifi-
w1 ' S . 1 
cation and analysis system. 111 This system, known as the entme 
system, relies heavily on claims data112 from both government and 
private health insurance programs to actively track adverse events, 
identify treatment trends and patterns, and export data in a form 
appropriate for further aggregation, statistical analysis, and rep?rting. 113 
While the FDA may have the authority to access the Medicare da-
tabases access alone does nothing to facilitate the cross-linking of the existin~ Part D pharmacy-generated outpatient pre~crip~i?n dr~g claim 
databases with the Part B physician-generated office v1s1t claim data-
bases necessary to link outpatient prescriptions to patient diagnoses, a 
significant weakness of the current Medicare ~ataba~e sy~tem. 114 Furt~er, 
patient information that does not have an immediate impact on reim-
bursement is often omitted from these systems. 115 Inclusion of ICD-10-
CM codes on Medicare Part D claims for outpatient prescription drugs 
as a condition of reimbursement would take care of both of these 
weaknesses in the current Sentinel system and significantly strengthen 
FDA's ability to track adverse events and the trends .and patt.erns of 
prescription drug use in patient populations di~propor~10nately msured 
through Medicare (i.e., the elderly and chromcally drnabled) and un-
derrepresented in the FDA pre-market approval process and most post-
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(last updated Jun. 25, 2009) (" [T]he Privacy Rule spec~fically permits 
covered entities (such as pharmacists, physicians or hos:p1tals) to. report 
adverse events and other information related to the quality, effectiveness 
and safety of FDA-regulated products both to the manufacturers and 
directly to FDA."). 
21 U.S.C. § 355(k)(3)(C)(i)(I) (2012) (referencing the HIPAA Privacy 
Rule). 
§ 355(k)(3)(C) (2012). 
§ 355(k)(3)(A) (2012) (providing a definition of "data" for purposes of 
active post-market risk identification). 
§ 355(k)(3)(C)(i). For an exam~le of how d~t~bases are used to identify 
off-label prescribing habits in children, see Mmam C. J.M. Sturkenbo?m 
et al., Drug Use in Children: Cohort Study in Three European Countr~es, 
337 BRIT. MED. J. 1338, 1339 (2008) (recognizing that this study, which 
relied upon physician-generated data from ele~tronic medical r~c?rd 
databases from three different European countries, reflects prescnbmg 
habits and not patient adherence). 
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C. Potential Role of Outpatient Prescription Drug Database for Compar-
ative Effectiveness Research and Coverage Decisions 
Prescribers are able to recommend any FDA-approved drug for any 
use they deem in their patients' best interests. 116 Often these recommen-
dations differ from the intended use(s) studied in the clinical trials and, 
in many specialties and diseases, become the standard of care.117 Like-
wise, previously accepted treatments are occasionally called into question 
by new research or evolving scientific thought, and CMS has tried to 
respond effectively to emerging evidence. 118 Instead of denying coverage 
outright for these newer or newly questioned technologies, CMS has 
occasionally used a "Coverage with Evidence Development" (CED) 
program to "provide Medicare coverage while further evidence is devel-
oped. "119 
CMS generally relies on clinical evidence to determine whether par-
ticular items or services should be considered "reasonable and necessary" 
for purposes of Medicare Part B coverage. 12° For prescription drugs 
covered under Part B, CMS looks to evidence beyond that considered for 
"medically accepted indications," including medical literature and other 
indicia of accepted standards of care. 121 Even with the expanded universe 
of evidence available for Part B coverage, information may still be 
significantly limited for both very new and older products, making well-
informed coverage determinations impossible.122 In particular, clinical 
116. These uses likely fall into the category of items and services where CMS 
"believed that the enthusiasm of interested parties was disproportionate to 
the persuasiveness of the then-current evidence base." Draft Guidance for 
the Public, Industry & CMS Staff Coverage with Evidence Development in 
the Context of Coverage Decisions, CTRS FOR MEDICARE & MEDICAID 
SERVS. (Nov. 29, 2012) [hereinafter Draft Guidance], 
http://www.cms.gov/medicare-coverage-database/details/medicare-
coverage-document-details.aspx?MCDid=23. 
117. See Kesselheim, supra note 3, at 238 ("[Scientifically unsupported] off-label 
use may also be reasonable and appropriate in circumstances where 
collection of rigorous evidence is impossible."). 
118. See Draft Guidance, supra note 116. 
119. CMS originally grounded its authority for this policy in Sections 
1862(a)(l)(A) and 1862(a)(l)(E) of the Social Security Act (42 U.S.C. § 
1395y(a)(l)), but more recently decided that the policy was not consistent 
with Section 1862(a)(l)(A). Id. 
120. 42 U.S.C. § 1395y(a)(l)(A) (2006); Draft Guidance, supra note 116. 
121. MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.4.2 ("FDA 
approved drugs used for indications other than what is indicated on the 
official label may be covered under Medicare [Part B] if the carrier 
determines the use to be medically accepted, taking into consideration the 
major drug compendia, authoritative medical literature and/ or accepted 
standards of medical practice." (emphasis added)). 
122. Draft Guidance, supra note 116. 
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evidence for new technologies subject to the FDA pre-m~rket ~pproval 
ocess (all new prescription drugs) may be limited to a smgle mtended 
pr · h · £ t· and clinical evidence may not provide muc m orma 10n on a 
use, . . . . . ,,123 Add" product's "real world benefit m typical pa~ient c~re s~ttmgs. . i-
tionally, recent studies on the informational bias. m peer-reviev:ed 
literature call into question the current body of evidence supportmg 
many, if not most, of the products on the market. 124 
Within the Department of Health and Human Services, the Agency 
for Healthcare Research and Quality (AHRQ) is charged with "con-
duct[ing] and support[ing] research with respect. to the outcomes, 
effectiveness, and appropriateness of health care servi_ces and procedures 
in order to identify the manner in which diseases, disorders, and other 
health conditions can most effectively and appropriately be prevented, 
diagnosed, treated, and managed clinically" con~!stent with ~he needs 
and priorities of the Medicare program.125 Indeed, [~HRQ] believes th~t 
the principal function of CED is to generate i:ew eviden~e. on the ben~fit 
or harm of an item or service among the Medicare beneficiary popula~wn 
based on rigorous scientific inquiry. "126 The Medicare pati~nt pop':lat10n, 
which includes the elderly, chronically disabled, and patients with end 
stage renal disease who are treated with dialysis, is often excluded from 
clinical trials conducted to evaluate products for FDA pre-market 
approval. 127 . . 
Similarly, many of the patients historically covered by Medicaid -
children, pregnant women, people with disabilities, an~ the elderly - _are 
also often excluded from clinical trials for both ethical and pra~tic~l 
reasons. Inclusion of diagnosis codes in the Medicare and Me~ic~1d 
claims databases would significantly increase the amount of prescnpti?n 
drug use data available for drug safety surveillance in these other~nse 
underrepresented patient populations, many of whom are 1?-or~ phy_si?al-
ly, socially, and economically vulnerable than those studied m chmcal 
trials. · t 
In an attempt to address the underrepresentation of these patien 




See, e.g., Andrew P. Prayle et al., Compliance with Mand~tory Reporting 
of Clinical Trial Results on Clinical Trials.gov: Cross-Sectional Stu_dy, 344 
BRIT. MED. J. 7373 (2012); Sylvain Mathieu et al., <?omparison of 
Registered 8 Published Primary Outcomes in Randomized Controlled 
Trials, 302 JAMA 977 (2009). 
42 U.S.C. § 1320b-12 (2012). Medicare coverage determinations may then 
be made pursuanj; to the research conducted by the Agency. See § 
1395y(a)(l)(E) (cross-referencing the research conducted pursuant to 42 
u.s.c. § 1320b-12). 
126. Draft Guidance, supra note 116. 
127. Id. 
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C. Potential Role of Outpatient Prescription Drug Database for Compar-
ative Effectiveness Research and Coverage Decisions 
Prescribers are able to recommend any FDA-approved drug for any 
use they deem in their patients' best interests. 116 Often these recommen-
dations differ from the intended use(s) studied in the clinical trials and, 
in many specialties and diseases, become the standard of care. 117 Like-
wise, previously accepted treatments are occasionally called into question 
by new research or evolving scientific thought, and CMS has tried to 
respond effectively to emerging evidence. 118 Instead of denying coverage 
outright for these newer or newly questioned technologies, CMS has 
occasionally used a "Coverage with Evidence Development" (CED) 
program to "provide Medicare coverage while further evidence is devel-
oped. "119 
CMS generally relies on clinical evidence to determine whether par-
ticular items or services should be considered "reasonable and necessary" 
for purposes of Medicare Part B coverage. 12° For prescription drugs 
covered under Part B, CMS looks to evidence beyond that considered for 
"medically accepted indications," including medical literature and other 
indicia of accepted standards of care. 121 Even with the expanded universe 
of evidence available for Part B coverage, information may still be 
significantly limited for both very new and older products, making well-
informed coverage determinations impossible.122 In particular, clinical 
116. These uses likely fall into the category of items and services where CMS 
"believed that the enthusiasm of interested parties was disproportionate to 
the persuasiveness of the then-current evidence base." Draft Guidance for 
the Public, Industry &J CMS Staff Coverage with Evidence Development in 
the Context of Coverage Decisions, CTRS FOR MEDICARE & MEDICAID 
SERVS. (Nov. 29, 2012) [hereinafter Draft Guidance], 
http://www.cms.gov/medicare-coverage-database/ details/medicare-
coverage-document-details.aspx?MCDid=23. 
117. See Kesselheim, supra note 3, at 238 ("[Scientifically unsupported] off-label 
use may also be reasonable and appropriate in circumstances where 
collection of rigorous evidence is impossible."). 
118. See Draft Guidance, supra note 116. 
119. CMS originally grounded its authority for this policy in Sections 
1862(a)(l)(A) and 1862(a)(l)(E) of the Social Security Act (42 U.S.C. § 
1395y(a)(l)), but more recently decided that the policy was not consistent 
with Section 1862(a)(l)(A). Id. 
120. 42 U.S.C. § 1395y(a)(l)(A) (2006); Draft Guidance, supra note 116. 
121. MEDICARE BENEFIT POLICY MANUAL, supra note 19, at § 50.4.2 ("FDA 
approved drugs used for indications other than what is indicated on the 
official label may be covered under Medicare [Part BJ if the carrier 
determines the use to be medically accepted, taking into consideration the 
major drug compendia, authoritative medical literature and/ or accepted 
standards of medical practice." (emphasis added)). 
122. Draft Guidance, supra note 116. 
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evidence for new technologies subject to the FDA pre-m~rket ~pproval 
process (all new prescription drugs) may b~ limited to_ a smgle __ mtended 
and clinical evidence may not provide much mformat10n on a ~:~duct's "real world benefit in t~pical pa~ient c~re s~ttings."123 ~ddi­
tionally, recent studies on the mformational bias. m peer-reviev:ed 
literature call into question the current body of evidence supportmg 
many, if not most, of the products on the market.124 
Within the Department of Health and Human Services, the Agency 
for Healthcare Research and Quality (AHRQ) is charged with "con-
duct[ing] and support[ing] research with respect. to the outcomes, 
effectiveness, and appropriateness of health care servi_ces and procedures 
in order to identify the manner in which diseases, disorders, and other 
health conditions can most effectively and appropriately be prevented, 
diagnosed, treated, and managed clinically" con~~stent with ~he needs 
and priorities of the Medicare program.125 Indeed, [~HRQ] believes th~t 
the principal function of CED is to generate 1:-ew eviden~e- on the ben~fit 
or harm of an item or service among the Medicare benefi~iary popula~ion 
based on rigorous scientific inquiry."126 The Medicare pati~nt pop1:lat10n, 
which includes the elderly, chronically disabled, and patients with end 
stage renal disease who are treated with dialysis, is often excluded from 
clinical trials conducted to evaluate products for FDA pre-market 
approval. 127 . . 
Similarly, many of the patients historically covered by Medicaid -
children, pregnant women, people with disabilities, an~ the elderly- _are 
also often excluded from clinical trials for both ethical and pra~tic~l 
reasons. Inclusion of diagnosis codes in the Medicare and Me~ic~id 
claims databases would significantly increase the amount of prescnpti?n 
drug use data available for drug safety surveillance in these other~"'nse 
underrepresented patient populations, many of whom are ~or~ phy_si?al-
ly, socially, and economically vulnerable than those studied m chrncal 
trials. · t 
In an attempt to address the underrepresentation of these patien 




See, e.g., Andrew P. Prayle et al., Compliance with Mand~tory Reporting 
of Clinical Trial Results on Clinical Trials.gov: Cross-Sectional Stu_dy, 344 
BRIT. MED. J. 7373 (2012); Sylvain Mathieu et al., ?omparison of 
Registered &J Published Primary Outcomes in Randomized Controlled 
Trials, 302 JAMA 977 (2009). 
42 U.S.C. § 1320b-12 (2012). Medicare coverage determinations may then 
be made pursuan! to the research conducted by the Agency. See § 
1395y(a)(l)(E) (cross-referencing the research conducted pursuant to 42 
u.s.c. § 1320b-12). 
126. Draft Guidance, supra note 116. 
127. Id. 
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ar~ alre~dy available and have been used for research purposes, 128 and 
private msurers a:e working to create a claims database covering a 
broader cross-sect10n of the population. 129 Increased use of electronic 
~edical records, especially those that meet the meaningful use standards 
issued under HITECH, 130 may provide robust databases for some 
research,131 but they are inherently provider-based datasets that may not 
128. The Dartm?ut~ Atlas ~roject has used Medicare claims data to provide 
comprehensive mformation and analysis about the national, regional and 
local markets, as well as individual hospitals and their affiliated physi~ians. 
FAQ, DARTMOUTH ATLAS OF HEALTH CARE 
~~tp://www.dartmouth~tlas.org/tools/faq/ (last visited Apr. 19, 2014) 
( The Centers for Medicare and Medicaid Services (CMS), the federal 
agency. that collects data for every person and provider using Medicare 
health msurance, makes available a uniform national claims database for 
rese3:rch purposes."). See also John Carreyou, Access to Widen on 
Medicare Data, WALL ST. J., Dec. 8, 2011, at A6 ("In an abrupt policy 
chan_ge, the J:?epartment of Health and Human Services will make its huge 
Medicare claims database more broadly available to the public, to help 
consumers and employers make better-informed decisions about medical 
care. In particular, the federal agency will relax its restrictions on the 
rele3:se of information about individual doctors who participate in 
Medicare, the $524 billion federal program for the elderly and disabled 
reversing a three-decade position that doing so would violate physicians; 
privacy rights."). 
129. See Anna Wilde Mathews, Health Insurers Will Give Claims Data to 
Institute,. WA~L ST. J. (Sept. 19, 2011), available at http:// 
www.onlme.WSJ.com/ article /SB100014240S311190337 4004576581131849595 
492.html ("Researchers have sometimes struggled to perform such studies 
on ~he commercially insured population. They often turn to Medicare data, 
which reflect a mostly elderly patient base as well as the federal 
government's unique payment model. The Health Care Cost Institute will 
start with claims from UnitedHealth Group Inc., Aetna Inc., Humana Inc. 
~~d. the nor_iprofit Kaiser Permanente, and the carriers are also providing 
m1tial fundmg to set it up."). 
130. David C. Classen & David W. Bates, Finding the Meaning in Meaningful 
Use, _365 NEW ENG. J. MED. 855, 856 (2011) ("The meaningful-use criteria 
~equi:e the collection of specific quality measures: in particular, 15 
mpat1ent and 6 outpatient quality measures that will have to be collected 
and reported to meet these criteria. The stage 2 criteria for quality 
measures will raise t~e bar further, although they are still in a draft stage. 
~roadl~, the hope 1s that stage 2 will encourage providers to begin 
1mprovmg process, whereas stage 3 will result in improved outcomes."). 
131. See, e.g., Kenne~h Jung et al., .Automated Detection of Systematic Off-
Label Drug Use in Free Text of Electronic Medical Records, 2013 AMIA SU_M~TS TRANSL_ATIONAL SCI. PROCEEDINGS 94 (2013). See also Peter Jaret, 
Mining Electronic Recor~s for Revealing Health Data, N.Y. TIMES, Jan. 14, 
2013, http://www.nyt1mes.com/2013/0l/15/health/mining-electronic-
records-~or-rev:aling-health-data.html ("The monitoring and analysis of 
electromc .medical records, some scientists say, have the potential to make 
every patient a i:articipant in a vast, ongoing clinical trial, pinpointing 
treatments and side effects that would be hard to discern from anecdotal 
case reports or expensive clinical trials."). 
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reflect patient adherence. 132 Medicare Part D and Medicaid outpatient 
prescription drug claims databases, if populated with d~a~nosis c?de~, 
have the unique value of both capturing off-label prescnbmg habits m 
typical community based treatment settings (as opposed to the special-
ized research settings of clinical trials) 133 and patient adherence data. 134 
Further, unlike the shorter-term clinical trials (which at their longest 
may extend to a year's use of a product), outpatient prescription drug 
claims databases populated with diagnosis information would allow 
researchers to follow patient adherence in the context of long-term 
management of chronic conditions over the course of years, including the 
combination therapies that often go untested in conventional clinical 
trials. 135 At a minimum, researchers could use the outpatient prescription 
drug claims data to identify and provide information on which treatr:ient 
regimens are better tolerated, or more consistently observed by patients 




STEVEN R. FELDMAN, COMPARTMENTS: How THE BRIGHTEST, BEST 
TRAINED AND MOST CARING PEOPLE CAN MAKE JUDGMENTS THAT ARE 
COMPLE;ELY AND UTTERLY WRONG 18 (2009) ("Dermatologists prescribe 
patients medications but don't get to see what p~tients do . with ~he 
medicines . . . . It turns out many patients don t use their topical 
medications as directed, and over the long run, their use of medication 
steadily drops. But dermatologists didn't know this."). 
The potential disconnect between clinical trial research centers and typical 
treatment settings is one factor that CMS will consider in its decision _to 
apply CED to items or services. In addition, CMS looks at. the potential 
disconnect between clinical trial endpoints and relevant patient outcomes 
in the Medicare population, the enrollment criteria of the clinical tri~ls 
(which often excludes elderly patients wi~h sign~fican.t: rel~va~~ comorb1d 
conditions), and whether later clinical evidence 1dent1f1es s1gmficant harm 
or lack of meaningful benefit of a previously-accepted treatment. Draft 
Guidance, supra note 116. 
See David Brandes et al., Implications of Real-World Adherence on Cost-
Effectiveness Analysis in Multiple Sclerosis, 16 J. MED. ECON. 547, 547 
(2013) (" [E]conomic analyses of [multiple scl:rosis] therapies sho~ld 
incorporate real-world adherence rates where ava1labl~, ra~her than relyn1:g 
exclusively on trial-based efficacy estimates .when co.nsi~ermg the e~ono1?1c 
value of treatment alternatives, and that highly eff1cac1ous therapies with 
low adherence may yield real-world efficacy that is substantially lower than 
that observed in closely monitored clinical trials."); Ruby Grymonpre et 
al., Validity of a Prescription Claims Database to Estimat~ fv!edication 
Adherence in Older Persons, 44 MED. CARE471, 476 (2006) (fmdmg strong 
correlation between prescription drug claim database information and 
actual patient adherence for discrete prescriptions to be taken regularly). 
135. See, e.g., Theodore Pincus, Limitations of Randomized ?Zin.ical Trials t.o 
Recognize Possible Advantages of Combination Therapies in Rheumatic 
Diseases, 23 SEMINARS IN ARTHRITIS & RHEUMATOLOGY 2, 3 (1993). 
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ar~ alre~dy available and have been used for research purposes, 12s and 
private msurers a:e working to create a claims database covering a 
broader cross-section of the population. 129 Increased use of electronic 
~edical records, especially those that meet the meaningful use standards 
ISsued under HITECH,130 may provide robust databases for some 
research, 131 but they are inherently provider-based datasets that may not 
128. The Dartm?ut~ Atlas ~roject has used Medicare claims data to provide 
comprehensive mformation and analysis about the national, regional and 
local markets, as well as individual hospitals and their affiliated physi~ians. 
FAQ, DARTMOUTH ATLAS OF HEALTH CARE 
~~tp://www.dartmouth~tlas.org/tools/faq/ (last visited Apr. 19, 2014) 
( The Centers for Medicare and Medicaid Services (CMS), the federal 
agency. that collects data for every person and provider using Medicare 
health msurance, makes available a uniform national claims database for 
rese8:rch purposes."). See also John Carreyou, Access to Widen on 
Medicare Data, WALL ST. J., Dec. 8, 2011, at A6 ("In an abrupt policy 
chan_ge, the J:?epartment of Health and Human Services will make its huge 
Medicare claims database more broadly available to the public, to help 
consumers and employers make better-informed decisions about medical 
care. In particular, the federal agency will relax its restrictions on the 
rele8:se of information about individual doctors who participate in 
Medicare, the $524 billion federal program for the elderly and disabled 
reversing a three-decade position that doing so would violate physicians; 
privacy rights."). 
129. See Anna Wilde Mathews, Health Insurers Will Give Claims Data to 
Institute,_ W~L ST. J. (Sept. 19, 2011), available at http:// 
www.onlme.WSJ.com/ article /SB1000142408311190337 40045 76581131849595 
492.html ("Researchers have sometimes struggled to perform such studies 
on ~he commercially insured population. They often turn to Medicare data, 
which reflect a mostly elderly patient base as well as the federal 
government's unique payment model. The Health Care Cost Institute will 
start with claims from UnitedHealth Group Inc., Aetna Inc., Humana Inc. 
~~d. the no1:1-profit Kaiser Permanente, and the carriers are also providing 
mitial fundmg to set it up."). 
130. David C. Classen & David W. Bates, Finding the Meaning in Meaningful 
Use, _365 NEW ENG. J. MED. 855, 856 (2011) ("The meaningful-use criteria 
:equr:e the collection of specific quality measures: in particular, 15 
mpatient and 6 outpatient quality measures that will have to be collected 
and report~d t? meet these criteria. The stage 2 criteria for quality 
measures will raise t~e bar further, although they are still in a draft stage. "!3roadl~, the hope is that stage 2 will encourage providers to begin 
1mprovmg process, whereas stage 3 will result in improved outcomes."). 
131. See, e.g., Kenne~h Jung et al., Automated Detection of Systematic Off-
Label Drug Use in Free Text of Electronic Medical Records, 2013 AMIA S~~TS TRANSL_ATIONAL Ser. PROCEEDINGS 94 (2013). See also Peter Jaret, 
Mining Electronic Recor~s for Revealing Health Data, N.Y. TIMES, Jan. 14, 
2013, http://www.nytimes.com/2013/0l/15/health/mining-electronic-
records-~or-rev~aling-health-data.html ("The monitoring and analysis of 
electromc_med1cal re~o_rds, so_me scientists say, have the potential to make 
every patient a ~artic1pant rn a vast, ongoing clinical trial, pinpointing 
treatments and side effects that would be hard to discern from anecdotal 
case reports or expensive clinical trials."). 
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reflect patient adherence. 132 Medicare Part D and Medicaid outpatient 
prescription drug claims databases, if populated with d~a~nosis c?de_s, 
have the unique value of both capturing off-label prescnbmg habits m 
typical community based treatment settings (as opposed to the special-
ized research settings of clinical trials) 133 and patient adherence data. 134 
Further, unlike the shorter-term clinical trials (which at their longest 
may extend to a year's use of a product), outpatient prescription drug 
claims databases populated with diagnosis information would allow 
researchers to follow patient adherence in the context of long-term 
management of chronic conditions over the course of years, including the 
combination therapies that often go untested in conventional clinical 
trials.135 At a minimum, researchers could use the outpatient prescription 
drug claims data to identify and provide information on which treatr_nent 
regimens are better tolerated, or more consistently observed by patients 




STEVEN R. FELDMAN, COMPARTMENTS: How THE BRIGHTEST, BEST 
TRAINED AND MOST CARING PEOPLE CAN MAKE JUDGMENTS THAT ARE 
COMPLE;ELY AND UTTERLY WRONG 18 (2009) ("Dermatologists prescribe 
patients medications but don't get to see what p~tients do . with _the 
medicines . . . . It turns out many patients don t use their topical 
medications as directed, and over the long run, their use of medication 
steadily drops. But dermatologists didn't know this."). 
The potential disconnect between clinical trial research centers and typical 
treatment settings is one factor that CMS will consider in its decision _to 
apply CED to items or services. In addition, CMS looks at. the potential 
disconnect between clinical trial endpoints and relevant patient outcomes 
in the Medicare population, the enrollment criteria of the clinical tri~ls 
(which often excludes elderly patients wi~h sign~fican_t~ rel~va~~ comorb1d 
conditions), and whether later clinical evidence 1dent1fies s1grnficant harm 
or lack of meaningful benefit of a previously-accepted treatment. Draft 
Guidance, supra note 116. 
See David Brandes et al., Implications of Real- World Adherence on Cost-
Effectiveness Analysis in Multiple Sclerosis, 16 J. MED. ECON. 547, 547 
(2013) ("[E]conomic analyses of [multiple sclerosis] therapies sho~ld 
incorporate real-world adherence rates where availabl~, ra~her than rely1~g 
exclusively on trial-based efficacy estimates.when co_ns1~ermg the e~ono1?1c 
value of treatment alternatives, and that highly efficac10us therapies with 
low adherence may yield real-world efficacy that is substantially lower than 
that observed in closely monitored clinical trials."); Ruby Grymonpre et 
al., Validity of a Prescription Claims Database to Estimat~ fv!edication 
Adherence in Older Persons, 44 MED. CARE471, 476 (2006) (fmdmg strong 
correlation between prescription drug claim database information and 
actual patient adherence for discrete prescriptions to be taken regularly). 
135. See, e.g., Theodore Pincus, Limitations of Randomized Clin_ical Trials ~o 
Recognize Possible Advantages of Combination Therapies in Rheumatic 
Diseases, 23 SEMINARS IN ARTHRITIS & RHEUMATOLOGY 2, 3 (1993). 
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to evaluate the comparative effectiveness of drugs within a treatment 
class. 136 
Comparative effectiveness research (CER) is "research that compares 
the clinical outcomes, effectiveness and appropriateness of items ser-
v~ces, and_ procedures that are used to prevent, diagnose, or treat 
diseases, disorders, and other health conditions. "137 Unlike most clinical 
t~ials, which are conducted to determine the safety and efficacy of a 
smgle drug, CER can provide information on the relative risks and 
benefits of multiple treatment options. There remains much debate on 
whether CER should be considering the costs of treatment options or 
used for drug coverage determinations in the United States 138 but there 
is wi~espread acceptance that the U.S. health care syst~m can only 
benefit from a better understanding of which treatment options work 
best for which patients.139 While the current Medicare and Medicaid 
out~atie~t prescription drug claims databases may be able to provide 
longitudmal data on drug use generally, the inclusion of ICD-10-CM 
codes would imbue the claims databases with the potential for deeper 
136. See. generally Lon S. Schneider et al., Effectiveness of Atypical 
Antipsychotic Drugs in Patients with Alzheimer's Disease, 355 NEW ENG. 
J. MED. 1525, 1525 (2006) (studying the number of patients with at least a 
~inimal impr_o"."e_ment on a standardized symptom rating scale during a 
timeframe of lmtial treatment to the discontinuation of treatment). 
137. Paul H. Keckley & Barbara B. Frink, Comparative Effectiveness: A 
Strategic Perspective on What It Is and What It May Mean for the United 
States, 3 J. HEALTH & LIFE. Ser. L. 53, 58 (2009) (citing DOUGLAS 
PEDDICORD, AM. MED. INFORMATICS Ass'N, THE AMERICAN RECOVERY AND 
REINVESTMENT ACT OF 2009 1 (2009)). See also INST. OF MED., INITIAL 
NATIONAL PRIORITIES FOR COMPARATIVE EFFECTIVENESS RESEARCH 1 
(2009), available at 
http://www.iom.edu/-/media/Files/Report%20Files/2009/ComparativeEff 
ect1venessResearchPriorities / CER%20report 320brief%2008-l 3-09. pdf. 
138. Many other countries have already decided to include costs in their 
comparative effectiveness programs. Keckley & Frink supra note 137 at 
56 ("~t least sixteen developed systems in the world fe~ture a comparative 
effectiveness program to define effective care. Comparative effectiveness 
prog:ams in Britain, Australia, Canada, Germany, and others align 
provi~er payments with adherence to recommendations of comparative 
effectiveness programs, but each program is unique in design and 
application."). 
139. CER has received Congressional support as part of the Medicare 
Modernization Act of 2003 and the American Recovery and Reinvestment 
Act ~f 2009. Keckl~y & Frink, supra note 137, at 59 (providing an 
overview of the ongomg debate about including treatment costs in CER)· 
INST. OF MED., KNOWING WHAT WORKS IN HEALTH CARE: A ROADMAP FO~ 
THE NATION 205 (Jill Eden et al. eds., 2008), available at 
http://www.nap.edu/openbook.php?record_id=l2038&page=205. 
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refinement in defining and understanding diseases and conditions, 
eventually leading to more customized medical management programs.140 
Given the underrepresentation of much of the Medicare and Medi-
caid patient population and informational bias in the existing universe of 
clinical evidence and the potential of a robust, accurately coded claims 
database to capture real-world prescription drug use information, which 
can in turn provide evidence of long-term efficacy and safety of drugs (or 
lack thereof), CMS should continue to provide Medicare and Medicaid 
prescription drug coverage while further evidence is developed consist~nt 
with the agency's existing CED program for Part B coverage. In domg 
so a revised Medicare Part D and Medicaid billing policy (as made 
p;ssible through electronic prescribing and ICD-10-CM coding) could 
play a critical role in better informing and reforming health care of those 
who have been traditionally underrepresented in the clinical evidence. 
CONCLUSION 
On first glance, adding ICD-10-CM diagnosis codes to outpatient 
prescriptions appears to be an obvious "win-win" situation for fiscal 
stability and public health - real-time coverage determinations for 
purposes of controlling federal health care costs and meaningful data 
collection to improve public health. CMS would be able to better police 
its Medicare Part D and Medicaid spending, and pharmacists, FDA, and 
researchers would have meaningful information for prescription review, 
drug safety surveillance, and comparative effectiveness research. B1:1t 
strict enforcement of Medicare Part D and Medicaid coverage laws m 
the short-term could undermine all of these policy goals. 
While most health care providers desperately try to comply with all 
relevant laws and regulations, they are also driven by their vocation to 
treat their patients effectively. Given the immediate nature of health and 
illness and the often abstract and distant nature of laws and regulations, 
combined with the sheer fact that at some point we will all be patients, 
it would be unwise to underestimate the likelihood (and fervent wish of 
many) that health care providers may take steps to effectively treat a 
patient despite the laws and regulations that stand in the way. One such 
step may be miscoding a diagnosis to get a needed prescription paid. 
Where coverage denials are perceived as arbitrary and out-of-pocket 
payment for prescription drugs is not a viable option, the "right" choice 
between accurately reporting diagnoses or effectively treating a patient 
can get blurred. When national health care policies are implicated, I 
140. Keckley & Frink, supra note 137, at 77. See also Travis B. Murdoch & 
Allan S. Detsky, The Inevitable Application of Big Data to Health Ca~e, 
309 JAMA 1351, 1351 (2013) ("Big data [such as that collected m 
insurance claims databases] offers the potential to create an observational 
evidence base for clinical questions that would otherwise not be possible 
and may be especially helpful with issues of generalizability."). 
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to evaluate the comparative effectiveness of drugs within a treatment 
class.136 
Comparative effectiveness research (CER) is "research that compares 
t~e clinical outcomes, effectiveness and appropriateness of items, ser-
v~ces, and procedures that are used to prevent, diagnose, or treat 
diseases, disorders, and other health conditions. "137 Unlike most clinical 
t~ials, which are conducted to determine the safety and efficacy of a 
smgle drug, CER can provide information on the relative risks and 
benefits of multiple treatment options. There remains much debate on 
whether CER should be considering the costs of treatment options or 
used for drug coverage determinations in the United States 138 but there 
is wi~espread acceptance that the U.S. health care syst~m can only 
benefit from a better understanding of which treatment options work 
best for which patients. 139 While the current Medicare and Medicaid 
out~atie~t prescription drug claims databases may be able to provide 
long1tudmal data on drug use generally, the inclusion of ICD-10-CM 
codes would imbue the claims databases with the potential for deeper 
136. See. generally Lon S. Schneider et al., Effectiveness of Atypical 
Antipsychotic Drugs in Patients with Alzheimer's Disease, 355 NEW ENG. 
J. MED. 1525, 1525 (2006) (studying the number of patients with at least a 
~inimal impr.o"."e_ment on a standardized symptom rating scale during a 
timeframe of rnitial treatment to the discontinuation of treatment). 
137. Paul H. Keckley & Barbara B. Frink, Comparative Effectiveness: A 
Strategic Perspective on What It Is and What It May Mean for the United 
States, 3 J. HEALTH & LIFE. SCI. L. 53, 58 (2009) (citing DOUGLAS 
PEDDICORD, AM. MED. INFORMATICS Ass'N, THE AMERICAN RECOVERY AND 
REINVESTMENT ACT OF 2009 1 (2009)). See also INST. OF MED., INITIAL 
NATIONAL PRIORITIES FOR COMPARATIVE EFFECTIVENESS RESEARCH 1 
(2009), available at 
htt?: / /www .iom.edu/-/media/Files /Report%20Files/2009 / ComparativeEff 
ectivenessResearchPriorities / CER%20report %20brief%2008-13-09. pdf. 
138. Many other countries have already decided to include costs in their 
comparative effectiveness programs. Keckley & Frink supra note 137 at 
56 ("~t least sixteen developed systems in the world fe~ture a comparative 
effectiveness program to define effective care. Comparative effectiveness 
pro~ams in Britain, Australia, Canada, Germany, and others align 
provi~er payments with adherence to recommendations of comparative 
effectiveness programs, but each program is unique in design and 
application."). 
139. CER has received Congressional support as part of the Medicare 
Modernization Act of 2003 and the American Recovery and Reinvestment 
Act ~f 2009. Keckl~y & Frink, supra note 137, at 59 (providing an 
overview of the ongorng debate about including treatment costs in CER)· 
INST. OF MED., KNOWING WHAT WORKS IN HEALTH CARE: A ROADMAP FO~ 
THE NATION 205 (Jill Eden et al. eds., 2008), available at 
http://www.nap.edu/openbook.php?record_id=l2038&page=205. 
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refinement in defining and understanding diseases and conditions, 
eventually leading to more customized medical management programs.140 
Given the underrepresentation of much of the Medicare and Medi-
caid patient population and informational bias in the existing universe of 
clinical evidence and the potential of a robust, accurately coded claims 
database to capture real-world prescription drug use information, which 
can in turn provide evidence of long-term efficacy and safety of drugs (or 
lack thereof), CMS should continue to provide Medicare and Medicaid 
prescription drug coverage while further evidence is developed consist~nt 
with the agency's existing CED program for Part B coverage. In domg 
so a revised Medicare Part D and Medicaid billing policy (as made p~ssible through electronic prescribing and ICD-10-CM coding) could 
play a critical role in better informing and reforming health care of those 
who have been traditionally underrepresented in the clinical evidence. 
CONCLUSION 
On first glance, adding ICD-10-CM diagnosis codes to outpatient 
prescriptions appears to be an obvious "win-win" situation for fiscal 
stability and public health - real-time coverage determinations for 
purposes of controlling federal health care costs and meaningful data 
collection to improve public health. CMS would be able to better police 
its Medicare Part D and Medicaid spending, and pharmacists, FDA, and 
researchers would have meaningful information for prescription review, 
drug safety surveillance, and comparative effectiveness research. B1:1t 
strict enforcement of Medicare Part D and Medicaid coverage laws m 
the short-term could undermine all of these policy goals. 
While most health care providers desperately try to comply with all 
relevant laws and regulations, they are also driven by their vocation to 
treat their patients effectively. Given the immediate nature of health and 
illness and the often abstract and distant nature of laws and regulations, 
combined with the sheer fact that at some point we will all be patients, 
it would be unwise to underestimate the likelihood (and fervent wish of 
many) that health care providers may take steps to effectively treat a 
patient despite the laws and regulations that stand in the way. One such 
step may be miscoding a diagnosis to get a needed prescription paid. 
Where coverage denials are perceived as arbitrary and out-of-pocket 
payment for prescription drugs is not a viable option, the "right" choice 
between accurately reporting diagnoses or effectively treating a patient 
can get blurred. When national health care policies are implicated, I 
140. Keckley & Frink, supra note 137, at 77. See also Travis B. Murdoch & 
Allan S. Detsky, The Inevitable Application of Big Data to Health Ca~e, 
309 JAMA 1351, 1351 (2013) ("Big data [such as that collected m 
insurance claims databases] offers the potential to create an observational 
evidence base for clinical questions that would otherwise not be possible 
and may be especially helpful with issues of generalizability."). 
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suggest erring on the side of accurate information at the cost of immedi-
ate, strict enforcement of the letter of the law to bolster better evidence-
based decisions in the future. Fortunately (at least in this context), 
administrative agencies are afforded tremendous discretion in their 
enforcement policies, especially when enforcement involves a complicated 
balancing of a number of factors that are peculiarly within the agency's 
t . 141 c· h 1 exper ISe. iven t e comp e:xity of the legal framework here the 
informational limits of scientific evidence and diagnostic coding: the 
vulnerability of the patient populations insured under Medicare and 
Medicaid, and the opportunities to improve both individual patient 
safety and public health tied up in this enforcement policy it seems 
unlikely that any federal court would compel CMS to apply' the strict 
letter of the coverage laws. 
Accordingly, in order to better control federal health care costs and 
improve public health in the long-term (possible only through collection 
and use of accurate information), CMS should make inclusion of an ICD-
10-CM diagnosis code a condition of payment for all Medicare Part D 
and Medicaid claims for outpatient prescription drugs but suspend strict 
enforcement of the coverage laws unless there is widespread consensus in 
the medical community that a particular treatment is always ineffective 
or harmful. The alternatives are unsatisfying: either a continuation of 
the status quo - essentially unchecked federal spending on prescription 
drugs that further threatens the fiscal stability of the Medicare and 
Me~icaid programs, exacerbated by poorly understood prescription drug 
use m vulnerable populations - or worse. 
While the inclusion of ICD-10-CM codes on outpatient prescriptions 
may be a simple proposal with significant potential for improving public 
health and patient safety, it is neither an easy nor inexpensive one. It 
would be a tremendous disservice to patients, taxpayers, health care 
providers, researchers, and policymakers alike to implement the proposal 
solely as a means of reducing federal health care spending on off-label 
prescriptions. With strict enforcement of the coverage laws and the 
accompanying systemic incentives to miscode created by widespread 
coverage denials, we could easily end up with the worst of all options - a 
significant investment of time and money in a claims database corrupted 
by inaccurate information that neither meaningfully polices federal 
health care spending nor provides sufficiently robust data for improved 
practice of pharmacy, drug safety surveillance, or comparative effective-
ness research. Let us hope it does not come to that. 
141. See. ~enerally Heckler v. Chaney, 470 U.S. 821, 831 (1985) (" [A]n agency's 
dec1s1on not to prosecute or enforce, whether through civil or criminal 
process, is a decision generally committed to an agency's absolute 
discretion."). 
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